var title_f34_39_35440="Congenital cholesteatoma";
var content_f34_39_35440=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F72870&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F72870&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Congenital cholesteatoma of the anterosuperior quadrant (right ear)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 371px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Congenital cholesteatoma of the anterosuperior quadrant. A white mass (arrows) behind an intact drum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Isaacson G. Diagnosis of pediatric cholesteatoma. Pediatrics 2007; 120:603. Copyright &copy; 2007 by the AAP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_39_35440=[""].join("\n");
var outline_f34_39_35440=null;
var title_f34_39_35441="Oblique fracture 4th metacarpal shaft";
var content_f34_39_35441=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F72535&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F72535&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Oblique fracture of the 4th metacarpal shaft",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 348px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Oblique fractures of the metacarpal shaft (black arrows) are more likely to shorten and rotate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin E Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_39_35441=[""].join("\n");
var outline_f34_39_35441=null;
var title_f34_39_35442="Nail psoriasis onycholysis";
var content_f34_39_35442=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85510&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85510&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Nail psoriasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Onycholysis with erythema of the nail bed and splinter hemorrages in a patient with nail psoriasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_39_35442=[""].join("\n");
var outline_f34_39_35442=null;
var title_f34_39_35443="Tracheal bronchus CT";
var content_f34_39_35443=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51135&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51135&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tracheal bronchus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 484px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHkAUADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5ms7WF7dXkUknPTI/z0qZbSBshYicd9x/xpdOUG1UHA4JH59a0I4yzfIcFlJPvQBVTTbcgZQ9+55NSJpdsSuY+v8AtGtG2hLJEGB3ZPue3erUcYXBKpwO5/nQBnJo9nty0PrzvI/rQ2k2O7YsO5+P4znn2zWzp1jdarMkFlAXZiFH1PpxXvnw7+CZiSK88RkQxYB8skbz9MDAoA8Q8O/DhtWkUR2krlmwF54+vNezeHP2dNHMAk1yELkA4WV1/wDZ69x0+2sNJhEOj2yQgDG/Ayf0q1++l5dmJPqaAPMrf4D/AA0jQK2iPctj7xvZl/lIKn/4UT8NmXjw0g/7f7n/AOOV6aqFQTv/AFpx9AeO+KAPL/8AhQ/w2x/yLgB/6/bn/wCOUv8Awob4b9/Dg/8AA65/+OV6eMnp0FNPzdaAPMv+FD/DbnHhscD/AJ/rnn/yJSj4DfDYn/kWx/4HXP8A8cr09R16Y6f59acE4xjt1oA8uPwG+G+f+RbGP+v65/8AjlH/AAof4bcY8Nfne3P/AMcr1F9igZb/AOtThESgOcgnrj/69AHlZ+A/w2Gf+KbHXGft1z/8cpf+FDfDbH/It9P+n65/+OV6k4jXA4J+lAUODg/y60AeXj4C/DXA/wCKbGf+v65/+OUf8KF+Gv8A0LX/AJPXP/xyvUdhU5JxSY/2jQB5h/woX4a4z/wjQx/1/XP/AMcoPwF+Gv8A0LY/8Drn/wCOV6gAe+PbinCMnkAkfgKAPKm+Avw3GceGwf8At+ueP/IlH/Chvhtj/kWuP73225/+OV6q/lxjMkgH41VN9aLIwL4I/lQB5mfgN8N8ZHhse3+nXP8A8coHwH+G56eGx/4G3P8A8cr0qS+tvsrOjbtvHf8AxrLl8QwfMqk7ugH+TQBxP/Ch/ht38Nf+T1z/APHKB8B/hvnnw2P/AAOuf/jldvDr8Tox5KrwTjFWYtRhlypBzxz9aAPPv+FD/Df/AKFsf+Btz/8AHKD8B/hx28OY/wC365/+OV6VHLGy5RgWPAGakyARnIPbnOaAPLX+A/w6H3fDnH/X7cf/AByoh8Dfh0hw/hkt9L25/wDjlesAj3NJ5akZA6e9AHli/BH4ZOCknhlo/wDbW+ucj8C+K5Xxb+zroRtHn8NQEjGQrTuSPzavd3twQc88+lV4/PtmJVmzjqDQB8Na/wCBn0O6aG8sHUqcHJb8x81YyaVYE/8AHuOMZy7D+tfeGu6Po3ie0eDV4UWfbxMBgj3NfOvxO+EGo6DJNfaUklzZH5gV5GPcUAeNf2NZbci3J/4E3H61FLo9puULER6/Mf8AGtMBxK8TqVcYypUg5/yKWRuAcZweeOn1oAwJNMgVv9USPXcap6raRQQq0SbTuwTzzwfWumbaZFUZ6gA1i+IYwlqnPOV47dGoAXR0DWcXAJ57D1rWtYNzMo67c5wKz9EjLWMJXknI/wDHq20Xy4JSeCFbknGPloAjTEdvudgOnvnP/wCqul8A+B9X8b6slvp6PFajDPJ0RR75FX/hL8PNR+IGsiZoZbXQoXzNORtBxyApzzmvrXStNstA02HStDt/ItUGCyjlvqaAMHwV4D0PwVbxpbxJe6jt+aWQAhT7cV1LCW5IaYnB7U+C22gO68+masH5eFH1x0oAjSIKefwqT6Ac+1ITgA9aRgQPlBPoSeM0AK3QHj0xSopcHsPyojQscsB+BqfaqKzynYmASc9qAGqmPuj60y7VYkDynap4yKxvEHiuy0a3YtIu/ooJ5PvXkHjT4rSurQxXKHYCwSM/MeKAPYdQ8R2djES7K5UZ+UZ/OuP1D4gb2KwywrnnGQOPr614LqnjS6uo32TBYu4DHn68VhXOsvKEYqxX724nge1AHtd78QLicqIZvLXcASeCT6VuL8QyumWi4G75vMcHpj1r5tluWjxudDvIOCckD61utfwixtmyTKI2Aw3agD14fEeeeQ7doUNgt2IHpXRWXj3ZGjAZ3kPjB6V8/Wk0KpMJZWDgbkX1Bq7HqhENuQ0ZDEqN44oA+lLPx3AYC8uwqDjdg5FXU8W2koGASWIUBB1r5jn1p7dVVguMgjAOG5rSXxAqv5dvDuL4K+YxGw+gA60AfSOreKLTTUhMwKtKC20nt+VclrXxLW2fy4Vwo+UsOcn1ryz4qSajpUunR6hIFla3WQDrtHpXCvqAuI5CSWZdy8MOfegD2e/8fTPD5gmOcjGfTFcte+OpwspVy8hTIO44PPavO5b9zDBHuhCY4BbnNVrm5EFoQ0gMki7VxjgUAej2Pj26RCkx3QNkSANgofasKXxhMl66BsqSdjs+cV5+3nIQGkwgXlNv3s+9Rl3BYM2WPBx2oA9a074gSIm2UiXnk7xzXb6N42iuBseQZwCD0bHv2r5yEs8MAjLZB+YbR1+p7VeGtTQPGQAqnaCPWgD6u0jV2v72C2tmBaVsLg/dUdSa7USwRjyI33YGC/XH418n+E/Hcul3RuI5mWRE2Lk9ATXf6H8QTIVMkxL4JKdj+NAHuSOrHBYZ7H1oU84OM1yGg+JbXVIVW3uSspPAbrnFdNpt7Heh42IW6iGGXGN3vQBaU4Jzkj09KMBgRxSEHHpQDznHsaAK8sBySnBA9KZFeFEaK8jMlueGUjPH0q6v1qKW3WTJXOTxQB4p8Xvg3DqEMur+FxsmGXeJR7dq+cgJEuHtriJoriIlXSTA29Pbmvu63lkspSFJZfQivKPjn8MbfxBYt4h8OQBb+IFpoYxgSAd8dzQB8zzoVVioGD3x0+lYWvk/YUB5/eD+R/xrei3jMc0bJOACysKx/FK4s429ZB/I0AXfDig6TAMgH5znPbNdF4O8MXPjzxhZeHrFnVCC91MORFFg5J7Z5wPrXM6XOLbw1FIx43EdM/x8498V9dfs/eDh4K8BQXV7F/xOdY23E5x80cZ+6gP05/GgDvdF0ux8PaLa6HokAhsrdQo9XxwSfUnFacVusSAFfmxzSQRCJSxxuOOnQVIcZzkigAcnPPNHvg7aRjg8dhQe/BI70ABGecYAp0ce/DY49PWljj3YOOB70+7uIdPtGuJxwo49qAHTstrbtLLjI6V5J8QviOlkTDbSK5H3yDwOfT2rA+KfxJ80y2llIVUqQWVjkce1eD3l5d31zJKwlbIKjPr0oA3PEni6/wBUyrkOd7fvAx5/DNc60k/mTu7o0hJUZHOMnipI0WHCOqGRmUgE/d9zUTw+dOsqfNHn5z6YNABFaNHa/NEFDNlFbjd600+ZEPKjg/dKpJXrj3pbqWa4nNxueRfuLhsBRT4Z50tpREWyV5J5oALpGjaOQRkqw4bHGcUkUpAR5LfnPJrY0O6tvPjGvl205BuUjkhselQXLaaju1pFPNbPzDKx2gH6UAQuksheRcxRtgZJFWNkiwL5UbHyv48jG76VTmSQzhJ4nBZdyjsatxEQWTOA6hjgq1AEc08kcQfczc7sH0r2L9nDwY+s3jeKtURv7PgcpZIw+Wdu7kHsO1edfDDwTdfErxUtt80Xh+xKnUJl/j7iIH1Pf2r7LggttOsYLOxgWC1gVUjjQYVVHQYoA8f/AGi/DzXwtNQQrtEZjOe2DmvnZbYxSkNwyjjnrzX2x4r02PWfDs8LxLK6AlQfXFfKfirRZLOZl8lFKnaPY5oA5q4EV95LWiKrBSrxk8em6oLi1aaEoZFUwvjarZ+XvTjJK/yRNHEQxBKHGfatCNLW1nRbx4pJpeTHGeufU9qAOeuJlecLvURpHhADVRGDADdyeldLpmo6Lp13qdveaa1wrKUQt/D7iqaQWE0E0un2mZAMdeeaAKKu6xK8SOf7wXvUSiV2VmwUDenArSN0+nRLDD5YDKGkynQ1nCRpZQMLudz8gU0ASSxkxAoAqEnI7t6VZtri4sWIdWVivyDdzTdQQ2sTKJd08blguR8vTiobiaaZ50kYGR9u1m42+1AHX6B4ovLOUF5tsqtnaT2r3Hwj4r/tmJWV4o9RhUHAbiQDmvl9mYiJS8YKA5Oev41f0jWrvTLxDExQKAdwPvQB9t6Nfx6xYiZAEmAxImeVYVOylTnqOteI+CPHhkkivFdPOQAXCdnXua9tsru31OyS7s33IRyFOcGgABAPbGKcp/u00rj/AHvejGCD6dxQAskazADd09aqQs9ncc5KN95SOD7VbX5SR6cU2eETRFWJzzn8qAPm79ov4exaTNH4s0NZBaSMq3ESjhSeAf514F4q2vpscilcNIpGB1BVq+/rmxt9Y0q+0fUlD292rIQ4zgnp/jXwX8SNGufDOp6hoV6jCS0vMI2MKY9vy4+ooA2/gx4YHjTxf4d0aQn7GrPdXXAOI0Ytj2yQB+NfczD7ROH+7ChO0L0wOBXzV+xvosi2viPxC64AjXT4D6kne35fLX0xEvloQCSM4yaAHk55GcHpmjrz37U3njnPFK3PBBJ75oAUffH60qqWOD0700nLKo6HtVqKNQpLcIvU0ANleK0t3uLjISMbvrXz78ZPiVI6z2Ng4XEiqzDIxxXRfGrx7BBCdOsZTnHzFTyTXzjJJ9uaWSaZl3ys53jIJAJ5/OgCvqE811cPJMz7RySxJ3HAqxpdmGzcXNwltbKNuTxgnp19elNaRLGWQOFkabAUt0H0qoredLL5x3owyQOgx0oAY6qHYAsZAxGR04qfTvLDzQyuq+YCMKeOlQ2luJ5GEkxiRiNzkcHg8UmxYjA0Z2oFG5h3oAUqnlCEDese7JWrjeSIhDFGPLcDzSTzTbwRxySSbZfs5jGJFzg1XjJlhZwrKhXt2oAfuQz5dBsQfKn9asfNFpyIuAruxkz6EcU2BQm94/MkbAXLcCpgT5cRkEnlgM7AdM9qALjOsLJulZ4Qg+U9uKTw5o+r+PPEcehaEmATmW5YZS2Tux9eOg9aseHfC+sePdefRdGiMaAo91dMARApHf3I6CvrbwD4L0nwJoQ0/R4yzthri4bmSd8dSaALvg3wvpngnw3baPo0ISKIAu/8Urnq7HuTWiW3c/5FPZjJk/ypAoIxjNAEkB6qw+VuuTXj3xV8O+TcvLFGPLlJxg169twelZPjCwN/oxaJFaWPJGR04oA+O9Zsjb5KRBQv8BH3azbiIpiURjzFKtx613/iTSmea4keL96TtLZ9/SuMvbXYxRpWCjglv60AV9UiEttHfqgUuyq4NVNFmkj1c7AFRwxz/dxUtvcGyjcKu+Nn5RvmGK2LPw42p2dxqdg6G2hjLyRhuaAMi+jaK6BSMujnlwfxqlbKVut75JiBYn6mtvRpotUtBHch4ljOPl9RSapp9hp8WAZZZXXG3P40AYwIjuHlfmNyO3Tmpr6wms1hnkA/0hfkGeoz1qvdwmTeoG1WYKB0PNXb7U57rSNKt2VS9i0igj72AfXvQBXtYibt9yg4Gcnuad5rJAWJRWYFtoGRgmrVrf7tLnd7eJZkOzjq465qtH5V3bp5cMUcy5JK9fxoAuaPqNxp07SRugRm5xx+GK9t+FXxATT74QXD4s5j86txsNeByeQhVSeUIDY4qxpmoG1nk3sT5q8gt78UAfdrqjxrNEdyMAQetQgHHJycda8v+CnjldSsU0q/lXz4/kVt3WvVJkwxHbOQaAI/x59PWnDPUd+aaM8Uq8njvQBHIm2YOnXI6j3r5l/bN8NrHPo/ieAKBdf6HcFR1dQxU/lkfhX0+uTt578cZrw39sN93wo09SRka1EcDtmGf/69AGz+zTaxWnwU8PtEAHvJ7m4l7bmEzRj9EH5V6tGAkSoC3AwN2c+nP5V5X+zWxf4R+FUzhVS57f8ATzN/jXq55JyeOnSgBASG9sUmQT7UvYc0o+Ztvc0ASQKc5OcZwK5j4keJbfQtAdzLtLHamDjJrpNTu10+yaU9SMfhXy18WvE82uazNCk4MForDYQMZNAHD6tdX+uapLc+YzB3YgMe/Ssm6SQRNDibCtkhjk5xzTnIhYGRxtCEEIMY461L5iI7g7pHkGMsMlQf4s0ARWz75I43LOrDaQe3FRpE1vIGtx5uWZQQST+VShbS2jife8z+btbjAFS2t/DardSrbCSZUcoyEYByKAKclpcs7xrDKVVRgAEdfUVLcaRqDRsBAeIgOvTOeKtT6zdyWighAC29ygB52kVnvNcsreTdyoApB285IyOn40AdnPYzaf8ACSO7vLUTXKOFfA521zAnS704NdW5jKLmPy+h+tdP4X8VSHS5NC1uRjEYCYZWIByByOnFcmswWdZAr7V2ZXqDycnHagC1psJlilO12jDjezcDFPP2m9vbDRtGR5NRvH8qGMHgMT976AZJqZyEhjVC4hkJYqemOxr1H9l7SLfVPHWt61Ltd9NgS3gBHAZ+Wb644oA9y+HHg6z8B+F4NOtz5122JLq5OA00ndifQdB6CuiJ3duT706dyWPPFRHIGeKADqTgZ96UmiigA4645p2AylGBOeMCm0cFTz170AeY+PfC8TbrqKPHzZfANeE+KdPjgziNjjIBxjPPevri8gjuoHifoRXiPxI8MvbwXBCgqjb157EUAeIPbC7hdIwikY59av8Agu8fS9ZaGVWS0uF2SKzcMTxVO2VUZ3IVSDjmmXdt5kLXMTGSZMEcYoAtvph0DxNJ5RQWVwSVJ+ZcH0pmtsGv2OBtxtAauv8ADOowT+C9RivrKO6uosOrnqKwNZFtOIJBZtEGXG3fk+vNAHNSBzwG5yMn+6OwotLWSZlSMKzksSSfalYmS/EccRQGTgZrUuppLSzjtwQsjA72HUCgDHEy28bxLGjljhj71InC3JSVcyJ0z79KYg2h9oRsc5A5/GoguUfnJZQMY9TmgCRLco48xiA7DKjrj2otVMhlRgTIgJwRycdc1HDhJHVlO5MEAd6t2CNbLJOsQfem3DdqALfhrWJ9I1e3ljfZKrDCjP8AKvsDwD4jj8RaNCzyI820AkcE++K+MWiZlUxrgt1GM4r0f4S+LZNJ1QQvjYzcEnb3oA+qCpDYPXGRTcg8j602zuUv7OO5jIG5QSvXk07o2c80ACcHivB/2wpd3w1sVwMHV4SP+/M4r3vkn5s14D+2HH5fw/shjg6rEf8AyDNQB0X7Osgi+Cvhxl4lIuFXn1uZa9MgvWJCuMEcZrzT9nOAf8KV8NzF+n2j5T/18y16Oz+Y6blAO4c0AXRIzEAnIIzVuzTKs5xgnrmqkK52oMBmPH0xVLxPrS6baCGHb5p4A6GgDg/i94qNpCywycBigwepr5kkd7iaa4cBDcAsWbkkg9Me9db8QPEMmr+IFso3YSoXUBR8p55/GuUuDGkrq25poyANrH5fWgCK8D4VjvEEoJC7OScCnJbzN57RRTFzyQyfLtxgYq1daldfu4beQIgJ/eMOhHTFUheXMiSvLcSNkbDk9e9AEe1UEXns6FCTw2STT3YTCV4nYxhPlUjvuFQRohKyO5I27sEcsc9KUs8MsYjYA+WAWHu2efyoAfbbjFcFTgeXIGz1GQBxUShVGGdo4yMru5zVyd4Z7IfY4jGArPLk/M545z6VWSZiqKx4QE8D1oAlmV8C6Ujdj5cn0FXj9knugZGaCUFFcdm+WoWtZf7GlmTHlmQJywyeOwPSmxxiS9BmJCOFHPbigC5NC4tIz5uI1BAA7ivXv2P7kve+MoHP7zzYpePQqR/SvJZEjk0eEJxJFKcr6r2rtP2Z9Qh074v3VoXZRqNiwVfVkbPP4ZxQB9WyHDNyc03nbxUk4w2KjHTuaABeRQajZvmIBUDvxUnB5xg0ALyTR160fw+xpB19u9AEDEg56d8Vx3xhtHk8G3F1BCpkjAZix4Fds4yvFUdcgW58K6rBIpKtbuDxnsaAPiWKZpvP3DMjPn/dxRp7mG6AYswm4Kk/xetQ2U0r+Y0Y3DeQOOwPSpp4w7pMAMAZagDX0K6Ng99HM37qdTgNypqK/kAsopCeM4Kk1k3l4FhkuHcDrhFG7J7D6Gvbrj4Q2Nr4Pi13V9UeSNYluXtxxGMjOAR9aAPJreytLCP+0dScsjrmFF65rFnlW6uJLh0wjybvvdsYrf1i0fUr/wA21ZWtETEabuFA6EfWsSa2NiMXOAzE4jPIz60AV0TdGzqHGAwAPpioVVVEqN96Qqm3Hccip4J2MNwFwvrimW5gW4ld3wUAx7GgDWWyisLRG1KIi/mKtCi/wgDqayUMksm9zhmYgFfXvVtrkXyym7aRwMMGzlgtVdq25WSNjKrMdp9v8aAHwxuJBvEiKATljwaltW+zTpLlQrk7cN3PtUCXTiRFfeeOB2NTGKOYZjQGRTzkdKAPpr4JeJY9RtBYTu3mFeATzx6c16ZKriZgowqn5j9O1fI/wx8SzaJr1u4deHGQ3YHrk19fWk8epWMN7CA0cyBuD6igDNku5BIwRRg814j+11J5vwv012GH/taLP/fmavb7mHyZTuU89DmvD/2uEjX4YafsyW/teLJz/wBMZqAOq/Zu8x/gt4aQr+7H2jn1/wBJlr0wRgZUKOv515l+zYhf4M+GxuOP9I47f8fMteooCxHGPegB8ksdlaSXUhUBQcZ9cV4T8V/EwW3ky6gydAh+YHsa9M+J+qR2NtaWRkClgzMOnY4r5W8X6n/at/IX3BV7A5yB1/GgDMWdoW+0QOVnVjljjPuarOXXeSwI3ZbDDknvVhrKVo55bSFjEvIZupH0pFkE0E4WIeYvSTsKAKcibVZG2lfvDOKaMqoU/dyWyPpUjBZZEXBEiEbgTSzq0cnyrtjPYcg0ABOYSqZIwueOenamyIm2M/NlQFYY6cVMzyraKyhd7tgMO3BpIHm8otLmSMgZGQO350ALalI0ZY1D7lz83bmjcFeIgcOMYFGy2aM7ZHhONvzc5yamjtrbeoe7jjjTGO5PBoAURtLb4JBVW3eWW4poMaGNZQVI5XnINRX9qkEfmWd7ESwwqMeS3uTXv/wP+FEWoeFbbV/GcbNePIXghDfKkfv9aAPDkk3XE75JQjkY6GrvgvURZ/FLwdc2zFZEu/KZBySrAg/hXfa98MbfUvHOq2WnXJt4ImUoVfG5fQHvivRvhT8K/D3hTWTq0yNdasFws0zbli/3R2PvQB69d4yMdarq+ThBk9BUsjB2zkYNeafHj4kH4ceGYTp8aTa5fsY7YSDKxju5HoPTuaAPS4oHG4kgZ7EZNRygo3zKdvrXxLpnxP8AGg1Bby81OaeR3zgZVQD7elfRnwi+KEXimQaPrDLFqboXhJ/5aqOuPcelAHpoOeRxQOmc9OtDROjYwD9aMEjpj6UABwQcd6CoaC5j6742GD9KUdc0+3P7wdMHg+9AHwhe2slpqWo2ezy/LvZcDPqxOasWVunluspfaFLN5Zyc+1dJ8abOPSviTfxAsqyOHAPHBrlkie3l3wTREuDlWOaAOr8I6J4e1Czu41N412EIVZQMD1rp/FPisN4ITw158ptIQImbdkuOw+leY2+oz6dNeeVLiYrhcDrzmk0xjq+vadYly13eTpHHH0AYHrigCX+0rfSL545C0SpGqCMH17msy5e41OQyQwTMZG3LuHJA4617z8TPBlh4X8MT6vr0dpJ5aBQ4X5mf0rx8eIZptOzbokG04zIMN0yOntQBUstAvTbyyXELRJJ9wHGSRVO5028hjeSXCwj5eCOP0qxdatqMyr9ou3bccbVHCelUmu7iS3YS3Ej7j86k9MUANWXGfLPVQpJIz1phZY498BYtgrk1IHjGBEzl26kio3RY955K44APX1oAsxssrYH+tQHn1qOGYtOrjJYqcgnpxVrwtLBFq8st3H5yLGxCerVEty04dJrdE67ccEDPegCKJzDdxNnaCMf7w459q+tPgDrS6l4S+xMf3trxyf4T0r5McgplVDDI+U+3vXs37NustD4ua0kkJW6gKdONyk8UAfRtzGrYzxt4r5+/a+UL8NdNxyTqsfP/AGymr6IlGJCD0NfPH7YMTR/DqxLEn/ibRAH/ALYzUAdV+zaF/wCFJeGyB82LjPP/AE8y16pEoO1iB0LflXln7NQVvgp4b+XLf6QP/JmWvTNSl+z6LdS4YFVIHr0oA+ePjT4ka51yZYVJK/KpLcD8K8fkl8u4NyFDsXyM8L9a1/GN9Leai8iq+RvJJ/EVhQsUVR5e9cDhj70ASSXMjIZDMwcvwQ3yj2IpC0D4hYmOV2BG1uCc05VhkSYmFvKIGSTkKasRfZV8pHjhcp824Dkj60AUbxJoLxxJGBhwcg5yPWnyBlmCdRgkgjsRmrMmst5yeXaK0a4ILdSOOKlfU7WZV+12Z83cNsiH7o9Md6AKUqo1lHIoZdhwyehxUaIv2cuql1zgGtu0g0WfTrhbWa5+0swKox+UVVbT2ux5cRWNt2ACcDOBQBnBcxiNsYHXNEoSKHEnlqWOV461u23gLVtQtgTqGn24bP33yQB0wK2Lrw1oGjWyHWtSN3cFBlYl+UkenpQBwwgS6PmXAzBGc4QZJbtXfzeOviNqXh9NNg8vStKIEfmop8zZ7VmJ41hs7crougQgq4AMoGTjuast4n1bV7YXOqrFFbLkJFAMUAbemeO4PDEFvbakBdbBkGJS0/1zXqPww+Jun+K9Sl02yuYBeYMkVvdJsZgPfua+d0Qsd58rLA5ZuWA9KfoV6dE8SWGqW0akxN94pjg9cUAfaH9pahaSEXmkkqGwHgbcMeuK+df2tNXi1WDSkgtCrW0mXeZMEKfSvVPBfji/1BIpFmhmtpATtYcp+NdnfWWieK7BrXWbC2uo3ABWRM5+h7UAfB9tMksACuGGBk9KTUJb21kgudOvGingcSwunBRx0Kn1PQg19GeKf2ZdFujLN4U1i5064Db0hm/exKfT1Fc74d/Z08SW+qo+tahY3FrG4IMZOSO/BoA9v+Gniq68SeGrOXVIoxfqiiVl6Fsda67t0ArM8PaNbaBpcVpEwZkG0nFaQyQDQAc8nd+GKeuQ3ykcGmU6Nip9fwoA+Yv2qk+zePdDmKjy54jlVUZYj1NeWXAcQ+aHURhdykCvXP2vwE1/wnORhSWXf/SvI9zMECAhFbGQR0J9KAMqbU/LNzKqXEiwgfMsZKgjrlsYFdd8FNOu9X+JOi62qjbZt5wh25Z12kE/rX094O13wPN4Rs7C2msWt5I/IlhZBlmx8wYeua89a50nwv4115jZy6RpcVm1vZSJhRIxA5UdfpQBzn7UnjA65q2n+GbSXy7OBvNuMj77kcA+w5ry1bWWexaK2IbI3bl/Kug8V3kXiDUPtMHmFol5kcDzCQDjNZeg3B0e6X7U5eJ25jYc+ufpQBjFZElKFgGj+8Pegx8ESOAXbJYehHFdP4p0e2ull1TTCzsFVtg6EbTnP0rm7YByx8po1XqrdhQA20TzZgjH5c4ORjj1prFELiNt2WwC3StXSYrUTRtdyMYuhK9hWhqnhi2RRqOmXkV1poY7wh+dD9KAMGNVSykmLEBvuYGCxqzbiOeDe5aNlVfvj72etRx3qzRrHHbkIj4Xf3/wponeQMJDvUnbs6YoAWRXGwtEpiH3SOhNdD8KL46X8QNHkiVyr3aR4HP3sg5rnA6xqkKB0iB3Atzhs0/RbgWfifS5Q7BxdRsSpwQPM60Afet0BuJPQ8V4D+2UoPwz01x/0Foh/wCQZq99mIMKPnPyg14J+2Rj/hVum+2sRf8AomagDof2a8j4JeGsDr9o/wDSmWvR9aQtoN4q4OVJ5Nec/s15/wCFJeGsD/n5/wDSmWvUHQTWc8bjKshyM8HigD4f8WCaHX5kCBCpk+XdgHJrN2xlWbcysMZQ4xzXWfGLT5LDxBNcW8TSb124PAGD2rm7W3jutquqCYngv6+hoAguFeG3Rdn7pmySMdaaSIlCkgFwQDxjrwKltIrn7Y8ADJHuIYjgAetTvfWVu0aQ6bDcgE4d2IwecmgDNi2NhGcBhxVvyl2pFNPGrByBkAHketTtewYd206MMTlPLOOfeo557eSLd9kQq3LEjkMBigCH+z72SRBYW8pYdJQMgnPtXYGztrPToB4iljinIPU/dHrVHSPE1zp+iTWFgBHESN82M4yAfl/Oua1Bp7m5la9LSgHGGOTjOQaAPQNN1TSbxfsFjJGL4jCFhzj2rnPENnfWF39muJiG2ZXzOep7etczKgtLu2uYT5eyRSrdCBk5r1vxfokOs2Wm3tzqMVq0UIJZlB3gjgD3oA89sNJuJZZPMCxWkbZaQHOABWzrKedpsa2qrhiPLPQHHeq/iDULFmgsrGV3t43CMQuDIcDNGvNbG9gtbacxQxIBnHK5oAzXguYJdzx7O2e1SyHasLooaT2bgGkG9GW3W6S4i7iQZOajfZuYn9zL3VT8pH9KAOv0HxiugXlh5UAMIBaZQc9etfS/hK/ttVsba5sihjdAeD0r49ZSYFTacjjb65969j/Zn1W5udVv9Kd8LBFvVRzgZ7+2aAPf0yp4696mWVvYg9s1BOSnQdM5oR1KgkFaAFl+bGcdetS4HHNQs+4hQOh/OpweBigBvenx88f1pB39KkgVVG8jAX2oA8D/AGub+1Tw9pGniGOW9+1LICRkonf6V4HDBG1sDI21WP8ACOcV6L8cNUTXvHlyRGGt4EEa57keteeyPsGVGEzjaaAF8PPLp+oEaZFI4klDSZ6BfX2r3JtM0n4j39qb67XzbSARpCsvKHHXHevEre+eK2kcGNS5ICg9BU3gy2ltdZm1WCR47hY8KwJBII5zQB0OraNpeheILxI5nnljO3bIeOOK5vWbyGe6SRVAAHJxwB6VQvH8/XLy6ld2eQ4J6jOOtNKho8l9q7MYzndQBp+GtY+z3vkzzbYJSAFK8KMDjNS+LEeOaMxIFspS26bdgsT0GKxZ4dsUTH+JfMyO3pXQaNcwarp40q+iAcDKSMw/MUAYELEsI0G5SoG31NWYZJNP/eWzJls71bgN+FP1HRLrSJUnylwgw0Zj/h471U1AK7CcMoUYGD70AXXuLbUkVGQwXOPvDhT9PWqk0ElsxEoJdhkeh5pkKnzFMvRSCgHGRWq939uts/aFMyj5Rt4IoAriCSErNM21ZAdobrVANKNTtAMH99F82P8AbFSyefIyiQs7DPJNSaPareeLNJsym6Sa9hRec/xrnj6A0AfehI+zQcjOxf5V4L+2R/yS7Tv+wxF/6Jnr3uYbEVRjCqFrwT9sn/kl+nf9hiL/ANEzUAdH+zQAfgj4a9/tOf8AwJlr1SEBTjOM5GT6Yryv9mb/AJIr4a5H/Lx/6Uy16smCcUAfP/xv0pbgSfvNjc/wj3rwXbERIsjTIynBwOSegr6d+L1pI5kTPBVjwOnWvnO9t3S/ZVdgwcbc8c9+1AEsSG5hhhj85DEfvt1cY9KzL6BICoMwkOcAKvetPS5fst6bm6f5lyhzn5s+nsKyDGwuZGC7oy5ZWHYE9aAEM0zRNCzZBcZIXBFWlt5Ll0UEC3UHcx6bc8/jU5trGytPtE0zT3LcooPA781FfX07xwBD5Ucg3FFHDeoNACX1ypYRjaLeNcjZxuYcD8KiRpLmXLK3m7lUELx26VC2BcELtchvlT156VuaXpctuz3F5MYHY/u4xkjGc9KAMURrczvBKXZC33iuDu7Cu7+Kd8tjoHhzSI5B9vA3zY5wuOAa5vSL61N0bgxSMsRLbugLfT8qp+ILsaxqJuSkgncbX+np+lAFjRVs4NTgWWFpGZgFPOBUfiDzBq9yrQyIC42sFzuHtS2KbrmBtu2SJCck9CKkttTuLqKdLmTlTxIBuFAFRFY3BeLLDH+c+9WEijmhTcS0j8NtPIp91awo0cttIbgyjawUbQp7mnkGAqXh2/Ku3Hc0AIsPlxOw2/IM5PU4r3b9lnw6LSx1jxBLEUmv3WNCwI+Ren614XpOlXPibxLaaLpYk8+5kBY9difxmvtnw/pEHh3QbPTLTPlwIEDdye5NAE7qGcsx59KUKo42nn9KQ5y2RilJ9jQBG0RA3IT+NMklMUW4kjNT9CSTVXVbJ7rT5ooDiUgtHnpkUAVpNWjj+RJFaTqRXIeO/F0enaXNi6WOXYduDg1w+t+KZNKeZbuIrdISrIPvAivKdf8AEFxr95LLO0hQEHYcYxQBXmkW6u5ZriU7nbfnPPPrWUbVHk+zKhUg53A5BFX7eOKZ5TubyzznPSoJpmt1VoolCtxuNAFdNNijJW9GE5Aw1b/hq7ZrS9CxKkaqVDH9PxrmriCR2jVVDtJkgAnGa2NLuv7LtLmOXaDOQMd14oAxf3U0kguHXfuKmRO/tSSwyKrqqqyKvOTjjtStb43+QquMliFOSKQK8srswfyyCePqMUAQusgjiUEBjGoAHapmEcewIVLDAZgOafb28xkEhCqjABmPUA4H+NLLDAHkPmH1wq9RQBNp+oXaMbZkSeHouflNMguYVgl86ELJFIFBxnJ68fSqzIgIWPeHznJPOKDFvhMfON4fPfOKAJLiCWacXUZBQnYP9k1L9kmZY9iqypzuB5qKKd7ePYCsis/Q9frTrZRFKFJYggtk9PpQBIPKdWQ4afoWB+UVvfBjTDq3xh0OGMKY7V/tch6khQ4z+ZFcy0bwsGUYBI2sBnk17N+yppZm8W61qjRKqQWyQAledxJJINAH0pdE78cZHIrwH9sn/kmWncHH9rxf+iZ697mbJJJHFeBfti5/4Vhp+T/zGIv/AETNQB037NJH/Ck/DJPGPtP/AKUy16spIcHsK8p/Zq/5Ij4b/wC3n/0plr1QcqvPPU0Aee/GuApYwXXPllSrFVJr5o1VlDtK0uVVjuwpBPtmvsvxPpY17w/d2Of3xUtE391h0r418Vxz2l7eW86EPFK0bIy/Nn3oAyWkAsjIIowWkBwMkgfWqscTO/OdinJPJH0xVi4mMqWkbKI41UK4NF5NHsjhgHkruIyT196AK0xV9zIwHIP3e1WjY3FyIRHlVwRlwAPqKZY23lMjytH5YXJ75qS2vlfzwXljhKEKFbjcaAJtQuLTTmxaNHc3OCvmE5CH2qqjXM1xFPPdPJIhBIzgAD/9dVLQFBkYcFgNwzkj1NXrj/R7IxCYb2feSq54oAfqLRi7UW7hbYZdCe59T+tVsBULoSm4/KwHJpdnmW0e1z8nzDPUjPSlQK6/M4CjkMAeKALNiQkNzIXcnyygcj5s0xY4xbOsJeCVFUlMfep88WAkVvKQwIIbfwT6mp3ZhFcKxDSMyjI5xj1oAIYyiI5/ikYHDU+MXNx5cKLIzBwiDGST/Wq9/OIrcM6gbjnkE8/hX0N8BvhwNP06LxDr0O67lG62gccRqejHPegDa+BPw7h8IaO2p6jGJNbvfmeQpho0/ujPSvTZH3MSefakMjMWLcHoBntTepFACdiB1pf50c/UUUAIOOnX3qSPG4OQMryMVHnrjORT1IyR6jFAHyx+0lpV5p/xJi1EhxpV9CpyinAlUHqenIrg7OWF0LFPNXABHevsnxZ4dtPFmgzaZeqBIAfLdhnaexr5G8V+H77wfrs+l6mgVvvQuckMnqtAGflHxCsTordT6CoNRcYMUS/Knep0JMZ3MAuOpFUJ1JlZhlvVk5FAEMoeHy5C0m/HylWxg1tadBb6jcW4uysO47S7cZNYDP5g3jfhVzjsDWq9u1zPpsJG2FR5jsT0oAi1rTJ9E1A2rBxCW3bhxkGoXun+zhEDbUU9BnJre8Va1JLrRIeJ4FjURpKmd3YjP0zWfDc25QXIhKyKcCJejUAZPnguiEF1Jww6YxzSJJuyXBAZCAAc89q14JLW58mKe2e2adyizoudjYzz9RVOfR7iN2aJVuIRkmQdcUAVxGGdwAN5Axz19cUH5nACjhTxuNRJNHvJjTcUO0kDpWncQafO5W3nltnjXkS9GagCnHGcKQF2ZzndSKoLliGYAbcq3SpTbsjRxu0a9ycg5/CmqkmGYqduCSCcZxQBDPNIQ0UaFpHOxYwTk9q+ufgB4TPhP4ewNcqPt+oObqfnOM/dHPoMV8+fDnTV1fX7O3t7VQzSq0kp5wuRkivsVkW3to4IwAiKFFAEUjnHy9Sa8G/bGXb8MNP/AOwvF/6Jmr3rHOfwFeDftj8/DLTztI/4m8Qz/wBsZqAOl/Zq/wCSI+GxgdLnn/t5lr1GPI3D+leX/s07T8EfDfTOLgf+TMtendRkccHqaALEblGB9+ffivCv2kfh3Ld2E3inQIPMnjUte26A5kAHDj3Fe4oxZRkYYdRnNTwuCCjfMrDoRx9KAPz5srgXjTTSDKu/Kqc/NjoKstFv2CTarAblz1A969j+OXwWksL258Q+C40MMxMl1p4zkN/fjx39q8WhuBJ5kbqRMo2yrICrKw6gg0ASlWXCRHC7SWz1BxzTztNmkPlh2bB3L2xmpYiDKWyFIU/w5HQ45pVRAgEhKZ/ujHGKAIp3227w7lWLZtzGfmzQ26SGOSPYMAK2T1pjLHlvuhMHBKmpIgqoQZF27uqqePxoAagEcOCfmU7iRz3p7fubba7bQzD+Ht7077OkeH81hv4AYYojUqVypyDgbhkNQA+FVcMEZVBPJ9R61Z2qLfzFUkynkBemKWQBZISBHEu3nA61DqF48OyCxd3vLg+XDAq5ZnPTgUAdb8EvCz+MfiFGkyv/AGVpWLm5z0L5+SM/zr7BuyEZFGAgxgAcfSuH+CvgUeAfBEdpclX1S7b7ReyDu57fQDiuynyY9xznNAD8EcZH4UD7wx61HB80e4A8ninkhQWz096AF6Hpye2KQsD3FQ7mY/eOM9KCB8uDzn1oAnx7mkPXjmo45A7bWyPepuQcbqAEL+WQxJ4PI9a8g/am8Prf+BIfEEERN9pMqyF14Pkk4cH2716zuJcoTwD6U/VNPg1rR77TLsZt7mJoXHsRigD4YhlSe23xu5VlB3Bd2RT8rap5AZnD8sp4Ap9/o1z4S8R6p4cu5G8yxfbGz8GWM/db6Yp8yxKCoYpgcspz0+tAGY0DzgxeWyoxwXIwB+NS62wPkpbO22NNjMecntSX6SznYuREBlVI4z9M1YtbdZJhcz5jEQyVJxv44P50AdTaadoOq6Q0OpSmHVFVfKUcYOOtcff2NxYXMkV5EFjDERPv6iqd2XfUJrlVb7QDlXJyVx6e1dnpeuafqPhi8TXrNp7q3OIiOjDHWgDk1lSNW8sbvMKruyeccDH51e8P3rWtzPGSy22zLqee/NZ0rCZsW4WGLeBGMfdFTrD5cdxIS+6TGV/GgC9utL6aVZkQY5QqdpPpVbUrdLOUeXCmEx5Z3FutVoYlmaVEjBULvZyOQM4/nTlJjbfM+YwR94dKAHmd/tHmkIP7wC8gU2aE3FytvCZCzqOnrTngLsNkmSSOFHPWu28G6E11qcYghWWRmA5PvQB6V8FPCkVrPDObY+ao3s7EnHI4r3G4Idz7d6yvDWkDRtNjiKKJGGWI7e1aTHJOBn6UANJAHQ5xXgv7YmP+FYad6nV4Sef+mM1e8SknCgjHWvCf2xf+SX6djp/a8Q+v7magDpv2acf8KR8NnjOLkc/9fMten4OP4c+leY/s1Jn4H+GmAz/x854/6eZa9NGOpHWgBqLiTK8EdvWrGSBz1Jqs+eDtyfrVhSHUNjGO1ADLyH7VCUIBbtzjNeB/E7wPZ3N29zPZrHdMxYyou0n/ABr6AAGBu6dfpVXU9Kh1a3SKfGVOQx5z7UAfGV7pT2kV0nJCgleONuMfyrGWBYdOghMrvLEDukY5JzmvffHfw91GxSaSzj823b+JOSAfavC9WX7FcFJfJD5KlWODxQBFdqbZgu7c7IMgDt6VNJaeTao0jnz3AKJjAH4VWivo1nedGjLhdrKxzz6ikm1CGS68ye5WR0KtgNyOO1AFmFJd3m3ZSW2UgOGPJGecfSppzFM0slpN5Q/uydAOw96qNfSXOIrSFJw3RVyCM85NdP4T+GXirxe2IIY7W3z809wpKoPVfU0AcrcX9zcXcVjZ273d9LgQQQjczk9OB2r6R+CHwhXwy8fiTxUBN4gdSYYM5SzU9QPVvU11fwy+F2g+ALRJbeJLrWGTZNfSD529h6Cu3ll4Z2OFX86ACeYDDs3y9qzw010+UyiDjNPSN7mTzpziLtH6VaDchRwB6UAIihEVAc4qO4J3KucAjNSHknkU2ZSyAgAle1AECspUg5P17U7JwNm0GoN5LMG+X3z0pMgA52nPPrQBK5YK5zzkYq5kY+tVNhkAAOATVtuOBzjigCvcqVcyoc1Ytpg4Doe/NAIUfMOD2qpJBJCRNalSByynuKAOC+OPwyTxzpSajo3lweJrJT9nkPAmXvG/qD2PY18s28twLiS1v4ngv7RylxBMu1o29CK+7bS5SaMPHxg4II6GvNvjF8JbTxwn9r6PKLDxLBGQkygbbgdkk9vfqKAPmOaMu+6KNBKwySf89aSYGCMQwsclDkt82fakuvt2i6hLpviSymsb+EbDGy4Xry6+oPqKWGVZJiA444wPTtQBDKUlG/d8wGee4qHT1Iju3BYy+XhRjjOf1q7AhIlO5xhT/D71LGWWBo48GVFJBPQ5HSgCvbXFrMPMvbMs8eOY+M+9NWESTeZbXDbGwpSQ9Mnp/wDXp/DOjx4LH5WB44xzUbIEYKBjDAjjOc+9ADGty25gVQMBH1POGz296S5gjuLeaGSXyiwAGzJz+dMudRRW2RK0kzthfLQt3x2+ldt4K+FvirxdcxyXO7S7ByGLyD5yuOwoAwNEtJ9U1ZIbWCV7iaTG2Mc4x6DpX1L8MvAsfhyxjub5Ab5lyQT90/41r+CPBGjeC7FIrCESXOAHuJBl2P1roZHLnJ//AFUAJI+5vbPWmMdq549qDwMtwKjY7ieKAEI55GR9a8K/bFwPhjp2B/zF4v8A0TNXurdckEA14Z+2MCPhZpxJ5OsRcf8AbGegDpf2Z32fBPw1k/KRc/8ApTLXp7x8bkJKnmvL/wBmnj4I+G8jr9o6jj/j5lr1GFuSpHXkGgCPac/xYxxxSoSjHJJzxjFSNGDkrkN+lR4IxkYx7UAT4z06UBsfhUUZKj5fu07eucHIP0oAsJM2AGGQeMGsbWPCnhvW/wDkK6LY3JYYJeIVp7lPRlP40p45JAHuaAPOr74FeBLsgw6e9qRnAhlIA/Cqtt8B/CltISkRdTjhznpXp3mqoOGyfQU4EkZx9OaAOb0X4feHdICGOxhd0GB8vFdOhjhhWGBEjQcBV4ApnzccU0kLnOTgUAOyWJz2qEfvpTvH7tegBpXbeCq8A9c8U2NPLI2n65PWgCck8nPFGMHJx9TTS6jkEZ6YNRHLEk5PpQBOF698j1pQcHrk+9Vl3r3Ge/NSI+Rhuo75oAbLbRyMGOcnilS2iBHGMVKSQQBgjPJz2pOv1oAXG3j+VAx60AhR71EZJD7HtxQBLj/Z6UgJUg/yqIPIB1FSq2/PQEdRQBG8eyYzxEKCPnX1qaOXIDKflPI+tI3yq24ewzVe1Dxlo3IKt0oAzvGPg7QPGtj9l8QWMc+0fu5RxIh9VYcivB/FvwG1PTLmS58PTvfWPO2ENiRfbngivpHoN2aekxXvmgD4pvPDut6fLcxTwlCMgqAcge+aqx6RqrsCtmrELj07Cvtu5trO9Rlu7WGUN/eQGso+EdC370tyjdflagD5BsfC+v6nKEhtordnOASMgV3Hh34Mz3U8L65ePICMlIwVUc19GQeHtOg/1W5cfSr8VvbwY8tM445FAHD+D/h9oXh2KP7Dp0QkAP7x13beSc8967uArChCDn1xTeAu0AAA9BR6CgAZt3OSfc0jsEGepPSlOAMmoGbfnGQM45FAAxZyCemeBSnqRg/QUA84OfpipAp6tt4OeKABE53HIP1rwj9sdifhfp2B8o1iIZ9f3M1e6sxYgAgA8dK8I/bF/wCSX6cS2SNXiHH/AFxmoA3v2bZJIvgr4dIOYz9oyrcAf6TLXq1vLGxUk7SOMMMV8qfBb47aX4N8FWPhzxDo+oTxWfmGKezVGb55GfBDMv8AePOa7R/2kfBoyE0nxIynput4Mj/yNQB79gdec9R70nbmvBo/2mPCSY/4lfiPA/6d4f8A49Uo/ab8HkfNpPiQfS2g/wDj1AHuZRT/AHh9KQpkdT+Irw3/AIab8H/9ArxJ/wCA8H/x6g/tNeDx10nxL/4Dwf8Ax6gD29ojgnA/CowATnByO9eLf8NNeEQc/wBkeJcf9e0H/wAeqJv2lvCLEk6P4j/C3h/+PUAe4A8jO8kUoJySQQD6V4aP2lPCPbR/EmO/+jw//HaVf2k/CSjA0rxL7f6PAf8A2tQB7mGJXvj3NIF+vTvXhw/aV8JDH/Ep8SZ/694P/j1H/DSnhEddI8S/+A8H/wAeoA9vQ5ZgRkA+lOwB2H49q8OH7SfhHn/iT+JP/AeD/wCPUH9pPwkP+YP4k/8AAeD/AOPUAe5ZHI5/OkwCT1/HNeID9pPwkRkaN4kx/wBe8H/x6gftI+E+g0bxN/34h/8AjtAHtygg9T+BpeCOrEfQV4kP2j/CuSf7F8S4/wCveD/49T1/aN8McY0TxNj/AK94P/j1AHt0Lbl5HIpzsVUkLk9q8Sj/AGi/DKbs6F4m5Of+PeD/AOPUj/tGeGGIxoXibr/z7wf/AB6gD2gKeCVXPfil2+34ZrxQ/tFeGc/8gPxN/wCA0H/x6j/horwwBzoXiXd6+RB/8doA9q79wfoaONx+YhuvSvFf+Gi/DGf+QH4l9/8AR4f/AI9QP2jfDA/5gniXHTBtoP8A49QB7UW5G4M4LY+n19qHVMYZExnqDXin/DR3hfOf7E8SYx1NtAf/AGtTJP2jvChXDaL4lA7/AOjwf/HqAPbkEsR4UhT2qQOT95f5V4QP2k/CKgAaT4k49beD/wCPU7/hpbwkAT/ZHiLA/wCnaD/49QB7ucEjaRRg14Qf2lvCJP8AyB/EYz0xbw//AB2j/hpbwiM7dI8SD/thD/8AHqAPdwCM8UmDXhI/aY8KDOdK8Rn/ALd4P/jtL/w014U/6BHiH/wGg/8Aj1AHuwz0H60jsqLksM14Sf2mvChH/IK8Rj/t3g/+O0wftLeEc5Ok+Ix/27wH/wBrUAe5O5kOWPFKoy3yYI+teHr+0t4O6nSfEh7/APHvB/8AHqk/4aa8ID/mD+I/wt4P/j1AHuCKIyWY9uTTHbeevA6CvEH/AGmPCLDA0jxJgdc28P8A8eph/aX8IBh/xKfEf/gNB/8AHqAPcMEEDOB64rwz9sYEfDDTsn/mMRDp/wBMZqc/7S/hIY8vR/ESj1NvD/8AHa8y+PHxa0b4geEbXS9IsNWgnivkuWa6ijVCoSRTgq7HOXHb1oA8XoHWjk0oyDQAfL6mnBSBkfiTSgE8GnAY7duc5NADdpHUfjT1TqBnp1pyR9MjFTpDxkHk9hQBCIixHBPr/wDWqRYD6cGpwqj0z6gVNDBPO22CFn3HqBgGgCqITzuPPTigonriuj0/wdql8Rungtt3Y5dsfhXV6b8J7OVN9/qt47gcrEgRT7dKAPMD5fGT2796ie5g5LSD0xmvbrb4VeHYoyz2V7cso6PKR/I1t2Pw98PKkYt9Bg8wdWk+Y0AfOL3sO77wJPpmrMEGoXCq1tp17IvHIiOPzxX0/a+FhDlbfSrSBAOMRAf0q/DoU8/yyTNCgGAFGBQB8yW/hfxPcAGPRbhVJ4L4UD86uQ+CPE8pIWzhB6HMlfUcHh+xESpPK8hHT5sGrrRaZaQsTbqABye5oA+arT4YeJ5MM72kasPUmtWD4Ua/kJNqNrGx6KFyTXu8MvnYSzh372+VAMk/Su78N+GorLZd6iitdYysZwQn/wBegD520j9nHxRfASXeu2tpEw7RFmxXRW/7L5IAuvGF0R3EVuo/rX0Y855x0qPzG9aAPA1/Zd0v+LxVrB/4Cn+FWY/2YfD4X954g1pz671H9K9y3tn3o3t2JoA8U/4Zk8KbMf2nqxbsTN0pj/s2eHo1UQ317Kem6R+hr2/ec9TmlDnjmgD5w1f4DDTomZIZLqJf+echzj1xXMyfCXSbr5YluEfGGTzDla+uEmbvyK87+KeiyWluusaWNmGxOijrnvQB4I3wS02ddqT30Ug55fOfpmsyf4GncfI1K7TJ4WSPJr1q31K9iBMkbMhX5SBz/KtGPW5Hj+cMHXoCuKAPCJfgfqo+W11mANj7sqkGsrUPg34stE8yCSxuV6fLLhh+FfRs2oxyIftKqrHpgVl35Rl3DeFJ52nmgD5n1DwP4r0/JuNIlZPWPDCsh9K1iLJl025XHfZ0r6YuLGS4AENy5BORvftWTNos+11WQEnJwx4NAHzw1rehfns5x9FoW3usf8ezn6iveU8OTDKuqgsM7ic4FA8JRTxjzdic4OMigDwbZMhw0LqR6DOaQhx96N8DnOK+gH8FWsYBjG4jr6VjX/gfzVKqUQdQAuMUAeMjlsZJB7HNLsBHHIwMYrvNR+H16sReFmYrnBwa5DVNL1PSmH261k2DI8zbxx9QaAKJj6859MUhjO5v7tSJLHKR5bZJ9qc8bI3zAjHINAFMdaeOuCDQBz0qQd8fhQA1QOmM4OPeplTOMZIpVXBxjv0qwiH7g++TjHf8KABYwoLHGe+ece1TrG5HIIUnqR/KrNnZNNcLDEgmnyAEAyF/xr17wN8NZ7ydLvWX2oACUK9vQUAeeeHfC1xqmPJgd3J+8y8V654U+F0zQk34wuMEAbea9T0jTtO0uKOG1iUIFwSF/KtdJxsz8zMPQ0AcxZeBdPs413hnK8dP61spoVmsaZjBC84x3qcTqE3OSMn1qtqGrxwRExgN680ATvYWqgCGMjaMkA9ailijCr5aKX7DuKzbPURMhkyqsfmbcegrhfG/xf0fw35kSbbu/HAjQ5/OgD0+3sJJ02lQq9SxNUdU1HQ9MRkuL+3VkHKu4r5P8VfGXxXr+Y7e4Njb84WHrj61wN1PfX0hlvLuWVyeSzkmgD631Tx34fVJTZ38LOM8AjJNTeEtSg8UMF80oQSNvrXx9HaMpDq20joR611PhHxvrfhjVIbiKcyRhtrKR1FAH3/4c0q1srFHgRTJjG7HIrWaMscnj618u/Df43Xk/jA214CbOVMlCeM+oqt8TPjnqUGsTxaV5kcSfdWgD6naErycAfWoyu3k9K+PPD/xw8SahrOnWkm+aSV1TZng5Pavr+B2/s+3e4CxysgLLnODjmgB2Pxo6dTUDXiDPIPf61Vm1RBkbkY5xj0oA0scUfjWOuqrgAsrH0q5BeK3XHrQBowJk5PQV89fF74/adp2rT+H9MtnmFu5S5lYAgkfwr/jXvmq30NloV/eSyKI4IHkZvQBSa/Nvf8A2hqF3eyAl55Xkyeepz/WgD6A0D42aRd21xaXieSWTKMU7+ma8+1b4q3cd5OlqrOCxGSccdiK8+ngjL/KBjHpTQiqcgDPqRQB1/8AwtDVvMLSRl88Alua0Yviq+zbcWs3mHhm3dPwrz/AxggGmbFJyV/XmgD1vS/G1tfKPJlUTHornBFbum6/O0wFxtyp6njivBHhH+sAIccjHr610GjeLLmyiFtf5lhbpIPvCgD6H03W/tS4RIj5fXjnFXheQI5MgVA/TjpXmvhbUrcQi5SdZYjyNvB/GvQomi1G0ilMi7W4G1en1oAvwSBtpWYFT0GKbKkv2gFCWUnkkdBWPIk2nuVDlo2HBArUs71BDHHdSPz0IGBQBM1szIygnHXGOtQSW1tcp5NzbiVW4ZSvBFXlnhdvJyxPTipEtpHOETy41OCS1AHmfif4UaXqnmNoUbWVwoLAZ+U15Trfh/WPDs7R6rZs9uP+WwHA96+pRbqko53YHzENwajuYLS/j+y3trHNAcgqxzgfWgD4/FTIOAQOegpnAPtU0Q3MCeMcmgCZSFB2gndwB6nNbGl6Re6lejT9NTzLxyBI4HEYz0zWfZERlpuP3WFRT0LHpX0X8KPCsOheHY7ySQnULn94zbeQTzQBL8PvAen+HLBGuszXmBklckGu4ExEgSNXKAcACs+WZ3cks+4cZxg/U04vIjKP3mOu4cigDUjmSIfvNwJ/Dmo47x3/AHXTuDnmsu9ulCEqQyHqC3OapxfaJJWli4wuPoKAL17qJjDoVZiOODmuennEoEjuEUfMdzYrSTSpYrF7u5UKv3iS1eCfFbx5LdXD6RpEwMMZw8oHJ9gaALXxK+JUzO+keH5F2AbZLhTzn0FeURwtIxlncmRjkluSafBCEGTy2KlPseDz0oAaoVTx16//AK6ceecge1JnPUYx0FLt6HI9KAHKNo5yR04p+0EEHj0HpTQcjofYVNGu4kLz757UAS2m6C7S5iYh0IOQcEird00l5dSXFzhmYY70kUfHHQU+G3n1C5S0sF3SscF+ye5oA7X9n/wnc+KfH41BVCafpQ82WZuBu7Ae9fU+oahMrtGkpdexNcT8F9Kj0PwcdKsYl3M2+4m6NI/r/SvQILMZIZV49KAMYXMzHD5BHQ7utSO0nUMhxxtxzWtPpsW0iNcuf0rMvLS4tQGRw49GH8qAM2R7pWO1mXA+/jOKSO5vUQlZ5G9+1XYJC6FmJRv7pqhqV5IIioHPUUAZ/ifULoeDdXgRpfNe1k+906GvjfSwPso2gk85Ar7BMv26zura8UmOSNkye4IxXyFHF5Nzd2yhh5Ujx/TBNAA5GeeQKiPA/CpZTnPf/CoyDg46UAMopehNJQAY69OOtNdFYY25HvTj1fHc5FAGaALGj6vc6FcK8JL25OZIux+ma+tfgnNonirSpIrS5yzDO043Ke4xXyDLGSpHGfYVpeC/FGo+CfEVvqenMwCMC8ZPDj0NAH2nrfg57RskNLbg/LjtXL6v4ankgAhV/JPzZBr1rwF4s0vx14VttV0yZJY5VCzRg8xSY5UjsazvEOny6ezSRBmt29OdtAHkcljPbxoUQ5Trg8mtLT594O5GY9DvbAFdiEhJGUUgjnis2fS4z5mAI8nj3oAyQUkjIGz5SOB3qwYHEzZCqoGQSetJFphtJGeMq6t1ZjwtOndkuxu2smMCgD43UDGDyO1WIjggYzjj0qsDkjgfhViIjdmgDofCVm2oaxpsAGQ91lsjOcV9RJK0FtHCQcIApGMYwO1fOHw0dV1qwYoxKSMeP519EDfcKDHub5gfm64oAdAyyy5YkgDODSmKQ/6qR0GfWnQxMFcugaTPOBU9rFG24kkFj0J4oAjSwWFQ0hLMec10nhTRBfK7PEqW27I/2qp6Vp02pakkMS7EjPzkngitv4qeKbP4efDu+1F1BcJ5FvGOC8rAhR/X8KAPBf2lPiLb2Ex8NeHpFaZRtmkXny/Ye9fOFvAdpL53Hnkd6TzJdQvprq7cyzTOXdjyST1NWM4xjHvigA4785GKQZ70p57AUDrQA3uTT1wSAc57EUEe9A6dqAHqMduh61dhXA5B685qqgzkn1qa4mEMLHuOf8+9AGv4e0bU/FfiG00LQog99cnG49Ik/ic+gAr608BfAvQvC1ipvZ2vtQbmSVgApPsKy/2YvAaeFvBy+ItQizq+soJASOYYP4V/EYJ+o9K9hmn35yQfagDlP7I/sqXbbn9xnoO1acWFX5JCAfWp7l9+4ADj1NY6eYs5ClcnkEntQBrhs7doDFjg1JJCXbDKAM96ihUlcso+q1MHVclic+lAGPqWlrGZJEYknqMda52WKKScqAwGeRmu53BgeNvpmuK8V6fcR3Mc1sxCn7+0UANksrYQtLOFCJyK+Svifp0WlePL37IrC1u28+MtwMnqB/nvX0VqeoSNcLCrSNHz8n+Ncj8VPB994n8Mi60+APcWIMqhR8xGORQB4FIOCScg81DjjtzS203mR7Wwp6emDTpFCkjnIoAhKjOMj60mOacxO7pnI4phPYAAUAAopvNFADwcEVHJCHTmnbQBjdn2zTuuMnnvQB23wN+JE/w28YCacSSaNeYivIVPRc8SKPVf1HFffMM1rq2mx3FtLHcWlzGHSRDlWUjIIr8yrqHeMjrjNfTP7HfxA/4+PBWpzMW+a409mbgD+OMf+hAfWgD1/XoBpV2UmYhDypx2rPn82RBJGpMbD7xOAK9E13S4dUs5IpY1aRRlCe1eU+I2vbPQ9QfymBi6AUAWHlXzFjd4wfyFR6jqmk2cLy3tzEoVSW+bpXjmu+IboWEEkUm2UrllJyRXMw6qtxY3X9o/MroSvfJoA83VWJBA4qTdsXdnAANNBAAGRx1JNOjiM00UI3DL4J9B6nNAHo3wv03zdTs5Hyrbc+3J4r6Kk8mOPy45MttHK884FfL8uuyWGkyRWLlLlhtjIHIWofCnirxBpdy7fbZpkPJVueaAPpxGIkb52C9yaga/jN/Z2EZIkuHCLx6147N8Qrq6jK3KsjkcnoAa98+DOiJqei22t6nCJWHNs7gg/WgD0fQdJj0u3CgZlI+Zj1r4r/aj8ev4t8ey6TZTE6RpDGBFByrzDh39+flHsPevrL4x+Kx4L+G+sassmy6ERhtecHzX4XHuOv4V+d9sTJK0shLuxJLE9T1oAswp5aDt7+tAP3eMZoORg49qQ9B7UAO49aVSM8mmHGfwooAlAByTkH09qXHAPQEVGpP9KkXkL7DPpQA+PlvlyT79Kbqpb7MeMA8HnHvTzg8YOCKS8UzWpH69aAP0X0Uxf8InpHlDEZtItgHpsBqo6yK+5E4964/9nfxbb+K/hZpsKyBtR0uMWl0jfeUrwrfQqAa7t/kbadpXtQBmh/McqwUOTzVO+j+ziORhhd3JPatyOyScBlUBvpWX4wsZj4euI4JlinYYQt0z2oAvw4ljARlwR1FSbcEgnp7VxXga41HS7Ex6/Gu5jgSZ/pXWNfRSRAo+c9MDmgCQszE+nqagnVJYGBywbionlZn+VzsHTI5NQyy72VPnGDnjigDgfFOlGyvDKMqjeg6fjVW21oaY0QRpGjb7wJ6+1eh6lZQahbvFMjAbeCeOa8puLMQa/JFeswtVz8xoA8b+Ofhq10HxLbatpTBdP1dTL5WOI3/iH5815+TvX5jnPFey/tBiGfQdOa3KNHbzYRk6gEYrxhAQo69etADW69aaetObqaYSM0AFB6UZ7UUAKCB2GR0oTsPwpKBwc0ASJ93GB+PSk0vUrzw/r9jq+nyFLq0mWaNhxypzg+x6H2NCtgDPIHQelMuE3xEkj1HNAH6P+CvEdp4u8JaZr2nspiu4RJtBzsf+JD7g5B+lc98Q/D1/eSR3GmSots/F1G56j1FeH/sY+MTDe6r4PvpfklBvLNWPRhxIo+o2nHs1fUt9b/aLO5g/vIQPr2oA+MvGWgX2kancM8atCc4ZegFcnayxrFKjx7mKnbnpXt+v+MNNvLTUdNvLUC5gZoW3JjDA4ryu3tUurkw28fTndjoKAPMGcKwABYnoF5JrotD0SYqJpWCu3ODxgelX9G8Mm2lZ5oJHnTndIOF/CuktrrSbG8ie5mWUg5MbHH4UATfDHStD1DUb2bxFM8SopCIARxTLlNOQXEdtbEEthSR1Gan1XxtpE8qrpGiGAgYZ+ufel06KbWpPNjhcrnJAHFAEGheB5/EfiGwsrV1UTsA2f4V6mvtLSNPh0rS7TT7TIhtoxGvuAOteQ/Azw9aLqt7qmMy2yiJefuls5/TivX7+8i0/T7u+uDiG3iaVz/sqMn+VAHyT+2P41OpeJLPwnaZ+z6die4ZW+/K44XH+yP1NeBQoFjAABJHOOfSrXiTV5vEvivVNZueZLy4ec8Y4J4H5YqHdjHX055oAaxyR/Om96U0cUAGOc0UUUAKOjc44zT8nIx7VH0p/RuKAHoRkg9fWrCYYbcHJ44NVwBt96ljZcL7cmgDpfht4rvPAfjK21K1neOzmYRXcefleMnqR7fn+dfXFj4s/tryn0vy7hDghgccfX1r4hv23QFQuWb5Rg8+gH54r70+C3hmHQfhboNpJGn2prYSzPjLb25Iz7Zx+FAFTVfHa6HGGmh3Njt3NcTr37Q2laSyJqumG4YjekEBBc+hOeBXT/E2xie2YWkPmy85VVzjFfFs0n9oavfXUwJZ52wCOgz0oA9o8YftEx+IlEMfhua1hU8OJtzke4wBVvwp8UhcQMyNIFTjaw5WvFFgTj1qWxuv7IvVu1iWWPG2VD3XPT696APrHw94uttSkQRTAjblsnvXTJqMVwGyGJH8Wa8V8JabcQWlrqenwJLp90oZZSc4B7V6XpVq1wi7CGVjyRkAUAdMHkG0W5Ur3AOTXE/ELTbl7Y3dpFuKD5gx6121nZPblSrooH51cuNNt7u0kSXczMuBQB8ieOryW98OXqSID5bKx45XmvN1HHHA/OvZfitaRaZpuuQOAu8ZUAf7QrxpMCPOTyvrQAw8U3cO4z69c05uaQOySo6Nh1+Ze/wClACEjBxgjtikpzNktnk9cn/PFNoAD0pAeRSHrQDg0ASbsL9e9OBwvXH4VGW3HvjsKcmAAe1AFjwxrt54S8WadrmnNtuLKYSL7joyn6qSPxr9IPC+t2viTw9p+sWDbra8hWVPbPb8DX5p3UZdPcnIr6E/ZH+JR0/Uh4M1Zz9mu2LWMjNwkndPx7e9AHQfGPQoNJ+IM8gUiHUFFwNo/i6H/AD71w8E8thrD7UJTABOPu17/APHvSftOm6bqW/YLSQh8Dkgj/wCtXjNpJFJdIsERnbvnn86ALTlbzNxeGYFsDcF2givOfEGj21xqplSJVjGSGzy34V9JlbcxFXs4JI2HK4ri/Fvh7SU0+a5gstrjkKOaAPKIbJLdU+yqp3gAgjmu78Falc6IfLFijRSDOeuDXM2c0kN4gW2Qqp6bTkiu7ttTiFmzG3EUhXAG3pxQB7X8LLVY/CiXghEU19I0rgfXA/lXPftLeJY/Dfwn1WPeRdaiv2OHBwct94/gM13vg6No/C2lK+A32dWIHTkZ/rXx1+1f4ybXvHZ0W2kc2umHYy5+UydzigDxezQYB496sMentSRLtG08Hoe1K3PFACfWkGPalNNQdaAHH8KMUmMnHoM0DnnuetAD16GgDHJptO+tADZm5UbioLYJHbPWu08b+E9N8L2Wk3WneIbfVheqHdFADQ8dCO1caUDLg0RwgNngt0BbkUAWWBZEdCN6EEY9fWvpHwD+0NoOj+HoLLxB/aEs0abQsUIwPxJr5wiI6HFdF4P1rT9G1eEappNnfRSyBd8yhilAHuWsftK+HpbK9i0Xw7fS3LxMIpJdvDEYycZOK+Y7K+jUu0z/ALx3LNwepOTX25PqvhPw54ZjujpmlRmWPKhYVP4dK8o0rXdE1XWZfsmm2G6RyfkiXBGfpQB4XFeCZS8McsqqeWSNmA+pApqR3mrzfZdLtbi4nYgYWM9ffsAK+ub/AMFvqSWj6FeQWUJXM0MarhvqK1l8MRW9kIrTCzD7zqgUk/hQBD8D/CV94d+HUGma5NbNKxMgQNu2A87a6+x0tNjeTMHVW4C8AV5//Yer2N6rm9IjP8PJA+tbHgy+kGpXifb5JMNjaTwKAOyNsEk+cAnviq8kR+YjzAMcYFXSS/WQlj7VUczI4V1JQ8ZzzQB89/HO1X+ydWkkjOPLJVj1JyK+d4/mjXuSoP6V9O/tGJLb6NMqOnlSxkNGepr5hhIEC7hn5aAFOAOcjj0qJzsTOOgz/wDX+lXdKsk1LWrKwubuDToriVUe6uDiOFT1dsdqm8WaSugeI7/SYtQtdSS3cBbu2PyS5GdwwT64xQBIfCmuDwWPFX2Rv7C8/wCzefuGd/8Au+meM1jo2RVz+3NX/sEaJ9vuRo4fzfshc7M+uKpgYHtQAd6Snfx0h6mgAHUU8dfrTB1FOoAcvHNRQ3E+l6lbX1m5juIJFkjcHowOQamXAx6VHcIHjPGD7dqAPur+37P4ifBiHVYWQs8aeepP3JVwHB/GuO8MaTBpsvmKIWMoyQOeK8t/Z48SG28NeINDmmPlSskqRnoM9T+gr2LTUMUUciODx6cgUAWEkmVwyeWFf+EEUG4Gxo5cMh6oVqmUiVWD5WYHgqcCrdm6tGSJJGbHRu1AFHVtOtZUj8hI4pD/ALFc9d2Mtnazm4mRgoO0iuoll86PMjfODjpjFYOtK01nOM5BGOaAPdLTVItN8BQ6nPxFb2CzN9Ama/OXWdRk13xHqGpzEh7qZ5iCfU9K+xvirqZb9mqdoSIna3SBgreh5H5Cvi6wA7/nQBbbjHf/AAqPv1p56mmGgApAc0tIoxmgBe9FFFABTqQDg+wzSng/rQAop47Z9fSmrThyRjBwaAJF9QeR/Kpyoljw3Q8ehqBF3Z5H4VZhGBk9D0oAvXmr6pJpiW1zdySQR8KTyQPavRfgR4N12SZ9bksJ49NcYidlx5nuM9q8p1FiLbeVDBSGwehwc4r748A6quv+G9L+zWscFnHaxl0XoDt+6ooAzfBXhy8SSS4mlaOFjwPWu2+ywDjBNTs2BtUAKOwpnegDM1vQY9RsZUtnaKcrgGvGNPtLjwjr00V2lxI7vkPXvaOVOc1l+JtEh1a3EyxqZ4xnkcsPSgDy7xV8VNP0GSOOYFZSBkZyRWOPjrYKm4wjp95mzivH/j/oVzp3i+3u5SW0+6X5CDwrjqprz17SAjIjBUe9AHafGLx5J4w1GJLR2+zr1K55Fefn5ew/wqyyiPcFAX1qs5+T9aAIpVVuG6Dt3pscap0xxxkZxUrDptIJ7VGFyOcdcUALnKj6c0lKRg0lADTnNGDSjjoSPpS9+meOpNADcGnUUoHy56+lACnPTvindsHn3B/KkAAHJ59qeo449KANTwBevZ+KraBWKrcuqHb9eK+t/sBjtYFCNyBwGHT3r448OKz+LtLVCVY3Ccg9Oa+4dP0K8u9E84b8bMhm9MUAc/5c+za0Kg9Q3GDUc9xLuI8tVfsQvSjUZkZwA2z0UnvWfI8saMDuJJxzQBPMzEiVmDHPzADpVdoY3WTOHVxg57VVD3WWQyJGOw29a7T4c6DLqUdxJeGMhWAG3vQB5l8Wr1bD4VzafIWMUnKBuRmvmewA2jBx6819W/tUaJLZeCt68QCRSGA+XqOPY18q2WPKx3P60ASnIGfWm4HPPPpipGIB5yB0phGD7UANopWHSkoAKKKKAFXv9DTj2HsKaOh+mKd1IoAcgw49jUgGXJAz60xTyfapY8A5PQ+9AD0XP3QPXFWAFxknA65NMTIyfWrvhrQdS8XeJrLQtERWu7kkb2yFjXuxPYAfzoAk0DRLjxTrEen2kZMKsrTuBwq5/ma++/COkJ4d8K2Ngg+aKNdxHXNec/Dn4W6f4QuLbToN80iMJ7q4Y8yOOn4Z7V63PJlsDHHSgCM9TR2/WjBPGOadsbqM/lQAw84qSJwGAzjPFNK9etNPHIHfJFAHkXx68KXOu+HtUtLS3jaTy/tNttXneuePqa+Pbe4LJskUpICVZSMEEdRiv0Q8Tts0r7WN2Lc7mwOSp6188/GT4H2tzoOo+MvCtxJFdeW11cWbAFZVHLFfRu+KAPnSYjdk9+BgVXfr0yBT7afz4B03mmyZC9ORQBE/zbiRtPbFIeScDt0p7dTwOKZ9KAAjqabTj3ptABRRRQADnpTl446/hRxgHAzSqDnI9KAHAY+oH50rnEefQUbflPPb6VVuZ9wWJFLE9Mdc/SgDuPgZ4Tm8ZfFLTbVA32S2f7VcuAfljU5x7EnA/Gv0AuRFbabKqqEijiIAHQADpXkP7MXw7m8E+DZNR1i3MOuariSRJB88MQ+4h9DySR7gHkV6b4nn8nw9eP3ZNg/GgDi/FGlxaJGJbiASWp4EgXOD7+lcfc6rp0mQl0A2PlBXpXuM9tDfWc1pdoJIZV2srdxXzV4o0l9A8RXenM8nlo2YyVzle1AHQPcDYuLgSFj/AHa7n4T3wa7v7Ng4k2hwWGAR0/rXlNts8pCzMuO4B5rp/CN6mleI7Cfz3KF/LfJ/hbjmgD1D4k+F4/GvgfVtCkYRvcxERSFc7JByp/MCvzqubK70bVrnTtSgeC7tpGilibqjA8iv04JCPkHg9/avnz9qH4Rv4htD4s8NWobVrZM3sMY+a5jA4YY6uoH4j6CgD5Q6/dBPfk0w89Dxj8qignUgK/DDrnt+FTjaegP544oAjbsKSpGUcE8gU1gM5OeelADaKXAowKAAdDTgKRVyeKein5d3Iz+dADlGCc55NTIPmC9vrTVVs4PXpUyIqDJ6jpigBJG8qEjI45J6cete3/s22i+GtH1TxffiNJL1Ta2QdsEqDlmHPcjH4V5L4D8KX3xB8aWOhacD5TMHuZgOIogfmcn8cD3xX178SfC2mf8ACLQ6aLSO3sbGNYrcIduAo4oA3fhl4nj19rpSAsyKDy2Sfeu12Fmr55+BriP4giG2hmEAt2Bccj8a9p+ImoXml+Fru506QRzDA8zbnaD1NACeIvGOkaA7QTSNPegcQQjc34+lcU/xB1i4kMkMUcEQ6IU3Z/GvO7G9ZpvOmuvMJ5Yuv3s9ya1F1m3Kja6KAeoPX8KAPR9O+JNtHbj+3LeWNhnMsSZAHuOtdjo+p6frlkt7pN0lzbk43oeh9COxrwG/1fzFVYcyEnoFFL8H/E96fipJolqojt5YjJPFxg4H3j7+9AHtPxFujYeA9anBIYW7AH0rzj4VePotQjTwrqcbyebGY1lYggqRgg/nXrXiKzF/pN3ZzRedbzIUde+DXzRaaVZeHvED2dzcFfnPlsvVeTigDw/xx4buPBXjfVtDugcQTbo224DxnlWHtg1kyck4GRnivo/43+CJfFfhy21PSA95rVgvJx800Pce5Havmq3nyGil3LIrYIYY5/oeKAFZSfXH8qaQO3H1qZ1/U/nTSmQAM8/pQBCaTFSMoCjuT0NJj2/WgBmKXA7U7Ht+tCjnrQA0DtnmpgBg+gFIgOQecdKdjaCc/L/9egCrdyiMDqWJr6Y/Zi+DJJtfGniy3BBAl0y0lXn1EzD9VH4+mfEfhB4Vfxv8StI0sx+ZZiUTXPcCJeWz9cAfjX6Hy8ARqMDpgUAI7GRgF+77VxnjzWYht02I73U7pCOi+gp3xB8Yp4dtvs1iol1KXp3EQPc+9eVq9zNIXmkd5X+ZnbnmgD2zwx4istfhY25MV0gy8LdR7j1Fc18XNFaWzi1e2C+bbjZICMgqe9cINQvLG8F3Yh454zuB28f/AKq9c8L63Z+L9AfzI8OVMVzAwxgkc49qAPEYiZEGXSOUfwE5U1YmNwYtstkjn+9GwqfxV4em8N6qbeaGOW0fLW8mcZX0PuKyo5Qn+pVVU4+Rm5FAHrPw48WnVof7J1SMwahAuIyxyJVHp7gfyruFYxnBzivmm9ujEgnhVoriJtySI/IPY17N8OPFFz4g0ZBqsDRXkfymQfdl9/rQB4x+0h8EI54bnxd4LtdlymZb6xiXiQdTKg/vdyO/Xr1+XbedZFAPDf5/xr9OYHz8rc5/Kvjf9oz4ZDSvFF1rHh21xDM3mzW6dAT1IHvzxQB4tj2BFJtGOB37UltNv4Z8NgDBGMHvxU5XcMZB+hoAhKkZ4/Gk255GOewqUqQ2MYz2zTVTDdMnOKAEVfm4H5daeEIB55+tP2HuO2aJJool3EgMOAQMkUASKnl/NnjGTT9NstQ8Razb6Pods91fXLbERB+eewHv2Fb3w8+H/iX4kX5i0K18uxjbE19PlYou+M/xN7Dn1wOa+zfhR8LdC+HNhs06P7Tqcq4uL+YDzJPZf7q+w/HNAFX4JfC+x+Gfh11d0n1i6UPfXXbjJCL6KMn69a8t+K3jvUvFWrXOm+HWtpNMifyRJySzd/1rtfjN4uv9RuP+EO8JOftU/F/dI2DBH3VT/ePf2rmdA8FWugxWyWW5pYmBfIDZPr+dAHpvwi8Ff8Ij4cSS9lM+q3KBppOyA8hB/Wuzu4IdQsp7O6XdFMhRh7Gs3S9dt7mCGG9dbe4PAD/KH+n+FazRshyOnrQB8yeLPC9x4TuZrZpWeAORE0g+8Oo5rnmugFbfsXjqBya+rtb0jT9f0+Sy1SBJYmHBxyvuD2NeJa3+zgt3fltM8VXlpZ5yI2iEjL7A5FAHm1pdrc6lDbQyTSXLNhI06se2K+g/hH4GTwyl1ql/bBNVvAFZmwXCjtntWV8MvgbofgjWRrNze3WsarGMQyXIAWE9yqjv7nPtXqzsZDgZxQACTD8VyHivwLYapcSanbwol5t+cEcOR39jXT6jeWek2T3epTrBCvJZj1+g6k15zqHxYYXJGm6Q8toOC8jYZh647CgC74C1F2upNK1q1hgZT+5lDY3e31rhvjP+z7Z+Imn1bwkY7HWSC7wE4iuT/wCyt71a1fxFa60YrqKxFrLE+8spyVrT+Hvxgs9f1yTQtRhdJFbZDcgfK31oA+NdVstR8PalLpevWctpdxNho5V29O4PcehHFMDI6ko/UcYr9C/HHg3w94ysBa+I9MivI8Hy5sYkizxlXHIr508bfsxzQF7rwLq4uFGT9kvCN3XoGHB/EUAfPzJ9NvfnNJ5ROPlIyK6XV/h5440WdobvQ7gsO8eHrDGjeIvMKLoOps/QBLaQ/wAhQBXCcgbcE9D0p2xwQTn6VqWvgvxvd4WDwrrjc8E2Mqj8yK6TTvgh8TNRaMDw/JbRSHBknnjjC/Vd279KAOHOxV3Z4HaqkkpuLhILYKZHO0HPGa+hfC37K2r3Ewk8V69bWsIbmKwUysy4/vMAFP4GvbvA/wAGvBPgtY5bLTFvL6P/AJe7zEsmfUfwr+AFAHHfsseCD4b0i81K4tnE92qj7RIhUsOuFB52+9e4HdI7BSVz39Ke77sKqjaOAMVna7q1voVg085HmkYjTux7UAcH8RdGtBdQQ24Amb55JGbJJ9/esBLJY0IS45z3HWqL6jLf6pcXl06vKzEjnge1b/hvTLrW5xFaOI41OZpsHC+oX3oAyoi+0rvXacnnuKveHLqTQtSW6s0Zw3+ujVuJF/xrPTaM+XI685w361IvmM25HBH1oA9c1Gy0/wAVaIFlAeKQblb+KNv6GvJ9W0STR7trW+tsjPySL92RfUZ7+1aOha7faPMXgJlgJ/eW7tw3up7GvQlk0vxhpBEb5Hp0khb6dqAPJmsbMw7liB29FIwa6jwHrttpbGzuh5VvM3yFsYDVma7od/oszi6bzYGOI5wOG+voayWiW6tpQ8Qfb/eOMUAe4OuGDKcjtgVkeIPDeleJIQmpQt5gGBLG21h+Ncj4E8WpbRx6ZqzkxrxFO/RfY/416L5YdQ8ZDKeQR0NAHzz40/ZgstUne60HXXtLhv4LiEMh+pXH54rynXP2dviLpWPslvZ6rEOM2lyoIH0k2n8s19tjenrTllfvQB+ed58P/H2n+a114T1oKoyXW0d1X8QCMVzLzXqyGNrSZZQdpUxnIPpjFfpqsx5yKR3Rh+9VcerUAfnLonhXxbr9ykOk6FqEzOcBhAyqPqx4r3/4cfs0QwLHqXxFujcOuGXT7Vjt+kjjk/QY+tfSwuYVOy32fhwKS8u7ezgae7nSNFGSS1ADNLtrWzsIbPTLRLS0iULHFEgRUHoAK5n4l+LD4d0GZbB1OpSrsizyFPqcVz2v/FASSyW2g2zsFODM44P0rgLm5n1q7ZruQbkOcFsUAXfhBYiS6uvt0Mb6hcks0xfLEnrXrJgs9GtXluSEKDOD1JryOC4NrdRyW1ogmT7kitzV3UNU1nUwBcGRAD0+8DQBX8Uaxquv33yLEtmv3Y2H6/Wtbwj4z1jw7MlrqyyX2lnjKjc8P+6e49qwhDIqfvJkznOCMGrVuSOBKgOOinNAHuttPBe2kdzZSLLBINysp6+1LuYHg5ryHQ/Ed74dufOLebp8jYkhY9P9oe9euWs8F/ZxXds26KVQwOelAD1DO2Oaw/FvieHw7bbYYHu79/uQoM4929BTvGOuPoOl7raFpLmXhNo4X3ryhmNxJJcTG6MrnMkkjZ/yKAKuqX15qd9Jday7TSHlVLALEOwArClNyrsbVf3Z9q6dUtRucPGrHk7uarokU5YSPj028UASRaT9psPNmvNu5cbN2D0/lXmmp+FrjTLprmzYE5ypzg//AF69JAhhXYqEoe3XFV5IBJIxk3kgZAIwBQBqeBPitc2cS2GvQGVYwFVkHP4mvWvD2u6Tr0Zm06VPNHVMgMPwr550+4s7q8nt5YWWROAVXrWklubGYS2s00JHIaMEGgD6KcDd88StnvjNKcIp8qJR9BXiqfEDxFYwBo4JL2IDlnXBqxY/GYPJ5N9p09u/95jxmgD18TSn+DApxmbHSvOLf4mWj/N58EmekbHBqWT4nwIhZNNeTA/gkFAHoBLvxzSSCOCNpLmVI41GSzNgD3zXlsvxK1W/JTTrK3tQR96R9xFcXrqajr13nUby4v5SfliUnYo9lHFAHqWv/EnRtPZoNMYajddvLP7sH3bv+FcXdX97rt4ZrpPMkJOOPlX0ArJ0L4da3fS7oYxbRA8PKCB+Vev+GPC1voUAM8gu7v8AvsuAv0oA43w34Pv9QuhLqMK21kOTkfM49B/jXpoFrpOmt5MSRW0K5CqMf5NOaQtwOBWD46L/ANibFZ1Ut823rQB5fZsl7b+ba3COB2PWpRbMrNnKr1yPWvE9Dvb6wj+16fINRte89vLuwP8AbXqv5V3+h+MLe4TbdRuM9xIP5UAdesbn5MMFBzuyOaZAbywvBfadc+VcxnOQflcejDvTrJ4rxPMtVEw7DzAalWJgWH2RQ2eV3ZoA9E8PeI9O8U2LWN8scd4ybZbVz1919a5HxJ4Lu9KaaewBurAjJX+OMe/qPesKaBo3EsNsElQgqwfkEc8Gu98FeLZLsrY6yyLcH5Ypf7/s3v70AeWQ2spZwZI1QnIHWrmm3Gv6XKW0rWHjjJz5L/vEP0B6V61rHhHS7+V5o41trtusiDgn3FclqHhfWrLcII0uIx0eIDOPpQA2H4gavZQJ9utra7buyApmrtr8ULR1zPpc6EdcODiuTvLa4jJS5EqMD0aMiqu6HZsEKbgOWLUAd0/xJt3yIbN4v9p+RWRdeLJLqQgSMwPTNcpJC+QVQOh/utUsSeXkx20u0j5sN+tAGldXl1cA+XqE0OeABWTcaX9oQrealdXK90ZjzU5lRY9o3qD3ZuahjeNHYrdEgdTnNAEYsrS2gb7NAWbGAN3Ss7QdLnhkmkuWjRmOVDNnIq8LyAOS0nmHPRVpwvJHJ82HYOxKdqAJ0WNGL3ACAdCOlOWGOVyRqPk8cj1qoJoOS0jY6YKkYpWaF3GIt57mgCZ4kWRtt4GUeq0+No1TgFif4lFZ0qcEJ5q59RwKg057iJXjLKQOm5sUAbdy6y2brPKu3bwrLya9M8AXFsnh+yhgkyUJBFeTK81wpH2bjHB3cmrPhbWtU0NZoVkUITkGQZxQB0fxJ1EzeKEt45z+6jAEatj8a5+aabcFa0aTtkNxWdqyT6jqZ1KRonnx1zT/ALXeBVRJkQN12UAWWumW4VGskjJHJxninrJvkZfI6HqayDYSPOZHnaQ+x6Vc8qfYVW4bafQc0AWpElXD8hfyAqOS4cEN5jAf7tQ/ZXSLY8khz3Y/0qGOKOOXIaSQ+m0gUAPihBmeaNnVz1OMVM1xcRMdl2gHoyZIqu4nkJEfmxrxgCq1yyWcn+mjAJ5Zm9aALr6rMDh0kkHrwBVC5vUlLeZp0Ugx97NXra002YLMtx5yMMYD1JNYWofFoFQHsx60Ac5Z6fDq2rQ2GlaaRfStjdu4H19q9e8N/CexsIvM1e7kuZ2HKp8qL9PWuV0AR6BrVrqDiMbW+faexr2+GeG+t0uLSVZYmGQVORQBh2nhDw/ZqRFYoSeSWOa1bWzsbL/j0tYoz6qtT+S2eTTWaCP/AFs8S/VhQA55mIPao+WJ/Sqc+t6Rbg+ZfRkjspzXN+JviVpWj2sjWoM8wGRu4WgDtkhyBmuP+I3ivw9oWlTR6pfKbjaQlvE4MhP07V4H4o+KHiPWp3RNSltoG4ENu2wsPw5NcoNJkbdfa5dQ6fAeWlvHzMw/2V6mgDzS1eezn86xuJbaU9WjbBP4d62YfEjPKo1S0SZxwLi3+SX6kfdb9K54Pk47+1SBvlKlfl/lQB32kaxfKfN0G9W6VTloj8kq/UHr+FdNpnxOu4Jvs+oxAsvVXjIb6140EBZXUsjr0dWII+hres/FOrWyiO5kh1G36eXeoGI+jDkUAe66T8QdFuztuWe1bHVlJH8q6LSrmwvb6CaLU4JI9wIwcEV862+taDd/8fVnfaZJ/egIljB+h5//AFVq6dHayn/iVazDJnojHyn/ACNAH3NBtmtonhlEg2j5gc5pcSJ618eafrPiTRGDWl7qUSr1CSblP5ZFemeEfjVdiJbbV4Eu3H/LQny2P17ZoA91cq/yyxq4/wBparPY6fJnfY2zZ65iFcpp/wATNHuyBLBLEx9w39a2ovFmkSqWjZ2HXhaANBdM01T8un2w/wC2YrL8X6Jp76FdzLHHbSxxllkQY5qtc+NrJDi1geU+4xXNa94nn1GBoZJUjjb/AJZqufwNAHj1rb60zO13OrIzNscA9M9+avsJ7SJVluEcgc4U10clpdSygxSmOMfwleDUsemNkMJPMY8EFOtAHJR6pfXEypBbBlH8QXH5Vrx/b7gbCmVI54Ga2ZI/swANxFCP+AgisO/1rRNNcyT6wskncK/I/KgC3HZzSTZmbfj+EVILeOMk7CjL781xl145gnZk0rTrq7Of9YMgVk6l4u1iHm5ns9OjYYBkkBYe2BQB6I68fNO3XOGGP6Vk3et2tq/luULdNwPP4V5Nd+MBlkfVri/bnCxRlVP4msJ/E2oFt0Cxw4JGX+Y0AezHxV5RZbdQ7dix5rLufFF486+cUVByQAa8qOvazL9682k8EpEBVZ72/mOZryZ/qcUAetReImgnaUsWRj93OQKvDxiAcR8jHIMZNeLi+vUwy3Ug7djSx6xqkMvmR6g4P+6D/SgD2SPx2sEgRgdv8W2NsVaTxxp7tmc3AB4yAVx9OK8dfxf4iIK/bYY1/wBiBP8ACqsniTXpWDyaiWIPQxJj+VAHvdr4w05x8krsOxbJP4CtCHWbaZ2aS4Cp3yRmvnG617WLoYkuVUHqYowh/OqFpPfWNx9ot7h/Mzlt7ZDfUd6APrW0ubO62+RPFIW4Hzdamm06CZgt7DFJn+EHdmvlyHxTqEMuZY0ZSQSIyV5/z/Otuy8eSWzZiu9QtX9CPMANAHvkek6fasRBGImHI4J/Sp4UAABkRyOmFrxOx+JTif8A0jVXK9zNbnH41rN8VXGBFq9gq4x/x7tn+VAHp90r78GX5c/dCZzWjpWrXelptgumhQnO3tXh2ofE/dG7JqM9zJ0Cw2+xfzNc6fHmryTeZDbQ/WYlj+IFAH1Hc+NnkJV752UDkxgn+Wawr7xRKbd5Le3unUAky3UnloPc5r56l8aeKLhcDVfs0Z/htoVTH49ayLl5r1t+o3t1etnP+kTM/wCVAHqeqfEiCa5kX7UhxwXtImdR+PQ1gXGvaNcStPeXWrXZznyo4gn/AI8fy/zmuODqMA9vSmFxnkk8UAdJP4ndFaPRLCDTU5Hm582c++4jAP4fpxXPzyPcStNcSPLMessjlmP4nNQNJjp/LFQvKfXHGOTQBR3cDkAfSlVvY4/nUJbHXAoViSecUAWN3ABJ9wKl3jgdcfyqqGPTqKdkZ64+poAuoy5yMFvpzUyhGxuGe1Z+SOnHOKnjlJIPbjmgDXs727sTmxvLiAYzhHOK1U8XawBib7Deqe1xAM/TcK5lZtqdeM9c1IJTjBHXr70AdNH4umSUyNo9nuHaKZ1q9b+PjCdz2moQH/p3uAw/WuM87puBOPekMo67SD9aAPQk+JNkQC9xrsLL22K4z9e9OT4l6btYvqWph+xa1GR+tebOw9MEds/yqu5U8EZPr+NAHqi/FezVMG+1KXHQ/Z1H9aoXHxPsJtxe61s8dF2rXmjKvIYDHXA6UEKfvBT6nHWgDqb3xnZS7vJ06+uSehubn/Csx/E11uBtNP0+1Pdthkb9ayMf3cn6ilPX7v6YoAu3esave4+06hPtGQEiwij8qz/syA5YbmYYJ96dnHrSq/pQA4ADAHQe3SlJ9z65qPdz0X8qN3PRfyoAk3EdG46CkzTN+Oy0ZfPBOPbpQBITgcE59KQHPQ49zTGbuRz+tN3Z7fWgCQk9OAfemnBHUioxyM4NDEknOcUAPLe3NLxnJXiouT2NJuOcZNAE5xk4/Kk2pgcA49aiyeO3NO3fNxgfhQBJhAMg/lQqKFwAOveo8kj5c8dc0vzcdT7EUATcZyT06HAqUORg9qqFyTz0pwY54oAuCYY6HJNOEwHJOOKo7vlJwD+NKrH1AoAttOMnrnPpimNLkdcfhVYtwevPOcUm4kliSPrQBOzk4yQV9BTN+RtPbvUfLc4o6UAK6AH8aRUBIz60UUAPSNSRx2zSYGM49qKKAHlBjB54zSpyMnrRRQA4dG9hmpEUYPXjkc0UUAKSQAck5z15oUk45/SiigCIsSRnvnijaNpOOQcdaKKAGAAk0KoIGfXrRRQBF1J9jSniiigA6jBqTHA+lFFABtB61FnrwKKKAHAAuoxwRTGbg8AiiigBepGehxxmnbQSR2wTiiigCusxwfkX9f8AGgyfIGKg/nRRQA3zec7F/X/Gm+ef7ifr/jRRQAeeT/An6/40eecj5F/X/GiigBGuW/uJ+v8AjSi5Y/wrRRQAn2lv7qfkactyx6qv6/40UUAElyyqGCJnOO/+NIt27dVT8BRRQArXLDPyr+tLDcMzgFVwfb/PpRRQBpJEpZeT82K7XS/BmnXOhi/mmu2k5GzeAv6DP60UUAf/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomography demonstrates an accessory bronchus originating from the right aspect of the distal trachea (bronchus suis).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_39_35443=[""].join("\n");
var outline_f34_39_35443=null;
var title_f34_39_35444="Severe pulmonary regurgitation";
var content_f34_39_35444=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70165&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70165&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 604px\">",
"   <div class=\"ttl\">",
"    Severe pulmonary regurgitation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 584px; height: 413px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Continuous-wave Doppler signal showing severe pulmonary regurgitation. In this patient, rapid equalization of pressures between the pulmonary artery and right ventricle results in rapid diastolic decay, shown between the arrows.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_39_35444=[""].join("\n");
var outline_f34_39_35444=null;
var title_f34_39_35445="Transesophageal echocardiography in the evaluation of aortic valve disease";
var content_f34_39_35445=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Transesophageal echocardiography in the evaluation of aortic valve disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/39/35445/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/39/35445/contributors\">",
"     Elyse Foster, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/39/35445/contributors\">",
"     Amy Gin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/39/35445/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/39/35445/contributors\">",
"     Warren J Manning, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/39/35445/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/39/35445/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/39/35445/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiography is the procedure of choice for the evaluation of valvular heart disease. Because of enhanced resolution and unobstructed visualization, transesophageal echocardiography (TEE) may provide further detail not obvious on transthoracic echocardiography (TTE). TEE also has a growing role in transcatheter aortic valve implantation (TAVI).",
"   </p>",
"   <p>",
"    This topic will discuss TEE evaluation of the aortic valve. Transthoracic echocardiographic (TTE) evaluation of the aortic valve is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/3/1082?source=see_link\">",
"     \"Echocardiographic evaluation of the aortic valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MORPHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;To characterize the aortic valve using TEE, the valve should be imaged in short- and long-axis views.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3341574\">",
"    <span class=\"h2\">",
"     Short-axis view",
"    </span>",
"    &nbsp;&mdash;&nbsp;The short-axis of the aortic valve can generally be visualized in a plane between 30 to 60&ordm; from the transverse (0&ordm;) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35445/abstract/1\">",
"     1",
"    </a>",
"    ]. In the short axis view, inspection should include identification of the number of aortic cusps, the presence and extent of any fusion, any leaflet perforation, malcoaptation, or vegetation. Adjustment of the imaging plane to a view that clearly demonstrates the coaptation of the leaflets provides another view for regurgitant jet assessment. Direct planimetry of the systolic orifice from this view is accurate to a level that equals, and may exceed, that of the standard continuity equation as applied to Doppler TTE. (See",
"    <a class=\"local\" href=\"#H12375015\">",
"     'Aortic stenosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3341608\">",
"    <span class=\"h2\">",
"     Long-axis view",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the long axis view, typically at 110 to 140&deg; from transverse (0&ordm;) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35445/abstract/1\">",
"     1",
"    </a>",
"    ], the presence of any vegetations or leaflet prolapse is usually evident and regurgitant jet width can be ascertained. In the long axis, the ascending aorta should be viewed from the valve to the right pulmonary artery. This view of the left ventricular outflow tract is usually optimal for excluding subvalvular lesions (eg, subvalvular membrane), measuring regurgitant jet width and for examining associated pathology of the aortic valve, aortic root, and ascending aorta (eg, aorto-annular ectasia, type I aortic dissection, and Marfan's syndrome).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3341615\">",
"    <span class=\"h2\">",
"     Identification of etiology of disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of aortic valve disease can often be better delineated by TEE than transthoracic echocardiography (",
"    <a class=\"graphic graphic_movie graphicRef80529 \" href=\"mobipreview.htm?20/47/21235\">",
"     movie 1",
"    </a>",
"    ). Patients with an intrinsically normal valve who have aortic regurgitation due to a correctable aortic lesion (aortic root dilation causing incomplete leaflet closure or dissection flap prolapse) are candidates for aortic valve repair. In contrast, irreparable valve abnormalities (eg, retracted calcified valve) require valve replacement. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/29/25050?source=see_link&amp;anchor=H20#H20\">",
"     \"Course and management of chronic aortic regurgitation in adults\", section on 'Aortic valve replacement or repair'",
"    </a>",
"    .) Causes of aortic valve disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/3/1082?source=see_link\">",
"     \"Echocardiographic evaluation of the aortic valve\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21706?source=see_link\">",
"     \"Clinical features and evaluation of aortic stenosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/9/38039?source=see_link\">",
"     \"Pathophysiology, clinical features, and evaluation of chronic aortic regurgitation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/35/20022?source=see_link\">",
"     \"Acute aortic regurgitation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a study of patients undergoing surgery for aortic regurgitation, lesions were visualized preoperatively on TEE and classified into three categories: root dilation, excess cusp motion, or deficient cusp quality or quantity. There was 93 percent agreement between the causal classification of regurgitation by TEE with that determined by surgical inspection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35445/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Congenital bicuspid aortic valve is associated with development of stenosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    regurgitation and dilatation of the aortic root [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35445/abstract/3\">",
"     3",
"    </a>",
"    ]. This dilatation is thought to be due to abnormalities of the aortic media, as opposed to being the sequelae of increased velocities through a stenotic bicuspid valve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35445/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. An increased incidence of aortic dissection has also been reported in patients with bicuspid aortic valve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35445/abstract/5\">",
"     5",
"    </a>",
"    ]. Thus, in patients with bicuspid aortic valve undergoing TEE, we recommend careful examination for associated pathology of the aortic root and ascending aorta. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/1/6169?source=see_link\">",
"     \"Clinical manifestations and diagnosis of bicuspid aortic valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TEE views can also define the severity and mechanism of aortic regurgitation that complicates acute type A aortic dissection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35445/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/35/20022?source=see_link\">",
"     \"Acute aortic regurgitation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/19/25914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of aortic dissection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Three-dimensional TEE is increasingly utilized in the evaluation of valvular disorders. With this modality, the internal contour of the valvular surface can be visualized (termed &ldquo;en face&rdquo; visualization). In a single-center study, the ability to identify leaflet perforation was compared between three-dimensional (3D) TEE and two-dimensional (2D) TEE. 3D and 2D transesophageal echocardiograms on patients with known perforated native valves were collected and combined with 3D and 2D transesophageal echocardiograms from patients with endocarditis. Of the 14 patients with known valve perforations, 15 perforations were diagnosed on 3D TEE (seven involving the aortic valve) versus 11 perforations (six involving the aortic valve) diagnosed on 2D TEE. 3D TEE was also associated with higher level of confidence in diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35445/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12375007\">",
"    <span class=\"h1\">",
"     GRADING HEMODYNAMIC SIGNIFICANCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12375015\">",
"    <span class=\"h2\">",
"     Aortic stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transthoracic Doppler echocardiography is an established method for determining the severity of aortic stenosis (",
"    <a class=\"graphic graphic_table graphicRef78535 \" href=\"mobipreview.htm?13/43/14011\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/3/1082?source=see_link\">",
"     \"Echocardiographic evaluation of the aortic valve\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21706?source=see_link\">",
"     \"Clinical features and evaluation of aortic stenosis in adults\"",
"    </a>",
"    .) Doppler determination of severity is less successful on TEE as it is difficult to achieve beam alignment to measure the maximal flow velocity across the valve (in some cases, the deep trans-gastric view on TEE can be utilized to obtain accurate velocities). However, transthoracic echocardiography often does not permit direct planimetry of a stenotic aortic valve, while TEE generally obtains better images of the stenotic orifice.",
"   </p>",
"   <p>",
"    In one study of stenotic valves, the correlation coefficient for valve area computed by planimetry on TEE and by continuity equation on TTE was 0.93, the percent difference between the two methods was small (11 percent), and the TEE method correlated even more closely with the catheterization-determined valve area (using the Gorlin formula) than did the transthoracic echocardiographic value (r = 0.91 versus 0.84) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35445/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/11/1208?source=see_link\">",
"     \"Aortic valve area in aortic stenosis\"",
"    </a>",
"    .) Planimetry by TEE has also been shown to correlate well with planimetry by computed tomography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35445/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12375064\">",
"    <span class=\"h2\">",
"     Aortic regurgitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transthoracic Doppler echocardiography methods for grading the severity of aortic regurgitation include use of continuous-wave Doppler imaging of the regurgitant jet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35445/abstract/10\">",
"     10",
"    </a>",
"    ], pulsed-wave Doppler imaging of reverse flow in the descending aorta [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35445/abstract/11\">",
"     11",
"    </a>",
"    ], and color flow Doppler imaging of the width of the regurgitant jet in the left ventricular outflow tract [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35445/abstract/12\">",
"     12",
"    </a>",
"    ] and the vena contracta; these methods are reliable and complementary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35445/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/3/1082?source=see_link\">",
"     \"Echocardiographic evaluation of the aortic valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TEE is rarely needed to evaluate severity of aortic regurgitation and is generally limited to patients with poor transthoracic acoustic windows. There are scant data on the comparative value of TEE and TTE in measuring the severity of aortic regurgitation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79069 \" href=\"mobipreview.htm?15/58/16288\">",
"     image 1",
"    </a>",
"    ). In patients with limited acoustic windows, the severity of aortic regurgitation may be best evaluated by combining available data from transthoracic echocardiography and TEE. Using either modality it is important to evaluate mitral inflow and regurgitant flows to determine whether severe aortic regurgitation is causing elevated filling pressures resulting in restricted mitral inflow or diastolic mitral regurgitation. &nbsp;",
"   </p>",
"   <p>",
"    TEE generally visualizes the left ventricular outflow tract well and is highly sensitive to even trivial degrees of regurgitation (",
"    <a class=\"graphic graphic_movie graphicRef54254 \" href=\"mobipreview.htm?8/2/8227\">",
"     movie 2",
"    </a>",
"    ). The vena contracta is the narrowest portion of the color flow jet as it leaves the aortic valve and enters the left ventricular outflow tract (receiving chamber). The width of the vena contracta (as well as the jet width in the left ventricular outflow tract just below the vena contracta) correlates with the severity of aortic regurgitation. One study found that the width and area of the vena contracta measured from TEE correlated well with the regurgitant fraction and regurgitant volume as measured with a flow probe at the time of surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35445/abstract/14\">",
"     14",
"    </a>",
"    ]. However, jet width is of limited utility for evaluation of AR severity in the presence of eccentric jets.",
"   </p>",
"   <p>",
"    Since TEE views are generally suboptimal for measuring continuous-wave Doppler signals of the aortic regurgitation jet or pulsed-wave Doppler of flow reversal in the descending aorta, TTE is generally preferred for evaluation of these variables. However, flow reversal in the descending aorta can also be identified by TEE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35445/abstract/15\">",
"     15",
"    </a>",
"    ]. Descending aorta flow reversal may be the only way to assess aortic regurgitation by TEE in patients with a mitral valve prosthesis in whom the left ventricular outflow tract cannot be adequately visualized. We have found that the descending aorta viewed in the long axis provides the most nearly axial Doppler angle obtainable from TEE. From this vantage, flow reversal associated with moderate and severe aortic regurgitation is most reliably and accurately seen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12375485\">",
"    <span class=\"h1\">",
"     INTRAOPERATIVE",
"    </span>",
"    &nbsp;&mdash;&nbsp;TEE is frequently used intraoperatively, and it has the potential to guide aortic valve surgery and improve outcomes. Prior to aortic valve replacement or repair, valvular pathology can be examined and final annular measurements can be obtained for correct prosthesis sizing. In the patient with endocarditis, careful inspection of the aortic root may reveal ring abscess that requires debridement. After the procedure is complete, prosthesis seating can be directly observed and color flow Doppler can detect perivalvular regurgitation. Multiplane mapping (particularly long-axis views) enables identification of the extent of any paravalvular leaks, which may need to be addressed prior to chest closure. When aortic valve repair is performed, TEE evaluation of valve function post-repair is essential [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35445/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A pooled analysis examined the impact of intraoperative TEE on surgeries for valvular heart disease. Eight observational studies with a total 15,540 patients were included in the study. TEE done intraoperatively prior to cardiopulmonary bypass resulted in changes to the planned surgical procedure 11 percent of the time. TEE findings resulting in alteration to the surgical plan included complications of endocarditis, left ventricular outflow tract obstruction, and measurement of the aortic annulus for homograft sizing. There was a 4 percent incidence of second pump runs based on residual valvular abnormalities seen on post-cardiopulmonary bypass intraoperative TEE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35445/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12375553\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The etiology of aortic valve disease can often be better delineated by transesophageal echocardiography than transthoracic echocardiography. Newer modalities such as 3D TEE have strengthened this diagnostic potential.",
"     </li>",
"     <li>",
"      TEE provides detail of the aortic root and the ascending aorta that can be helpful in excluding subvalvular and aortic pathologies. Given the association with dilatation of the aortic root, patients with congenital bicuspid aortic valves undergoing TEE should have careful examination of the aortic root and ascending aorta.",
"     </li>",
"     <li>",
"      TEE is unlikely to become a first line diagnostic technique in aortic stenosis or regurgitation, but should be considered as an adjunct to transthoracic echocardiography in the following circumstances:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      When there are conflicting data from invasive and non-invasive studies as to the hemodynamic severity of aortic regurgitation or stenosis.",
"     </li>",
"     <li>",
"      When coexistent aortic valve disease needs to be excluded in a patient undergoing CABG or other intracardiac repairs.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35445/abstract/1\">",
"      Shanewise JS, Cheung AT, Aronson S, et al. ASE/SCA guidelines for performing a comprehensive intraoperative multiplane transesophageal echocardiography examination: recommendations of the American Society of Echocardiography Council for Intraoperative Echocardiography and the Society of Cardiovascular Anesthesiologists Task Force for Certification in Perioperative Transesophageal Echocardiography. J Am Soc Echocardiogr 1999; 12:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35445/abstract/2\">",
"      le Polain de Waroux JB, Pouleur AC, Goffinet C, et al. Functional anatomy of aortic regurgitation: accuracy, prediction of surgical repairability, and outcome implications of transesophageal echocardiography. Circulation 2007; 116:I264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35445/abstract/3\">",
"      Keane MG, Wiegers SE, Plappert T, et al. Bicuspid aortic valves are associated with aortic dilatation out of proportion to coexistent valvular lesions. Circulation 2000; 102:III35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35445/abstract/4\">",
"      Fedak PW, de Sa MP, Verma S, et al. Vascular matrix remodeling in patients with bicuspid aortic valve malformations: implications for aortic dilatation. J Thorac Cardiovasc Surg 2003; 126:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35445/abstract/5\">",
"      Michelena HI, Khanna AD, Mahoney D, et al. Incidence of aortic complications in patients with bicuspid aortic valves. JAMA 2011; 306:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35445/abstract/6\">",
"      Movsowitz HD, Levine RA, Hilgenberg AD, Isselbacher EM. Transesophageal echocardiographic description of the mechanisms of aortic regurgitation in acute type A aortic dissection: implications for aortic valve repair. J Am Coll Cardiol 2000; 36:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35445/abstract/7\">",
"      Thompson KA, Shiota T, Tolstrup K, et al. Utility of three-dimensional transesophageal echocardiography in the diagnosis of valvular perforations. Am J Cardiol 2011; 107:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35445/abstract/8\">",
"      Stoddard MF, Arce J, Liddell NE, et al. Two-dimensional transesophageal echocardiographic determination of aortic valve area in adults with aortic stenosis. Am Heart J 1991; 122:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35445/abstract/9\">",
"      Klass O, Walker MJ, Olszewski ME, et al. Quantification of aortic valve area at 256-slice computed tomography: comparison with transesophageal echocardiography and cardiac catheterization in subjects with high-grade aortic valve stenosis prior to percutaneous valve replacement. Eur J Radiol 2011; 80:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35445/abstract/10\">",
"      Teague SM, Heinsimer JA, Anderson JL, et al. Quantification of aortic regurgitation utilizing continuous wave Doppler ultrasound. J Am Coll Cardiol 1986; 8:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35445/abstract/11\">",
"      Touche T, Prasquier R, Nitenberg A, et al. Assessment and follow-up of patients with aortic regurgitation by an updated Doppler echocardiographic measurement of the regurgitant fraction in the aortic arch. Circulation 1985; 72:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35445/abstract/12\">",
"      Perry GJ, Helmcke F, Nanda NC, et al. Evaluation of aortic insufficiency by Doppler color flow mapping. J Am Coll Cardiol 1987; 9:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35445/abstract/13\">",
"      Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 2003; 16:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35445/abstract/14\">",
"      Willett DL, Hall SA, Jessen ME, et al. Assessment of aortic regurgitation by transesophageal color Doppler imaging of the vena contracta: validation against an intraoperative aortic flow probe. J Am Coll Cardiol 2001; 37:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35445/abstract/15\">",
"      Sutton DC, Kluger R, Ahmed SU, et al. Flow reversal in the descending aorta: a guide to intraoperative assessment of aortic regurgitation with transesophageal echocardiography. J Thorac Cardiovasc Surg 1994; 108:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35445/abstract/16\">",
"      Van Dyck MJ, Watremez C, Boodhwani M, et al. Transesophageal echocardiographic evaluation during aortic valve repair surgery. Anesth Analg 2010; 111:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35445/abstract/17\">",
"      Michelena HI, Abel MD, Suri RM, et al. Intraoperative echocardiography in valvular heart disease: an evidence-based appraisal. Mayo Clin Proc 2010; 85:646.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5327 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-A7177AF1CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_39_35445=[""].join("\n");
var outline_f34_39_35445=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12375553\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MORPHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3341574\">",
"      Short-axis view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3341608\">",
"      Long-axis view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3341615\">",
"      Identification of etiology of disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12375007\">",
"      GRADING HEMODYNAMIC SIGNIFICANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12375015\">",
"      Aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12375064\">",
"      Aortic regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12375485\">",
"      INTRAOPERATIVE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12375553\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/5327\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5327|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?15/58/16288\" title=\"diagnostic image 1\">",
"      TEE color Doppler severe AR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5327|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?20/47/21235\" title=\"movie 1\">",
"      TEE bicuspid aortic valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?8/2/8227\" title=\"movie 2\">",
"      TEE aortic regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5327|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/43/14011\" title=\"table 1\">",
"      Severity of aortic stenosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/35/20022?source=related_link\">",
"      Acute aortic regurgitation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/11/1208?source=related_link\">",
"      Aortic valve area in aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21706?source=related_link\">",
"      Clinical features and evaluation of aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/19/25914?source=related_link\">",
"      Clinical manifestations and diagnosis of aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/1/6169?source=related_link\">",
"      Clinical manifestations and diagnosis of bicuspid aortic valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/29/25050?source=related_link\">",
"      Course and management of chronic aortic regurgitation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/3/1082?source=related_link\">",
"      Echocardiographic evaluation of the aortic valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/9/38039?source=related_link\">",
"      Pathophysiology, clinical features, and evaluation of chronic aortic regurgitation in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_39_35446="Resection of uterus";
var content_f34_39_35446=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65415&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65415&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 506px\">",
"   <div class=\"ttl\">",
"    Resection of uterus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 486px; height: 511px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_39_35446=[""].join("\n");
var outline_f34_39_35446=null;
var title_f34_39_35447="Facial allergic contact dermatitis";
var content_f34_39_35447=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F82705&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F82705&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Allergic contact dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Inflammatory, weeping plaques are present on the face.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_39_35447=[""].join("\n");
var outline_f34_39_35447=null;
var title_f34_39_35448="Therapies of uncertain benefit in basic and advanced cardiac life support";
var content_f34_39_35448=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Therapies of uncertain benefit in basic and advanced cardiac life support",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/39/35448/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/39/35448/contributors\">",
"     Charles N Pozner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/39/35448/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/39/35448/contributors\">",
"     Ron M Walls, MD, FRCPC, FAAEM",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/39/35448/contributors\">",
"     Richard L Page, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/39/35448/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/39/35448/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/39/35448/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1957, electric cardioversion of nonperfusing cardiac rhythms was first described, marking the advent of a new era in resuscitation of patients with sudden cardiac arrest (SCA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/1\">",
"     1",
"    </a>",
"    ]. Soon thereafter, researchers described the use of mouth-to-mouth ventilation and external chest compressions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Other important advances in the management of SCA include primary prevention, increased availability of skilled rescuers and equipment, particularly automatic defibrillators, and development of treatment protocols, namely advanced cardiac life support (ACLS).",
"   </p>",
"   <p>",
"    In 2010, the American Heart Association (AHA) published its latest guidelines for emergency cardiovascular care (2010 ACLS Guidelines) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. These guidelines focus on the interventions most likely to improve survival from SCA, as determined by an extensive evidence-based review process.",
"   </p>",
"   <p>",
"    Although some treatments are well-supported by evidence and widely recommended, controversies in the management of SCA remain. Those controversies related to the techniques and medications used in the performance of basic and advanced life support are discussed here. The performance of basic and advanced life support and the evidence supporting ACLS are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/25/36248?source=see_link\">",
"     \"Basic life support (BLS) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13850?source=see_link\">",
"     \"Advanced cardiac life support (ACLS) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/34/23079?source=see_link\">",
"     \"Basic airway management in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/24/8585?source=see_link\">",
"     \"Supportive data for advanced cardiac life support in adults with sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INSPIRATORY IMPEDANCE THRESHOLD DEVICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;An inspiratory impedance threshold device (ITD) is designed to modulate intrathoracic pressures during passive inspiration after positive pressure ventilation in order to enhance return of blood to the heart during cardiopulmonary resuscitation (CPR). The device is a plastic appliance with a silicone diaphragm placed between the airway and the bag ventilator.",
"   </p>",
"   <p>",
"    The generation of negative intrathoracic pressure during passive or active decompression of the chest wall during chest compressions increases venous return to the heart (ie, preload). Without an ITD, passive airflow into the patient's airways during either active or passive decompression of the chest wall during CPR mitigates the generation of negative intrathoracic pressures, resulting in decreased venous return (preload) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Decreased venous return results in lower systolic blood pressures generated with active chest compressions.",
"   </p>",
"   <p>",
"    The ITD permits positive pressure ventilation and exhalation but prevents the flow of air into the patient's airway during chest wall relaxation. Employing an ITD during active or passive decompression of the chest with CPR augments negative intrathoracic pressures and improves both preload and myocardial perfusion.",
"   </p>",
"   <p>",
"    Most studies of ITDs have been done with active compression-decompression CPR and therefore cannot be directly extrapolated to all types of CPR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Nevertheless, ITDs are likely to augment all types of CPR and should not affect standard CPR guidelines, such as the compression to ventilation ratio (30 to 2).",
"   </p>",
"   <p>",
"    The ITD is effective at enhancing the generation of negative intrathoracic pressures in patients ventilated using a bag-mask, but correlation with improved clinical outcomes in these patients remains unproven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/10\">",
"     10",
"    </a>",
"    ]. When the ITD is used as part of bag-mask ventilation, it is crucial to maintain a good mask seal, and for this reason a two-person ventilation technique is recommended. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/34/23079?source=see_link\">",
"     \"Basic airway management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical trials of ITDs have reported mixed results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a multicenter trial in which 400 out-of-hospital cardiac arrest patients received treatment with active compression-decompression CPR and were randomly assigned to ventilation incorporating either an active ITD or a sham device, survival at 24 hours (primary endpoint) was achieved in 32 percent of patients in the ITD group and 22 percent in the sham group (OR 1.64; 95% CI 1.07-2.6) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/11\">",
"       11",
"      </a>",
"      ]. Among patients who survived to hospital discharge, 6 of 10 in the ITD group had normal neurologic function compared with 1 of 8 in the sham group, but this outcome did not reach statistical significance.",
"     </li>",
"     <li>",
"      In a study of 230 cardiac arrest patients, 25 percent of those randomly assigned to resuscitation incorporating an ITD survived to ICU admission versus 17 percent of patients whose treatment involved a sham device [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/12\">",
"       12",
"      </a>",
"      ]. Planned post-hoc analyses based on arrhythmias found that among patients with pulseless electrical activity (PEA) at any time during resuscitation, those treated with an ITD had higher ICU admission and 24 hour survival rates (41 and 27 percent) compared with patients not treated with an ITD (20 and 11 percent) (OR for ICU admission 2.82; 95% CI 1.19-6.67) (OR for 24 hour survival 3.01; 95% CI 1.07-8.96).",
"     </li>",
"     <li>",
"      Conversely, in a multicenter prospective trial of 8718 cardiac arrest patients given CPR and randomly assigned to treatment with an ITD or a sham device, no significant difference was found in neurologically satisfactory (modified Rankin score &lt;3) survival (254 (5.8 percent) survivors in the active ITD group versus 260 (6 percent) survivors in the sham ITD group) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/13\">",
"       13",
"      </a>",
"      ]. In addition, there was no difference between groups in adverse events or in secondary outcomes, including return of spontaneous circulation on arrival or survival to hospital discharge.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2010 ACLS Guidelines state that ITDs may be used by trained personnel in adult cardiac arrest. However, these Guidelines were published prior to the publication of the large negative trial described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/13\">",
"     13",
"    </a>",
"    ]. It remains to be determined whether ITDs may benefit particular subgroups of cardiac arrest patients (eg, those treated with active compression-decompression CPR) and therefore further research with ITDs is justified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     AUTOMATIC COMPRESSION DEVICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Researchers have developed automated devices that perform chest compressions and generate artificial circulation in much the same way as manually performed chest compressions. Two types of devices exist. One type uses a load-distributing band wrapped around the chest that rhythmically squeezes the chest circumferentially. A second type employs a piston placed on the sternum that compresses the chest in an anteroposterior plane. Both devices deliver closed chest compressions automatically, enabling rescuers to perform other interventions, minimizing interruptions in the performance of compressions, and eliminating the risk of decreased perfusion due to rescuer fatigue.",
"   </p>",
"   <p>",
"    A pilot study performed in in-hospital cardiac arrest patients found that an automated circumferential band compression device generated higher coronary perfusion pressures, thoracic aortic pressures, and right atrial pressures compared with manual chest compressions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies have assessed whether automated compression devices improve survival:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ASPIRE study, a multicenter randomized trial involving patients with out-of-hospital cardiac arrest, found no significant difference in outcome among 554 patients resuscitated with a load-distributing band device and 517 patients receiving manual chest compressions. The trial was stopped early when an independent safety review board recommended doing so at the first interim monitoring. Although there was no difference in the primary endpoint of survival to four hours from the time of EMS notification (24.7 percent automated group versus 26.4 percent manual group), survival to hospital discharge was lower in the automated group (5.8 versus 9.9 percent) and cerebral performance was also worse [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An observational cohort study of 783 adult out-of-hospital nontraumatic cardiac arrest patients found that patients treated with an automated load-distributing band device had improved return of spontaneous circulation (ROSC) and survival to hospital discharge (9.7 versus 2.9 percent) compared with the manual chest compression group (OR for ROSC 1.94; 95% CI 1.38-2.72) (OR for survival 2.27; 95% CI 1.11-4.77). There was no significant difference in cerebral performance among discharged patients in the two treatment groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective review using case-matched controls found a higher rate of ROSC (39 percent) among out-of-hospital cardiac arrest patients treated with an automated load-distributing band device compared with patients treated with manual chest compressions (29 percent). The effect appeared to be more pronounced in patients with asystole [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Recommendation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Further study is needed before a general recommendation can be made.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PERFORMANCE OF INTERPOSED ABDOMINAL COMPRESSION CPR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interposed abdominal compression CPR (IAC-CPR) refers to the application of external chest compressions with interposed midabdominal compressions performed by a second rescuer during the upstroke of the chest compression. Multiple animal studies have shown that IAC-CPR can increase systolic and diastolic BP, myocardial blood flow, and cerebral blood flow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis identified 38 peer-reviewed studies of IAC-CPR (25 were animal or mechanical model studies), of which 34 found significant benefit over standard CPR (S-CPR) based primarily on return of spontaneous circulation (ROSC), two found no difference in outcome, and two found IAC-CPR to be inferior to S-CPR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/19\">",
"     19",
"    </a>",
"    ]. The studies reported a single adverse event of likely traumatic pancreatitis in a single patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of four prospective randomized trials included in the meta-analysis, three were in-hospital studies, all of which found an increased rate of ROSC in the IAC-CPR arm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/21,22\">",
"     21,22",
"    </a>",
"    ], with one study reporting improved survival to discharge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/23\">",
"     23",
"    </a>",
"    ]. The lone prehospital study found no significant difference in ROSC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Recommendation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preliminary data supports the use of IAC-CPR in the in-hospital setting when performed by trained rescuers, and the 2010 ACLS Guidelines state that the technique may be used in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ACTIVE COMPRESSION-DECOMPRESSION CPR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Active compression-decompression CPR (ACD-CPR) is a method of chest compression that uses a suction device to convert the passive recoil of the chest wall into active expansion, thereby enhancing venous return. Studies in swine and humans using this method have demonstrated increased cerebral and myocardial perfusion and improved stroke volume [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although two preliminary studies demonstrated small but significant benefit in return of spontaneous circulation, survival to 24 hours, survival to one year, and improved neurologic outcome in patients receiving ACD-CPR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/27,28\">",
"     27,28",
"    </a>",
"    ], a meta-analysis of 10 studies showed no significant benefit in outcome, including immediate mortality, hospital discharge, and neurologic function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although one prospective randomized study found a significant increase in rib and sternum fractures among patients receiving ACD-CPR compared with standard CPR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/30\">",
"     30",
"    </a>",
"    ], the meta-analysis cited above found no significant difference in major complications (eg, rib or sterna fractures, hemothorax, pneumothorax), although skin trauma and ecchymosis were more common in the ACD-CPR group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A multicenter randomized trial of patients with out-of-hospital cardiac arrest, published after the meta-analysis described above, reported that 75 of 849 patients (9 percent) treated with both ACD-CPR and an impedance threshold device survived to hospital discharge compared to 47 of 813 patients (6 percent) treated with standard CPR (OR 1.58; 95% CI 1.07-2.36) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/31\">",
"     31",
"    </a>",
"    ]. The trial was stopped early because of enrollment and funding difficulties. Other challenges with this trial include the difficulty of determining the impact of the device&rsquo;s metronome and force gauge, used only in the intervention arm, on the quality of CPR independent of ACD-CPR, and the inability to control for the contribution of the ITD to the outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Recommendation",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to the 2010 ACLS Guidelines there is insufficient evidence to recommend for or against the use of ACD-CPR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     USE OF TRANSCUTANEOUS PACING IN ASYSTOLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transcutaneous pacing (TCP) is the delivery of a rhythmic electrical current to induce electrical conduction and mechanical activity in the heart. The current is conducted between two electrodes placed on the skin in a manner that ensures the heart lies between them.",
"   </p>",
"   <p>",
"    Multiple studies of TCP performed in the late 1980s found no significant survival benefit among patients in cardiac arrest from asystole and bradyasystole [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/32-36\">",
"     32-36",
"    </a>",
"    ]. A larger, subsequent randomized trial of TCP in out-of-hospital asystolic cardiac arrest also found no benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/37\">",
"     37",
"    </a>",
"    ]. A systematic review found no evidence to support the use of TCP for out-of-hospital bradyasystolic arrest, but found insufficient evidence to determine its role with symptomatic bradycardia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Recommendation",
"    </span>",
"    &nbsp;&mdash;&nbsp;TCP is not recommended for management of asystole or pulseless electrical activity in the 2010 ACLS Guidelines. The use of TCP in the emergent treatment of symptomatic bradycardia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13850?source=see_link&amp;anchor=H11#H11\">",
"     \"Advanced cardiac life support (ACLS) in adults\", section on 'Bradycardia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)",
"    </span>",
"    &nbsp;&mdash;&nbsp;ECMO for the treatment of cardiac arrest, sometimes referred to as extracorporeal life support (ECLS), involves cannulating a major vein and artery, typically the femorals. Venous blood is then circulated using a mechanical pump through an oxygenator and then back to the patient's arterial circulation. ECMO and cardiopulmonary bypass are temporizing measures that allow other treatments to be initiated. ECMO is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/62/37863?source=see_link\">",
"     \"Extracorporeal membrane oxygenation (ECMO) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of ECMO in adult cardiac arrest patients is the subject of several limited observational studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one prospective case series, 59 patients with in-hospital cardiac arrest received ECMO in addition to standard treatment. ECMO patients had higher survival rates when compared with unmatched controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective review of 176 in-hospital cardiac arrest patients treated with ECMO reported a 30 day survival rate of 28 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/40\">",
"       40",
"      </a>",
"      ]. Other reviews have found similar results [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective cohort study of 17 patients admitted to the intensive care unit with cardiac arrest unresponsive to standard ACLS treatment and subsequently managed with ECMO reported an 18 percent one year survival rate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/42\">",
"       42",
"      </a>",
"      ]. All survivors had sustained a drug overdose.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to excellent basic cardiopulmonary resuscitation, the successful use of ECMO depends upon appropriate patient selection and skillful implementation (eg, rapid response ECLS teams). However, the subset of cardiac arrest patients best suited for ECMO treatment is unknown. A shorter period of arrest prior to ECMO appears to improve outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/41,43\">",
"     41,43",
"    </a>",
"    ]; elevated prearrest lactate levels and noncardiac causes of arrest bode poorly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/43\">",
"     43",
"    </a>",
"    ]. The expense of ECMO must also be considered when determining whether to implement this treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Recommendation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2010 ACLS Guidelines state that ECMO may be of benefit for in-hospital patients who sustain a cardiac arrest when the period without blood flow is brief and the condition precipitating arrest is reversible (eg, drug overdose) or treatable by heart transplantation or revascularization. We concur that the evidence does not support routine use of ECMO in cardiac arrest.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MAGNESIUM SULFATE IN CARDIAC ARREST",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although initial case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/45\">",
"     45",
"    </a>",
"    ] and pilot studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/46\">",
"     46",
"    </a>",
"    ] suggested a benefit from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    in cardiac arrest, subsequent trials have been disappointing:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one randomized trial, patients with out-of-hospital cardiac arrest received either 5 g",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      or placebo as first line pharmacotherapy followed by standard ACLS treatments [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/47\">",
"       47",
"      </a>",
"      ]. Researchers found no benefit from magnesium when assessing return of spontaneous circulation (ROSC) or survival to discharge.",
"     </li>",
"     <li>",
"      A randomized trial involving 116 prehospital, nontrauma patients presenting with ventricular fibrillation found no benefit from",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      in ROSC, survival to admission, or survival to discharge [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/48\">",
"       48",
"      </a>",
"      ]. Patients in this trial who did not respond to initial defibrillation attempts received epinephrine and either placebo or magnesium.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Recommendation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2010 ACLS Guidelines state that in cases of cardiac arrest",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    should be used only for torsades de pointes associated with a long QT interval. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13850?source=see_link&amp;anchor=H8#H8\">",
"     \"Advanced cardiac life support (ACLS) in adults\", section on 'Ventricular fibrillation and pulseless ventricular tachycardia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     FIBRINOLYSIS IN CARDIAC ARREST",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocardial infarction and pulmonary embolism account for an estimated 50 to 70 percent of cases of sudden cardiac arrest (SCA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. Although fibrinolysis would seem to be a promising treatment for refractory SCA, studies have failed to demonstrate benefit:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A large, prospective multicenter trial (Thrombolysis in Cardiac Arrest, or TROICA, trial) was stopped early when preliminary analyses of 1050 patients failed to detect a difference between those receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/39/14966?source=see_link\">",
"       tenecteplase",
"      </a>",
"      and those receiving placebo in the primary endpoint of 30-day survival [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/52\">",
"       52",
"      </a>",
"      ]. There was also no significant difference in the secondary end points of hospital admission, return of spontaneous circulation, 24-hour survival, survival to hospital discharge, or neurologic outcome.",
"     </li>",
"     <li>",
"      Another randomized, double-blinded, controlled trial found no difference in survival to hospital discharge among patients with SCA and pulseless electrical activity (PEA) treated with tissue plasminogen activator (t-PA) in addition to standard resuscitation (n = 117) compared with patients treated with standard resuscitation alone (n = 116) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/53\">",
"       53",
"      </a>",
"      ]. Patient characteristics in the two groups were similar.",
"     </li>",
"     <li>",
"      A prospective trial of 90 out-of-hospital SCA patients demonstrated a significant improvement in return of spontaneous circulation (68 versus 44 percent) and survival to ICU admission (48 versus 30 percent) in patients treated with rt-PA compared with controls who received standard treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/51\">",
"       51",
"      </a>",
"      ]. However, no significant differences were noted in 24-hour survival or survival to hospital discharge.",
"     </li>",
"     <li>",
"      A post-hoc analysis of a prospective randomized trial designed to compare epinephrine and vasopressin in SCA evaluated 99 patients treated with fibrinolytics and found no difference in survival to hospital admission or discharge [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other studies have failed to find statistically significant benefit from fibrinolytic therapy in SCA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/51,54,55\">",
"     51,54,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Recommendation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2010 ACLS Guidelines conclude that it is reasonable to administer fibrinolytics when pulmonary embolism is the presumed or likely cause of SCA. However, the Guidelines further state that fibrinolytic therapy given during CPR for a presumed acute coronary occlusion does not improve outcomes and its routine use is not recommended. The use of thrombolytics in the management of acute coronary syndrome or stroke is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/43/1721?source=see_link\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/8/41098?source=see_link\">",
"     \"Reperfusion therapy for acute ischemic stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SODIUM BICARBONATE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reversing the acidosis caused by global hypoperfusion during cardiac arrest with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    makes physiologic sense. However, sodium bicarbonate&rsquo;s efficacy remains unproven in cardiac arrest and it may cause intracellular acidosis, metabolic alkalosis if perfusion is restored, and hypernatremia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40646?source=see_link\">",
"     \"Bicarbonate therapy in lactic acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies demonstrating a lack of benefit in cardiac arrest include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective randomized multicenter trial of 874 prehospital cardiac arrest patients found no improvement in overall survival in those treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective randomized trial of 502 adults suffering asystole or ventricular fibrillation (VF) refractory to initial defibrillation showed no difference in survival to discharge in patients treated with a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      -trometamol-phosphate mixture compared with controls treated with 0.9 percent saline [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35448/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Recommendation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2010 ACLS Guidelines recommend against the routine use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    for patients in cardiac arrest. However, sodium bicarbonate may be useful in particular circumstances, such as severe hyperkalemia or tricyclic antidepressant overdose Although some clinicians use sodium bicarbonate in patients with severe preexisting metabolic acidosis (pH below 7.10), there is no evidence for its benefit in this setting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/54/17258?source=see_link\">",
"     \"Treatment and prevention of hyperkalemia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36231?source=see_link\">",
"     \"Tricyclic antidepressant poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40646?source=see_link\">",
"     \"Bicarbonate therapy in lactic acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     AMIODARONE VERSUS LIDOCAINE IN REFRACTORY VF/VT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence supporting the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    for refractory ventricular fibrillation or pulseless ventricular tachycardia is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/24/8585?source=see_link\">",
"     \"Supportive data for advanced cardiac life support in adults with sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Recommendation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence that treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    improves rates of neurologically intact survival to hospital discharge among patients with cardiac arrest. The 2010 ACLS Guidelines state that amiodarone may be used in the treatment of VF or pulseless VT unresponsive to CPR, defibrillation, and vasopressor therapy (eg, epinephrine). The 2010 ACLS Guidelines further state that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    is without proven efficacy for VF or pulseless VT and consider it an alternative antiarrhythmic to be used when amiodarone is not available. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13850?source=see_link&amp;anchor=H8#H8\">",
"     \"Advanced cardiac life support (ACLS) in adults\", section on 'Ventricular fibrillation and pulseless ventricular tachycardia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98779146\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard management of patients in sudden cardiac arrest (SCA), cardiac arrhythmia, and related critical illness is thoroughly discussed in several UpToDate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13850?source=see_link\">",
"     \"Advanced cardiac life support (ACLS) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/25/36248?source=see_link\">",
"     \"Basic life support (BLS) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/28/35274?source=see_link\">",
"     \"Post-cardiac arrest management in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/34/23079?source=see_link\">",
"     \"Basic airway management in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/14/36068?source=see_link\">",
"     \"Advanced emergency airway management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of potential therapies for patients with SCA continue to be the subject of clinical study. Such therapies include resuscitation techniques, mechanical devices, and medications. Therapies that are the subject of clinical research but are not generally accepted as part of the standard resuscitation of patients in SCA are reviewed in this topic.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/1\">",
"      KOUWENHOVEN WB, MILNOR WR, KNICKERBOCKER GG, CHESNUT WR. Closed chest defibrillation of the heart. Surgery 1957; 42:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/2\">",
"      SAFAR P, ESCARRAGA LA, ELAM JO. A comparison of the mouth-to-mouth and mouth-to-airway methods of artificial respiration with the chest-pressure arm-lift methods. N Engl J Med 1958; 258:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/3\">",
"      KOUWENHOVEN WB, JUDE JR, KNICKERBOCKER GG. Closed-chest cardiac massage. JAMA 1960; 173:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/4\">",
"      Field JM, Hazinski MF, Sayre MR, et al. Part 1: executive summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/5\">",
"      Cave DM, Gazmuri RJ, Otto CW, et al. Part 7: CPR techniques and devices: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/6\">",
"      Lurie KG, Coffeen P, Shultz J, et al. Improving active compression-decompression cardiopulmonary resuscitation with an inspiratory impedance valve. Circulation 1995; 91:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/7\">",
"      Plaisance, P, Soleil, C, Ducros, L, et al. Measurement of intrathoracic pressures during basic and advanced cardiac life support which performing active compression decompression cardiopulmonary resuscitation with an inspiratory impedance threshold valve. Crit Care Med 2001; 29:A73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/8\">",
"      Langhelle A, Str&oslash;mme T, Sunde K, et al. Inspiratory impedance threshold valve during CPR. Resuscitation 2002; 52:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/9\">",
"      Plaisance P, Lurie KG, Payen D. Inspiratory impedance during active compression-decompression cardiopulmonary resuscitation: a randomized evaluation in patients in cardiac arrest. Circulation 2000; 101:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/10\">",
"      Plaisance P, Soleil C, Lurie KG, et al. Use of an inspiratory impedance threshold device on a facemask and endotracheal tube to reduce intrathoracic pressures during the decompression phase of active compression-decompression cardiopulmonary resuscitation. Crit Care Med 2005; 33:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/11\">",
"      Plaisance P, Lurie KG, Vicaut E, et al. Evaluation of an impedance threshold device in patients receiving active compression-decompression cardiopulmonary resuscitation for out of hospital cardiac arrest. Resuscitation 2004; 61:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/12\">",
"      Aufderheide TP, Pirrallo RG, Provo TA, Lurie KG. Clinical evaluation of an inspiratory impedance threshold device during standard cardiopulmonary resuscitation in patients with out-of-hospital cardiac arrest. Crit Care Med 2005; 33:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/13\">",
"      Aufderheide TP, Nichol G, Rea TD, et al. A trial of an impedance threshold device in out-of-hospital cardiac arrest. N Engl J Med 2011; 365:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/14\">",
"      Timerman S, Cardoso LF, Ramires JA, Halperin H. Improved hemodynamic performance with a novel chest compression device during treatment of in-hospital cardiac arrest. Resuscitation 2004; 61:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/15\">",
"      Hallstrom A, Rea TD, Sayre MR, et al. Manual chest compression vs use of an automated chest compression device during resuscitation following out-of-hospital cardiac arrest: a randomized trial. JAMA 2006; 295:2620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/16\">",
"      Ong ME, Ornato JP, Edwards DP, et al. Use of an automated, load-distributing band chest compression device for out-of-hospital cardiac arrest resuscitation. JAMA 2006; 295:2629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/17\">",
"      Casner M, Andersen D, Isaacs SM. The impact of a new CPR assist device on rate of return of spontaneous circulation in out-of-hospital cardiac arrest. Prehosp Emerg Care 2005; 9:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/18\">",
"      Ward KR, Sullivan RJ, Zelenak RR, Summer WR. A comparison of interposed abdominal compression CPR and standard CPR by monitoring end-tidal PCO2. Ann Emerg Med 1989; 18:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/19\">",
"      Babbs CF. Interposed abdominal compression CPR: a comprehensive evidence based review. Resuscitation 2003; 59:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/20\">",
"      Waldman PJ, Walters BL, Grunau CF. Pancreatic injury associated with interposed abdominal compressions in pediatric cardiopulmonary resuscitation. Am J Emerg Med 1984; 2:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/21\">",
"      Sack JB, Kesselbrenner MB, Jarrad A. Interposed abdominal compression-cardiopulmonary resuscitation and resuscitation outcome during asystole and electromechanical dissociation. Circulation 1992; 86:1692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/22\">",
"      Babbs CF. Simplified meta-analysis of clinical trials in resuscitation. Resuscitation 2003; 57:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/23\">",
"      Sack JB, Kesselbrenner MB, Bregman D. Survival from in-hospital cardiac arrest with interposed abdominal counterpulsation during cardiopulmonary resuscitation. JAMA 1992; 267:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/24\">",
"      Mateer JR, Stueven HA, Thompson BM, et al. Pre-hospital IAC-CPR versus standard CPR: paramedic resuscitation of cardiac arrests. Am J Emerg Med 1985; 3:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/25\">",
"      Lindner KH, Pfenninger EG, Lurie KG, et al. Effects of active compression-decompression resuscitation on myocardial and cerebral blood flow in pigs. Circulation 1993; 88:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/26\">",
"      Tucker KJ, Redberg RF, Schiller NB, Cohen TJ. Active compression-decompression resuscitation: analysis of transmitral flow and left ventricular volume by transesophageal echocardiography in humans. Cardiopulmonary Resuscitation Working Group. J Am Coll Cardiol 1993; 22:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/27\">",
"      Cohen TJ, Goldner BG, Maccaro PC, et al. A comparison of active compression-decompression cardiopulmonary resuscitation with standard cardiopulmonary resuscitation for cardiac arrests occurring in the hospital. N Engl J Med 1993; 329:1918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/28\">",
"      Plaisance P, Lurie KG, Vicaut E, et al. A comparison of standard cardiopulmonary resuscitation and active compression-decompression resuscitation for out-of-hospital cardiac arrest. French Active Compression-Decompression Cardiopulmonary Resuscitation Study Group. N Engl J Med 1999; 341:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/29\">",
"      Lafuente-Lafuente C, Melero-Bascones M. Active chest compression-decompression for cardiopulmonary resuscitation. Cochrane Database Syst Rev 2004; :CD002751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/30\">",
"      Baubin M, Sumann G, Rabl W, et al. Increased frequency of thorax injuries with ACD-CPR. Resuscitation 1999; 41:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/31\">",
"      Aufderheide TP, Frascone RJ, Wayne MA, et al. Standard cardiopulmonary resuscitation versus active compression-decompression cardiopulmonary resuscitation with augmentation of negative intrathoracic pressure for out-of-hospital cardiac arrest: a randomised trial. Lancet 2011; 377:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/32\">",
"      Paris PM, Stewart RD, Kaplan RM, Whipkey R. Transcutaneous pacing for bradyasystolic cardiac arrests in prehospital care. Ann Emerg Med 1985; 14:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/33\">",
"      Dalsey WC, Syverud SA, Hedges JR. Emergency department use of transcutaneous pacing for cardiac arrests. Crit Care Med 1985; 13:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/34\">",
"      Hedges JR, Syverud SA, Dalsey WC, et al. Prehospital trial of emergency transcutaneous cardiac pacing. Circulation 1987; 76:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/35\">",
"      Rosenthal E, Thomas N, Quinn E, et al. Transcutaneous pacing for cardiac emergencies. Pacing Clin Electrophysiol 1988; 11:2160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/36\">",
"      Barthell E, Troiano P, Olson D, et al. Prehospital external cardiac pacing: a prospective, controlled clinical trial. Ann Emerg Med 1988; 17:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/37\">",
"      Cummins RO, Graves JR, Larsen MP, et al. Out-of-hospital transcutaneous pacing by emergency medical technicians in patients with asystolic cardiac arrest. N Engl J Med 1993; 328:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/38\">",
"      Sherbino J, Verbeek PR, MacDonald RD, et al. Prehospital transcutaneous cardiac pacing for symptomatic bradycardia or bradyasystolic cardiac arrest: a systematic review. Resuscitation 2006; 70:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/39\">",
"      Chen YS, Lin JW, Yu HY, et al. Cardiopulmonary resuscitation with assisted extracorporeal life-support versus conventional cardiopulmonary resuscitation in adults with in-hospital cardiac arrest: an observational study and propensity analysis. Lancet 2008; 372:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/40\">",
"      Chillcott S, Stahovich M, Earnhardt C, Dembitsky W. Portable rapid response extracorporeal life support: a center's 20-year experience with a registered nurse-run program. Crit Care Nurs Q 2008; 31:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/41\">",
"      Younger JG, Schreiner RJ, Swaniker F, et al. Extracorporeal resuscitation of cardiac arrest. Acad Emerg Med 1999; 6:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/42\">",
"      M&eacute;garbane B, Leprince P, Deye N, et al. Emergency feasibility in medical intensive care unit of extracorporeal life support for refractory cardiac arrest. Intensive Care Med 2007; 33:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/43\">",
"      Huang SC, Wu ET, Chen YS, et al. Extracorporeal membrane oxygenation rescue for cardiopulmonary resuscitation in pediatric patients. Crit Care Med 2008; 36:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/44\">",
"      Mahle WT, Forbess JM, Kirshbom PM, et al. Cost-utility analysis of salvage cardiac extracorporeal membrane oxygenation in children. J Thorac Cardiovasc Surg 2005; 129:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/45\">",
"      Craddock L, Miller B, Clifton G, et al. Resuscitation from prolonged cardiac arrest with high-dose intravenous magnesium sulfate. J Emerg Med 1991; 9:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/46\">",
"      Miller B, Craddock L, Hoffenberg S, et al. Pilot study of intravenous magnesium sulfate in refractory cardiac arrest: safety data and recommendations for future studies. Resuscitation 1995; 30:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/47\">",
"      Fatovich DM, Prentice DA, Dobb GJ. Magnesium in cardiac arrest (the magic trial). Resuscitation 1997; 35:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/48\">",
"      Allegra J, Lavery R, Cody R, et al. Magnesium sulfate in the treatment of refractory ventricular fibrillation in the prehospital setting. Resuscitation 2001; 49:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/49\">",
"      Silfvast T. Cause of death in unsuccessful prehospital resuscitation. J Intern Med 1991; 229:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/50\">",
"      Spaulding CM, Joly LM, Rosenberg A, et al. Immediate coronary angiography in survivors of out-of-hospital cardiac arrest. N Engl J Med 1997; 336:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/51\">",
"      B&ouml;ttiger BW, Bode C, Kern S, et al. Efficacy and safety of thrombolytic therapy after initially unsuccessful cardiopulmonary resuscitation: a prospective clinical trial. Lancet 2001; 357:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/52\">",
"      B&ouml;ttiger BW, Arntz HR, Chamberlain DA, et al. Thrombolysis during resuscitation for out-of-hospital cardiac arrest. N Engl J Med 2008; 359:2651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/53\">",
"      Abu-Laban RB, Christenson JM, Innes GD, et al. Tissue plasminogen activator in cardiac arrest with pulseless electrical activity. N Engl J Med 2002; 346:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/54\">",
"      Stadlbauer KH, Krismer AC, Arntz HR, et al. Effects of thrombolysis during out-of-hospital cardiopulmonary resuscitation. Am J Cardiol 2006; 97:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/55\">",
"      Lederer W, Lichtenberger C, Pechlaner C, et al. Long-term survival and neurological outcome of patients who received recombinant tissue plasminogen activator during out-of-hospital cardiac arrest. Resuscitation 2004; 61:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/56\">",
"      Standards for cardiopulmonary resuscitation (CPR) and emergency cardiac care (ECC). I. Introduction. JAMA 1974; 227:Suppl:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/57\">",
"      Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 6: advanced cardiovascular life support: section 6: pharmacology II: agents to optimize cardiac output and blood pressure. The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. Circulation 2000; 102:I129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/58\">",
"      Aufderheide TP, Martin DR, Olson DW, et al. Prehospital bicarbonate use in cardiac arrest: a 3-year experience. Am J Emerg Med 1992; 10:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/59\">",
"      Vukmir RB, Katz L, Sodium Bicarbonate Study Group. Sodium bicarbonate improves outcome in prolonged prehospital cardiac arrest. Am J Emerg Med 2006; 24:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35448/abstract/60\">",
"      Dybvik T, Strand T, Steen PA. Buffer therapy during out-of-hospital cardiopulmonary resuscitation. Resuscitation 1995; 29:89.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 280 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-201.211.0.116-8A73E14F39-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_39_35448=[""].join("\n");
var outline_f34_39_35448=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H98779146\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INSPIRATORY IMPEDANCE THRESHOLD DEVICES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      AUTOMATIC COMPRESSION DEVICES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Recommendation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PERFORMANCE OF INTERPOSED ABDOMINAL COMPRESSION CPR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Recommendation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ACTIVE COMPRESSION-DECOMPRESSION CPR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Recommendation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      USE OF TRANSCUTANEOUS PACING IN ASYSTOLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Recommendation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Recommendation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MAGNESIUM SULFATE IN CARDIAC ARREST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Recommendation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      FIBRINOLYSIS IN CARDIAC ARREST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Recommendation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SODIUM BICARBONATE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Recommendation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      AMIODARONE VERSUS LIDOCAINE IN REFRACTORY VF/VT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Recommendation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98779146\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13850?source=related_link\">",
"      Advanced cardiac life support (ACLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/14/36068?source=related_link\">",
"      Advanced emergency airway management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/34/23079?source=related_link\">",
"      Basic airway management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/25/36248?source=related_link\">",
"      Basic life support (BLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40646?source=related_link\">",
"      Bicarbonate therapy in lactic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/62/37863?source=related_link\">",
"      Extracorporeal membrane oxygenation (ECMO) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/43/1721?source=related_link\">",
"      Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/28/35274?source=related_link\">",
"      Post-cardiac arrest management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/8/41098?source=related_link\">",
"      Reperfusion therapy for acute ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/24/8585?source=related_link\">",
"      Supportive data for advanced cardiac life support in adults with sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/54/17258?source=related_link\">",
"      Treatment and prevention of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36231?source=related_link\">",
"      Tricyclic antidepressant poisoning",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_39_35449="Heart rate variability: Uses other than after myocardial infarction";
var content_f34_39_35449=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Heart rate variability: Uses other than after myocardial infarction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/39/35449/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/39/35449/contributors\">",
"     Phyllis K Stein, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/39/35449/contributors\">",
"     Ary L Goldberger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/39/35449/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/39/35449/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/39/35449/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/39/35449/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/39/35449/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart rate (RR interval) variability (HRV) measurements provide a low-cost, widely available, non-invasive method for assessing cardiac autonomic function in humans and for predicting cardiovascular events, especially cardiac death and sustained ventricular arrhythmias, in coronary heart disease patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the clinical applications (primarily cardiopulmonary) of commonly-available tests of HRV in conditions other than after myocardial infarction. Its predictive value in patients who have had a myocardial infarction is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/22/10601?source=see_link\">",
"     \"Heart rate variability: Use after myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Variation in RR intervals derived from intervals between normal heart beats can be measured by many methods that can be categorized as time domain measures, frequency domain measures and",
"    <span class=\"nowrap\">",
"     nonlinear/complexity-based",
"    </span>",
"    measures (",
"    <a class=\"graphic graphic_table graphicRef79145 \" href=\"mobipreview.htm?15/22/15725\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Various commercial Holter and signal averaged ECG (SAECG) software provide estimates of short- and long-term HRV. The measures most often available from commercial software include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Standard deviation of NN (normal to normal RR) intervals over a 24-hour period (SDNN) or over a brief (usually five minute) measuring period",
"     </li>",
"     <li>",
"      Standard deviation of the average NN intervals for the 288 five-minute intervals in a 24-hour continuous ECG recording (SDANN)",
"     </li>",
"     <li>",
"      pNN50 and rMSSD",
"     </li>",
"     <li>",
"      Total power, ultra-low frequency (ULF) power, very-low frequency (VLF) power, low-frequency (LF) power, high-frequency (HF) power, and the ratio of",
"      <span class=\"nowrap\">",
"       LF/HF",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Detailed definitions for these HRV indices and for others that are primarily used in research are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/10/4264?source=see_link\">",
"     \"Heart rate variability: Technical aspects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Open source software for HRV analysis, along with open access databases and tutorials, is also freely available at the website of the",
"    <span class=\"nowrap\">",
"     NIH/NCRR",
"    </span>",
"    Research Resource for Complex Physiologic Signals (",
"    <a class=\"external\" href=\"file://www.physionet.org/\">",
"     www.physionet.org",
"    </a>",
"    ). Another well-known free resource for HRV software can be found at Kubios HRV (",
"    <a class=\"external\" href=\"file://kubios.uku.fi/\">",
"     file://kubios.uku.fi/",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Data documenting the reproducibility of these measurements and the role of the autonomic nervous system in promoting the development of arrhythmias are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/22/10601?source=see_link\">",
"     \"Heart rate variability: Use after myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL USES OF HRV",
"    </span>",
"    &nbsp;&mdash;&nbsp;HRV remains predominantly a research tool [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/4\">",
"     4",
"    </a>",
"    ]. As stated by the Task Force on HRV, there are two widely recognized clinical uses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prediction of risk of cardiac death or arrhythmic events after acute myocardial infarction",
"     </li>",
"     <li>",
"      Detection and quantification of autonomic neuropathy in patients with diabetes mellitus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Guidelines for the routine use of ambulatory monitoring to determine HRV were also published in 1999 by a task force of the American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/5\">",
"     5",
"    </a>",
"    ]. The considerable subsequent research on HRV will likely result in expanded clinical recommendations from a future task force, but this has not yet occurred.",
"   </p>",
"   <p>",
"    HRV research, based on both short-term measurements under controlled conditions and ambulatory Holter monitoring, encompasses a huge range of disciplines, more than can possibly be covered in this section. Here we will sample some of the cardiopulmonary-related RR variability research. Broadly speaking, this research falls into one of three categories: RR variability as a predictor of outcome, RR variability as a marker of the autonomic changes associated with various normal and pathological processes, and RR variability as a marker of the autonomic effect and possible mode of efficacy of different interventions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     RR variability and outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the most frequent uses of HRV analysis is for risk stratification for cardiac and arrhythmic death after a myocardial infarction. However, this technique has been used in a number of other settings. The predictive value of RR variability for nonfatal myocardial infarction or death when measured in patients who have angina pectoris without previous myocardial infarction is not yet clear. Similarly, it has not yet been definitively demonstrated that RR variability predicts mortality, particularly arrhythmic death, in patients with nonischemic dilated cardiomyopathy, hypertrophic cardiomyopathy, valvular heart disease, or congenital heart disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Low RR variability and outcome in the general population",
"    </span>",
"    &nbsp;&mdash;&nbsp;HRV has been evaluated from ECG rhythm strips in several population studies. Low RR variability is associated with mortality and the risk of cardiac events in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/6\">",
"     6",
"    </a>",
"    ]. As an example, the importance of low RR variability in the general population was evaluated in a random sample of 900 patients enrolled in the ARIC (Atherosclerosis Risk in Communities) study who had time-domain measures of RR variability determined from a two minute ECG rhythm strip [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/7\">",
"     7",
"    </a>",
"    ]. Subjects with low RR variability (SDNN &lt;23.9 ms) had an adverse cardiovascular risk profile. Compared to patients with an intermediate (SDNN 23.9 to 35.4 ms) and high RR variability (&ge;35.4 ms), those with low RR variability had a higher risk of coronary heart disease (relative rate 1.09 after adjusting for other coronary risk factors), cardiovascular death (adjusted relative risk 1.98), all-cause death (adjusted relative risk 1.50), and cancer death (adjusted relative risk 1.18).",
"   </p>",
"   <p>",
"    Using a different measure of HRV but with similar results, a study of 470 consecutive patients undergoing elective coronary angiography found that patients with obstructive CHD (&gt;50 percent stenosis) had significantly reduced HRV based on five-minute supine measurement, especially in the low frequency range (180 with versus 267 ms",
"    <sup>",
"     2",
"    </sup>",
"    without obstructive CHD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/8\">",
"     8",
"    </a>",
"    ]. In a multivariate analysis using a cutoff of 250 ms",
"    <sup>",
"     2",
"    </sup>",
"    , persons with low frequency power below 250 ms",
"    <sup>",
"     2",
"    </sup>",
"    were at significantly greater risk of obstructive CHD (adjusted OR 2.4, 95% CI 1.3-4.4) independent of baseline Framingham Risk Scores.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Low RR variability and outcome in older adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from the Framingham Heart study suggest that reduced RR variability predicts mortality in a population-based sample of elderly subjects. In a study of 1825 surviving participants, 736 with an average age of 72 years who underwent two hour ambulatory ECG monitoring were selected for analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/9\">",
"     9",
"    </a>",
"    ]. The clinical characteristics of the participants were similar to those of the nonparticipants. Frequency domain analysis was performed on 100 sec blocks of data, sampled at 128",
"    <span class=\"nowrap\">",
"     samples/sec,",
"    </span>",
"    and power spectral density was calculated using a fast Fourier transform method. After an average follow-up of 3.9 years, decreased low frequency power (the same HRV measure used in the angiography study cited above) was the best of eight time and frequency domain measures of RR variability for predicting death of all causes with a relative risk of 1.87. After statistical adjustment for age, sex, and clinical risk factors (history of myocardial infarction, heart failure, diuretic use, and frequent or complex ventricular premature complexes), the relative risk of mortality was 1.70.",
"   </p>",
"   <p>",
"    In a study of risk factors for cardiovascular disease in elderly individuals from the Cardiovascular Health Study, a combination of decreased values for the non-linear measure short-term fractal scaling exponent and abnormal values for heart rate turbulence (HRT) from 24-hour Holter recordings had a stronger relationship to cardiovascular mortality than did traditional time and frequency domain HRV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/10\">",
"     10",
"    </a>",
"    ]. Even in the lowest stratum of Framingham Risk Score, abnormal values for these measures identified a group with a significantly increased relative risk of mortality (7.7) compared to those in the same stratum with normal HRV.",
"   </p>",
"   <p>",
"    In a reanalysis of the same data, elderly individuals were characterized as having no CVD risk factors (healthy), subclinical CVD, and having clinical CVD (a CVD event). The ability of 24-hour heart rate turbulence (HRT) to identify those in each stratum at increase risk of CVD mortality on up to 12 years of follow-up was compared with that of elevated C-reactive protein (CRP &gt;3.0",
"    <span class=\"nowrap\">",
"     mg/L)",
"    </span>",
"    in an adjusted model stratified on CVD status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/11\">",
"     11",
"    </a>",
"    ]. Having abnormal HRT and high CRP identified healthy adults at markedly increased risk of mortality, but only HRT was associated with increased risk in those with subclinical or clinical disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Low RR variability and outcome in patients referred for 24-hour Holter recording",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hypothesis that a disturbance in autonomic nervous system activity may play a role in sudden cardiac death was evaluated in 6693 consecutive patients who underwent 24-hour ambulatory electrocardiographic recordings. The reasons for the test included evaluation of palpitations, dizziness, syncope, or angina pectoris; risk assessment after myocardial infarction; evaluation of antiarrhythmic therapy; or as a search for a cardiac cause of transient cerebral events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/12\">",
"     12",
"    </a>",
"    ]. Three time domain measures of RR variability were used: pNN50, short-term variation (mean over 24 hours of per-minute standard deviations of RR intervals), and long-term variation (standard deviation over 24 hours of per-minute means of RR intervals). Although the last two measures are not orthodox, the measure of short-term variation is similar to SDNNIDX (averaged 5-min standard deviation of RR intervals) or LF power and the measure of long-term variation is similar to SDANN or ULF power.",
"   </p>",
"   <p>",
"    After a two-year follow-up period, patients with low values for these three measures of RR variability had a higher relative risk of experiencing sudden cardiac death (1.8 for pNN50, 3.0 for short-term variation, and 2.7 for long-term variation). These results indicate that RR variability has predictive value in a consecutive, heterogeneous group of patients referred to a Holter laboratory.",
"   </p>",
"   <p>",
"    The potential predictive value of HRV in an unselected cohort of apparently healthy people was further illustrated in a cohort of 260 subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/13\">",
"     13",
"    </a>",
"    ]. Over an eight year follow-up, four of these patients experienced sudden cardiac death. These individuals were at or below the 95% confidence limit for both SDNN and pNN6 percent (percent of successive NN intervals differing by more than 6 percent of mean NN) compared to the 140 subjects who remained healthy.",
"   </p>",
"   <p>",
"    This question was examined in the Cardiovascular Health Study, in which 49 older adults who died of sudden cardiac death were matched by age, gender, diabetes, history of MI, and beta blocker use with controls. Except for decreased normalized low frequency power, time and frequency domain HRV measures were not associated with sudden death. However, being in the upper half of PVC counts (odds ratio [OR] 6.9, 95% CI 2.3-19.1) and having a short-term fractal scaling exponent of less than 1.05 (OR 5.0, 95% CI 1.8-16.6) were independently associated with SCD. When these risk factors were combined having both higher VPCs and lower short-term fractal scaling exponent was associated with an OR 9.6 (95% CI 3.7-24.6) for SCD compared with 3.1 (95% CI 1.2-8.1) for having either. Thus, certain measures of RR variability from 24-hour Holter-type recordings may add to the identification of higher risk of sudden death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     RR variability and outcome in heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data that RR variability may be of predictive value in dilated cardiomyopathy and heart failure in general, and many of the existing studies include heart failure patients of mixed etiologies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/15-20\">",
"     15-20",
"    </a>",
"    ]. However, one study of 64 patients with dilated cardiomyopathy found that measures of RR variability were reduced compared to controls and that reduced RR variability was associated with disease severity measures such as NYHA functional class, left ventricular diastolic dimension, reduced left ventricular ejection fraction, and peak O2 consumption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/15\">",
"     15",
"    </a>",
"    ]. At 12 months, patients with an SDNN less than 50 ms had a lower survival rate free of progressive heart failure than those with a higher value.",
"   </p>",
"   <p>",
"    A much larger group of 433 outpatients with heart failure was evaluated in 431 outpatients with class I-III heart failure from the UK-HEART study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/19\">",
"     19",
"    </a>",
"    ]. After a follow-up of 482 days, SDNN was found to be an independent predictor of all-cause mortality and the most powerful predictor of death from progressive heart failure. The risk ratio for 41.2 ms decrease in SDNN was 1.62. The annual mortality for those with SDNN of &gt;100 ms, 50 to 100 ms, and &lt;50 ms was 5.5, 12.7, and 51.4 percent, respectively (",
"    <a class=\"graphic graphic_figure graphicRef62928 \" href=\"mobipreview.htm?31/59/32701\">",
"     figure 1",
"    </a>",
"    ). In another study of 116 patients, a reduced SDNN &lt;100 ms was predictive of arrhythmic events and sudden cardiac death (",
"    <a class=\"graphic graphic_figure graphicRef68774 \" href=\"mobipreview.htm?2/5/2141\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HRV may also be a predictor of sudden death in patients with heart failure. In one report, a multivariate survival model was developed with data from 202 patients with moderate to severe HF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/22\">",
"     22",
"    </a>",
"    ]. Several measures of HRV were analyzed for inclusion in the model, and low-frequency (LF) power was significantly correlated with sudden death. In a validation sample of 242 patients, the correlation of LF power with sudden death was confirmed; the overall sudden death rate at three years was 8 percent among these patients, with a relative risk of 3.0 for those with LFP &le;11 ms",
"    <sup>",
"     2",
"    </sup>",
"    .",
"   </p>",
"   <p>",
"    Some studies have found that the predictive value of depressed HRV is independent of other known risk factors, including NYHA functional class, ejection fraction, peak oxygen consumption, and the presence of ventricular arrhythmia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/18\">",
"     18",
"    </a>",
"    ]. In contrast, the DIAMOND-CHF study of 499 patients found that measures of HRV were predictive of mortality in patients with class II heart failure, but did not provide independent prognostic information in patients with the most severe functional impairment (class IV heart failure) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/20\">",
"     20",
"    </a>",
"    ]. Consistent with this finding, RR variability measures were higher in NYHA class II patients without diabetes, but that this difference was significant among NYHA class III patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Improvement in HRV is seen with effective heart failure therapy, as with cardiac resynchronized therapy (CRT). Patients with improved HRV after CRT have better outcomes than those in whom HRV is not improved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/36/10823?source=see_link\">",
"     \"Rationale for and mechanisms of benefit of cardiac resynchronization therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     RR variability in spontaneous ventricular tachycardias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Changes in autonomic tone play an important role in arrhythmogenesis. Increased",
"    <span class=\"nowrap\">",
"     sympathetic/decreased",
"    </span>",
"    parasympathetic activity, manifested as an increase in heart rate, precedes the onset of sustained ventricular tachycardias (VT) in the majority of patients in whom the initiation of the VT has been recorded [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. In one study of 47 patients with spontaneous VT recorded on 24 hours of ambulatory monitoring, all patients had an increase in heart rate 15 minutes prior to VT onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/28\">",
"     28",
"    </a>",
"    ]. However, 68 percent had a decrease in total power, LF power, and",
"    <span class=\"nowrap\">",
"     LF/HF",
"    </span>",
"    ratio 15 minutes prior to VT, and these patients had a higher baseline level of these parameters during the two hours before VT. The remaining patients who had a lower baseline level of total power, LF power, and",
"    <span class=\"nowrap\">",
"     LF/HF",
"    </span>",
"    ratio had an increase in these parameters prior to VT. These data suggest that change in the dynamics of RR intervals, rather than the direction of change, facilitates VT induction in most patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     RR variability in atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Though the presence of atrial fibrillation precludes the use of standard RR variability analysis, analysis of the variability and irregularity of the ventricular response interval (VRI) may provide useful information. This was addressed in one series of 107 patients with chronic atrial fibrillation who underwent 24 hour ambulatory monitoring for VRI variability and irregularity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/29\">",
"     29",
"    </a>",
"    ]. After a follow-up of 33 months, reductions in all VRI variability and irregularity measures were associated with an increased risk for cardiac death, but not fatal stroke. The five year cardiac mortality for the upper, middle, and lower tertiles of VRI irregularity was 0, 13, and 43 percent, respectively.",
"   </p>",
"   <p>",
"    RR variability may also predict early recurrence of atrial fibrillation after cardioversion. This was seen in a study of 93 patients who underwent cardioversion during",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    therapy and had RR variability measured in sinus rhythm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/30\">",
"     30",
"    </a>",
"    ]. The recurrence rate at two weeks in those with a",
"    <span class=\"nowrap\">",
"     LF/HF",
"    </span>",
"    ratio &ge;2, an indicator of increased sympathetic and reduced vagal activity, was significantly higher than in patients with a ratio &lt;2 (73 versus 9 percent); a value of &ge;2 predicted recurrence with a sensitivity and specificity of 76 and 90 percent, respectively. This ratio was not predictive of late recurrences of the arrhythmia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/41/31384?source=see_link&amp;anchor=H7#H7\">",
"     \"Paroxysmal atrial fibrillation\", section on 'Natural history'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     RR variability in renal failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autonomic dysfunction has been a consistent finding in patients with chronic kidney disease who are also known to be at increased risk for both high-grade ventricular arrhythmias and sudden death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/31\">",
"     31",
"    </a>",
"    ]. Abnormal HRV has been associated with risk of sudden cardiac death in patients with end-stage renal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/32\">",
"     32",
"    </a>",
"    ]. In chronic hemodialysis patients, SDNN &lt;75 ms was reported to be an independent predictor of mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/33\">",
"     33",
"    </a>",
"    ]. Patients with diabetes mellitus and renal failure have also been shown to have more abnormal HRV and worse survival, consistent with what has been shown in other populations. As an example, one study reported that SDNN was &lt;50 ms in 60 percent of patients referred for kidney transplantation who subsequently died [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/34\">",
"     34",
"    </a>",
"    ]. Diabetes was associated with the worst HRV, but those who exercised had better HRV. Also, although heart transplantation is associated with a near total loss of HRV, kidney transplantation has been shown to markedly improve it [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/35\">",
"     35",
"    </a>",
"    ]. Thus, ESRD patients may represent a population in whom HRV measures might have great clinical potential.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     RR variability in stroke patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;RR variability is also adversely affected in ischemic stroke patients; it has a gradual recovery during the months that follow. However, HRV values remain below those of normal controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/36\">",
"     36",
"    </a>",
"    ]. More abnormal autonomic function, has been associated with worse motor impairment and aerobic function both acutely and within three months of ischemic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/37\">",
"     37",
"    </a>",
"    ]. In another study, HRV measured as SDNN predicted an unfavorable outcome to post-stroke rehabilitation in 85 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/38\">",
"     38",
"    </a>",
"    ]. Although not all studies have found that HRV predicts the probability of functional recovery, these results do suggest a potential role for HRV in post-stroke rehabilitation. There do not appear to be any studies using HRV as a marker for recovery in the post-stroke population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     RR variability to detect and quantity obstructive sleep apnea hypopnea syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Very low-frequency periodic oscillations in cardiac interbeat intervals (every thirty seconds to every two minutes) are often associated with prolonged cycles of sleep apnea or hypopneas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. These oscillations reflect the abrupt tachycardia associated with the periodic arousal from sleep that follows each apneic event and results in the (however brief) restoration of normal airway patency. A number of techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/41-43\">",
"     41-43",
"    </a>",
"    ] have been applied to detect and quantify these periods of pathologic cyclic heart rate behavior, thereby differentiating periods of prolonged apnea from periods of normal respiration. The source code for one fully automated technique [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/41,42\">",
"     41,42",
"    </a>",
"    ] is freely available at the NIH PhysioNet website along with annotated databases from subjects with obstructive sleep apnea and controls (",
"    <a class=\"external\" href=\"file://www.physionet.org/physiotools/apdet\">",
"     www.physionet.org/physiotools/apdet",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     RR variability in amyloidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autonomic dysfunction is a feature of amyloidosis and its presence is associated with an increased mortality, especially in patients with AL amyloidosis. This was illustrated in a series of 45 patients with AA and AL amyloidosis. Among the 23 with AL amyloidosis, SDNN &le;50 ms was associated with an increase in overall mortality (risk ratio 11.5 compared to SDNN &gt;50 ms); the mean survival for those with SDNN &le;50 ms was 93 days, while 80 percent of those with an SDNN &gt;50 ms were alive at one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/31/1530?source=see_link\">",
"     \"An overview of amyloidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/10/23722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of amyloid cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     RR variability: effects of interventions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Effect of exercise on HRV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endurance athletes generally have higher HRV than do sedentary subjects. This has led to the assumption that their higher HRV is a direct result of their exercise program [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/45\">",
"     45",
"    </a>",
"    ]. However, the effect of exercise training on the cardiovascular system has a strong genetic component [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/46\">",
"     46",
"    </a>",
"    ]. It is clear that exercise training produces a reduction in resting heart rate, believed to be due to an increase in parasympathetic tone. In a study of 13 healthy older (&ge;60 years) and 11 healthy younger patients (&le;32 years) who underwent six months of intensive aerobic training, HRV in the time domain at rest increased by 68 percent in older patients and 17 percent in the younger patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/47\">",
"     47",
"    </a>",
"    ]. However, in another study of intensive, nine month exercise training in healthy older adults, the modest (12 percent) increase in SDNN was entirely attributable to the decrease in nighttime heart rates and there were no changes in parasympathetically-mediated HRV indices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Exercise training has increased HRV in patients with coronary artery disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/49\">",
"     49",
"    </a>",
"    ]. The improvement in HRV associated with exercise training may, in part, account for the benefit of exercise in reducing all cause and cardiovascular mortality. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/28/14793?source=see_link\">",
"     \"Exercise and fitness in the prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H452457250\">",
"    <span class=\"h3\">",
"     Effect of caloric restriction on HRV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Caloric restriction has been shown to prolong life spans in laboratory rodents. In these animals, markers of inflammation and other cardiovascular risk factors are markedly reduced. As a result, voluntary caloric restriction had been adopted by certain individuals in the hope that a similar, age-retarding effect will be seen in humans. HRV has a known decline with normal aging, and it is possible that a slower decline in HRV with age would be seen with caloric restriction. This possibility was tested in a cross-sectional study comparing HRV in 22 individuals who had practiced caloric restriction for at least five years and 20 age matched controls eating western diets. [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/50\">",
"     50",
"    </a>",
"    ]. This study found that HRV was markedly higher in the calorie-restricted individuals and that their HRV was similar to or better than normative values for individuals 20 years younger, while HRV in those on normal diets was exactly as predicted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     RR variability to study drug effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of drugs can influence heart rate and may have an effect on RR variability. These include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    , beta blockers, calcium channel blockers,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , angiotensin converting enzyme (ACE) inhibitors, and antiarrhythmic drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Anticholinergic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A high dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    can abolish both HF and VLF power and markedly attenuate LF power [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. These findings indicate that, in normal individuals, parasympathetic modulation of RR intervals is totally responsible for HF power and contributes importantly to LF power. VLF power, although abolished by atropine, is also increased by ACE inhibition, suggesting that parasympathetic activity is not the sole determinant of this component of HRV. Low doses of atropine or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/31/33264?source=see_link\">",
"     scopolamine",
"    </a>",
"    enhance vagal modulation of RR intervals, ie, they increase HF power, via a central action. This has been demonstrated in both normal subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/53,54\">",
"     53,54",
"    </a>",
"    ] and those with congestive heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, RR variability responses to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    do not appear to have a relationship to parasympathetic measures of HRV, which are often described (incorrectly) as \"measuring overall vagal tone\". In a study of 61 healthy adults, stepped vagotonic doses of atropine were given while subjects breathed at 15",
"    <span class=\"nowrap\">",
"     times/min",
"    </span>",
"    and both maximum bradycardia and the peak HRV were measured [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/56\">",
"     56",
"    </a>",
"    ]. Although there was a strong correlation between amount of atropine given and RR interval, the peak of RR variability corresponded with the peak vagotonic effect in only 10 percent of subjects. Moreover, the change in the indices from baseline to the peak vagotonic dose correlated poorly with the change in RR interval. HRV measures, particularly short-term ones may represent cardiac vagal tone modulation, rather than overall vagal tone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of the beta blocker",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    on time and frequency domain measures of RR variability calculated from 24-hour continuous ECG recordings was evaluated in 18 normal volunteers given atenolol,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    , and placebo in random order [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/57\">",
"     57",
"    </a>",
"    ]. During treatment with atenolol, the 24-hour average NN interval increased 24 percent and measures of phasic vagal activity (HF power, r-MSSD, pNN50) were also significantly increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/57\">",
"     57",
"    </a>",
"    ]. In another report, beta blockade with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    enhanced resting HF power and reduced LF power [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/58\">",
"     58",
"    </a>",
"    ]. Results of RR variability analysis suggest that evening doses of beta-blocker may be more efficacious than morning doses, at least in patients with heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effects may be different with certain other beta blockers that have additional activities. As an example,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/15/10487?source=see_link\">",
"     pindolol",
"    </a>",
"    , a beta blocker that has intrinsic sympathomimetic activity, decreased total, LF, and HF power in normal subjects, while",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35544?source=see_link\">",
"     labetalol",
"    </a>",
"    , which has combined alpha- and beta-adrenergic blocking activity, produced no significant change in these parameters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, beta blockade causes a substantial increase in vagal modulation of RR variability unless the beta blocker has other actions, such as intrinsic sympathomimetic activity or alpha-adrenergic blocking activity. Since there is little sympathetic nervous activity in resting normal persons, the effects of beta blockade on sympathetic modulation of RR intervals are variable and smaller. One study showed that chronic beta blockade blunted the marked increase in LF power that normally occurs during 90&ordm; head-up tilt [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     Carvedilol",
"    </a>",
"    is a nonselective beta blocker and an alpha1-adrenergic antagonist. Therapy with this agent in chronic heart failure increases cardiac vagal modulation of heart rate (eg, increased SDNN, r-MSSD, high frequency power) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/62,63\">",
"     62,63",
"    </a>",
"    ], which may contribute to its beneficial effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Calcium channel blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variable effects on RR variability have been reported with the different calcium channel blockers. In one study,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    had no significant effect on 24-hour average RR interval or on any measure of heart period variability in normal subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/57\">",
"     57",
"    </a>",
"    ]. In another report, however, the administration of diltiazem, but not",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    , during head-up tilt reduced the increase in LF power to the same degree as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    in nine postinfarction patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Digoxin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    on RR variability were investigated in a study of 20 normal subjects who were randomized to digoxin or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/65\">",
"     65",
"    </a>",
"    ]. Ambulatory monitoring for 24 hours was performed after five days of treatment, and 10 subjects also had tilt table studies. The average RR interval did not change significantly during digoxin treatment, but HF power increased by approximately 50 percent and LF power by approximately 30 percent, suggesting that digoxin increased the vagal modulation of RR intervals without changing the mean value for the RR intervals. Digoxin had no significant effect on the autonomic response to head-up tilt in these healthy subjects.",
"   </p>",
"   <p>",
"    The effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    on heart rate variability with chronic heart failure and systolic dysfunction have also been investigated. The Dutch Multicenter Ibopamine Trial (DMIT) Study Group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/66\">",
"     66",
"    </a>",
"    ] studied 59 patients with mild to moderate chronic heart failure associated with systolic dysfunction. After three months, patients randomized to digoxin showed a significant (p&lt;0.01) increase in both pNN50 and in high-frequency power, which are markers of cardiac vagal modulation. In contrast, these indices showed a decrease in the placebo group. Similar HRV findings consistent with an enhancement of vagal tone activity with long-term digoxin therapy in patients with mild to moderate chronic heart failure have been reported in other studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/67,68\">",
"     67,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, short-term HRV measures like pNN metrics and high-frequency spectral power do not distinguish between physiologic increased RR variability associated with greater respiratory sinus arrhythmia and pathologic increased RR variability associated with more random HR patterns due to subtle supraventricular ectopy or sinus node dysfunction. The former finding is probably beneficial and the later has been associated with increased risk of cardiovascular mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     ACE inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of ACE inhibitors on RR variability appears to vary with the patient population being studied. There may be no significant effect on RR variability or the autonomic response to head-up tilt in normal subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/68\">",
"     68",
"    </a>",
"    ]. In comparison, in a series of 32 patients with class III heart failure,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    increased the median NN50, a clear suggestion of increased cardiac parasympathetic modulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been suggested that ACE inhibitors increase parasympathetic activity by reducing angiotensin II levels, thereby removing the cardiac vagal inhibitory activity of angiotensin II [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/71\">",
"     71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36825?source=see_link\">",
"     \"Actions of angiotensin II on the heart\"",
"    </a>",
"    .) It is possible that the increase in vagal activity during ACE inhibitor therapy might contribute to the increase in survival produced by these agents in patients with congestive heart failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16090?source=see_link\">",
"     \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Antiarrhythmic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of three antiarrhythmic drugs on RR variability was evaluated in a study of patients with cardiac disease being treated for nonsustained ventricular arrhythmias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/72\">",
"     72",
"    </a>",
"    ]. NN50 was used to assess the impact on parasympathetic modulation of RR intervals.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"     Flecainide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    decreased NN50 by 56 and 64 percent, respectively, while",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    had no effect. It was suggested that the substantial decrease of NN50 during the administration of class IC antiarrhythmic agents reflected an antivagal effect. It is possible that this contributes to the occasionally deleterious effect of these drugs on mortality in postinfarction patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/38/31336?source=see_link\">",
"     \"Prophylaxis against ventricular arrhythmias following myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As first mentioned in the section on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , these studies illustrate an important caveat in the interpretation of HRV indices of cardiac vagal modulation, both in older adults and in patients with heart failure. Although increases in HRV indices like pNN50 may reflect enhancement of cardiac vagal control, they could also reflect an abnormal increase in short-term randomness in HR patterns, as noted in the Zutphen study discussed above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/73\">",
"     73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/10/4264?source=see_link\">",
"     \"Heart rate variability: Technical aspects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, time domain measures like SDNN, SDANN and frequency domain measures such as total- and ultra-low frequency power are relatively insensitive to abnormalities in beat-to-beat changes in HRV; however, low values for them do capture one important aspect of abnormal HRV, namely a lack of circadian rhythm, usually mediated by a failure of the heart rate to decrease at night, something that cannot be captured by a supine 5-minute recording. A very low value for beat-to-beat HRV, which can be captured by a short-term recording, is also an unequivocal marker for abnormal autonomic function. However, in addition to decreased beat-to-beat variability, another aspect of abnormal HRV is increased randomness of beat-to-beat changes, especially in populations where abnormal HRV patterns are prevalent. This would result in higher but not necessarily better values for beat-to-beat HRV measures like rMSSD, pNN50, and HF power, although since LF power captures HR changes on a slower scale, it could be less affected. In those populations, or really in the case of any remarkably high values for beat-to-beat HRV, further testing, perhaps using graphical analysis techniques or newer",
"    <span class=\"nowrap\">",
"     nonlinear/complexity-based",
"    </span>",
"    measures should be employed before assuming that vagal control of the heart is \"better\" in certain subjects or has improved with an intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35449/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4189833\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Heart rate (RR interval) variability (HRV) measurements provide a low-cost, non-invasive method for assessing cardiac autonomic function in humans and for predicting cardiovascular events, especially cardiac death and sustained ventricular arrhythmias, in coronary heart disease patients. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While HRV remains predominantly a research tool, two widely recognized clinical uses include the prediction of risk of cardiac death or arrhythmic events after acute myocardial infarction and detection and quantification of autonomic neuropathy in patients with diabetes mellitus. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical uses of HRV'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/22/10601?source=see_link\">",
"       \"Heart rate variability: Use after myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      HRV has also been studied in a variety of other clinical situations (eg, heart failure, atrial fibrillation, renal failure, stroke) but is not routinely measured in these situations. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical uses of HRV'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/1\">",
"      Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 1996; 93:1043.",
"     </a>",
"    </li>",
"    <li>",
"     Dynamic Electrocardiography, Malik M, Camm AJ (Eds), Blackwell Futura, Elmsford 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/3\">",
"      Huikuri HV, M&auml;kikallio T, Airaksinen KE, et al. Measurement of heart rate variability: a clinical tool or a research toy? J Am Coll Cardiol 1999; 34:1878.",
"     </a>",
"    </li>",
"    <li>",
"     Neural Mechanisms in Cardiac Arrhythmias, Schwartz PJ, Brown AM, Malliani A, Zanchetti A (Eds), Raven Press, New York 1978.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/5\">",
"      Crawford MH, Bernstein SJ, Deedwania PC, et al. ACC/AHA guidelines for ambulatory electrocardiography: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee to revise the guidelines for ambulatory electrocardiography). Circulation 1999; 100:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/6\">",
"      Tsuji H, Larson MG, Venditti FJ Jr, et al. Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study. Circulation 1996; 94:2850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/7\">",
"      Dekker JM, Crow RS, Folsom AR, et al. Low heart rate variability in a 2-minute rhythm strip predicts risk of coronary heart disease and mortality from several causes: the ARIC Study. Atherosclerosis Risk In Communities. Circulation 2000; 102:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/8\">",
"      Kotecha D, New G, Flather MD, et al. Five-minute heart rate variability can predict obstructive angiographic coronary disease. Heart 2012; 98:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/9\">",
"      Tsuji H, Venditti FJ Jr, Manders ES, et al. Reduced heart rate variability and mortality risk in an elderly cohort. The Framingham Heart Study. Circulation 1994; 90:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/10\">",
"      Stein PK, Barzilay JI, Chaves PH, et al. Novel measures of heart rate variability predict cardiovascular mortality in older adults independent of traditional cardiovascular risk factors: the Cardiovascular Health Study (CHS). J Cardiovasc Electrophysiol 2008; 19:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/11\">",
"      Stein PK, Barzilay JI. Relationship of abnormal heart rate turbulence and elevated CRP to cardiac mortality in low, intermediate, and high-risk older adults. J Cardiovasc Electrophysiol 2011; 22:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/12\">",
"      Algra A, Tijssen JG, Roelandt JR, et al. Heart rate variability from 24-hour electrocardiography and the 2-year risk for sudden death. Circulation 1993; 88:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/13\">",
"      M&oslash;lgaard H, S&oslash;rensen KE, Bjerregaard P. Attenuated 24-h heart rate variability in apparently healthy subjects, subsequently suffering sudden cardiac death. Clin Auton Res 1991; 1:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/14\">",
"      Stein PK, Sanghavi D, Sotoodehnia N, et al. Association of Holter-based measures including T-wave alternans with risk of sudden cardiac death in the community-dwelling elderly: the Cardiovascular Health Study. J Electrocardiol 2010; 43:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/15\">",
"      Yi G, Goldman JH, Keeling PJ, et al. Heart rate variability in idiopathic dilated cardiomyopathy: relation to disease severity and prognosis. Heart 1997; 77:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/16\">",
"      Szab&oacute; BM, van Veldhuisen DJ, van der Veer N, et al. Prognostic value of heart rate variability in chronic congestive heart failure secondary to idiopathic or ischemic dilated cardiomyopathy. Am J Cardiol 1997; 79:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/17\">",
"      Fauchier L, Babuty D, Cosnay P, et al. Heart rate variability in idiopathic dilated cardiomyopathy: characteristics and prognostic value. J Am Coll Cardiol 1997; 30:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/18\">",
"      Ponikowski P, Anker SD, Chua TP, et al. Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1997; 79:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/19\">",
"      Nolan J, Batin PD, Andrews R, et al. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). Circulation 1998; 98:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/20\">",
"      M&auml;kikallio TH, Huikuri HV, Hintze U, et al. Fractal analysis and time- and frequency-domain measures of heart rate variability as predictors of mortality in patients with heart failure. Am J Cardiol 2001; 87:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/21\">",
"      Fauchier L, Babuty D, Cosnay P, Fauchier JP. Prognostic value of heart rate variability for sudden death and major arrhythmic events in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1999; 33:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/22\">",
"      La Rovere MT, Pinna GD, Maestri R, et al. Short-term heart rate variability strongly predicts sudden cardiac death in chronic heart failure patients. Circulation 2003; 107:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/23\">",
"      Stein PK, Deedwania P. New York Heart Association functional class influences the impact of diabetes on cardiac autonomic function. J Electrocardiol 2010; 43:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/24\">",
"      Fantoni C, Raffa S, Regoli F, et al. Cardiac resynchronization therapy improves heart rate profile and heart rate variability of patients with moderate to severe heart failure. J Am Coll Cardiol 2005; 46:1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/25\">",
"      Landolina M, Gasparini M, Lunati M, et al. Heart rate variability monitored by the implanted device predicts response to CRT and long-term clinical outcome in patients with advanced heart failure. Eur J Heart Fail 2008; 10:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/26\">",
"      Shusterman V, Aysin B, Gottipaty V, et al. Autonomic nervous system activity and the spontaneous initiation of ventricular tachycardia. ESVEM Investigators. Electrophysiologic Study Versus Electrocardiographic Monitoring Trial. J Am Coll Cardiol 1998; 32:1891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/27\">",
"      Nemec J, Hammill SC, Shen WK. Increase in heart rate precedes episodes of ventricular tachycardia and ventricular fibrillation in patients with implantable cardioverter defibrillators: analysis of spontaneous ventricular tachycardia database. Pacing Clin Electrophysiol 1999; 22:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/28\">",
"      Shusterman V, Aysin B, Weiss R, et al. Dynamics of low-frequency R-R interval oscillations preceding spontaneous ventricular tachycardia. Am Heart J 2000; 139:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/29\">",
"      Yamada A, Hayano J, Sakata S, et al. Reduced ventricular response irregularity is associated with increased mortality in patients with chronic atrial fibrillation. Circulation 2000; 102:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/30\">",
"      Lombardi F, Colombo A, Basilico B, et al. Heart rate variability and early recurrence of atrial fibrillation after electrical cardioversion. J Am Coll Cardiol 2001; 37:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/31\">",
"      Kirvela M, Salmela K, Toivonen L, et al. Heart rate variability in diabetic and non-diabetic renal transplant patients. Acta Anaesthesiol Scand 1996; 40:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/32\">",
"      Hayano J, Takahashi H, Toriyama T, et al. Prognostic value of heart rate variability during long-term follow-up in chronic haemodialysis patients with end-stage renal disease. Nephrol Dial Transplant 1999; 14:1480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/33\">",
"      Oikawa K, Ishihara R, Maeda T, et al. Prognostic value of heart rate variability in patients with renal failure on hemodialysis. Int J Cardiol 2009; 131:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/34\">",
"      Cashion AK, Cowan PA, Milstead EJ, et al. Heart rate variability, mortality, and exercise in patients with end-stage renal disease. Prog Transplant 2000; 10:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/35\">",
"      Rubinger D, Backenroth R, Sapoznikov D. Restoration of baroreflex function in patients with end-stage renal disease after renal transplantation. Nephrol Dial Transplant 2009; 24:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/36\">",
"      Lakusic N, Mahovic D, Babic T. Gradual recovery of impaired cardiac autonomic balance within first six months after ischemic cerebral stroke. Acta Neurol Belg 2005; 105:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/37\">",
"      Katz-Leurer M, Shochina M. Heart Rate Variability (HRV) parameters correlate with motor impairment and aerobic capacity in stroke patients. NeuroRehabilitation 2005; 20:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/38\">",
"      Bassi A, Colivicchi F, Santini M, Caltagirone C. Cardiac autonomic dysfunction and functional outcome after ischaemic stroke. Eur J Neurol 2007; 14:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/39\">",
"      Guilleminault C, Connolly S, Winkle R, et al. Cyclical variation of the heart rate in sleep apnoea syndrome. Mechanisms, and usefulness of 24 h electrocardiography as a screening technique. Lancet 1984; 1:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/40\">",
"      Lipsitz LA, Hashimoto F, Lubowsky LP, et al. Heart rate and respiratory rhythm dynamics on ascent to high altitude. Br Heart J 1995; 74:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/41\">",
"      Mietus, JE, Peng, CK, Ivanov, PCh, Goldberger, AL. Detection of obstructive sleep apnea from cardiac interbeat interval time series. Comput Cardiol 2000; 27:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/42\">",
"      Penzel T, McNames J, Murray A, et al. Systematic comparison of different algorithms for apnoea detection based on electrocardiogram recordings. Med Biol Eng Comput 2002; 40:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/43\">",
"      Stein PK, Duntley SP, Domitrovich PP, et al. A simple method to identify sleep apnea using Holter recordings. J Cardiovasc Electrophysiol 2003; 14:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/44\">",
"      Reyners AK, Hazenberg BP, Reitsma WD, Smit AJ. Heart rate variability as a predictor of mortality in patients with AA and AL amyloidosis. Eur Heart J 2002; 23:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/45\">",
"      Sacknoff DM, Gleim GW, Stachenfeld N, Coplan NL. Effect of athletic training on heart rate variability. Am Heart J 1994; 127:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/46\">",
"      Prud'homme D, Bouchard C, Leblanc C, et al. Sensitivity of maximal aerobic power to training is genotype-dependent. Med Sci Sports Exerc 1984; 16:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/47\">",
"      Levy WC, Cerqueira MD, Harp GD, et al. Effect of endurance exercise training on heart rate variability at rest in healthy young and older men. Am J Cardiol 1998; 82:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/48\">",
"      Stein PK, Ehsani AA, Domitrovich PP, et al. Effect of exercise training on heart rate variability in healthy older adults. Am Heart J 1999; 138:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/49\">",
"      Iellamo F, Legramante JM, Massaro M, et al. Effects of a residential exercise training on baroreflex sensitivity and heart rate variability in patients with coronary artery disease: A randomized, controlled study. Circulation 2000; 102:2588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/50\">",
"      Stein PK, Soare A, Meyer TE, et al. Caloric restriction may reverse age-related autonomic decline in humans. Aging Cell 2012; 11:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/51\">",
"      Akselrod S, Gordon D, Madwed JB, et al. Hemodynamic regulation: investigation by spectral analysis. Am J Physiol 1985; 249:H867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/52\">",
"      Taylor JA, Carr DL, Myers CW, Eckberg DL. Mechanisms underlying very-low-frequency RR-interval oscillations in humans. Circulation 1998; 98:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/53\">",
"      Ali-Melkkil&auml; T, Kaila T, Antila K, et al. Effects of glycopyrrolate and atropine on heart rate variability. Acta Anaesthesiol Scand 1991; 35:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/54\">",
"      Vybiral T, Bryg RJ, Maddens ME, et al. Effects of transdermal scopolamine on heart rate variability in normal subjects. Am J Cardiol 1990; 65:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/55\">",
"      Casadei B, Conway J, Forfar C, Sleight P. Effect of low doses of scopolamine on RR interval variability, baroreflex sensitivity, and exercise performance in patients with chronic heart failure. Heart 1996; 75:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/56\">",
"      Picard G, Tan CO, Zafonte R, Taylor JA. Incongruous changes in heart period and heart rate variability with vagotonic atropine: implications for rehabilitation medicine. PM R 2009; 1:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/57\">",
"      Cook JR, Bigger JT Jr, Kleiger RE, et al. Effect of atenolol and diltiazem on heart period variability in normal persons. J Am Coll Cardiol 1991; 17:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/58\">",
"      Hayano J, Sakakibara Y, Yamada A, et al. Accuracy of assessment of cardiac vagal tone by heart rate variability in normal subjects. Am J Cardiol 1991; 67:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/59\">",
"      Targo��ski R, Sadowski J. The effect of an evening dose of a long-acting beta-blocker on the autonomic tone in patients with congestive heart failure. Kardiol Pol 2009; 67:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/60\">",
"      Stein PK, Conger BM, Kleiger RE. The effect of pindolol and labetalol on heart rate variability in normal subjects (abstract). J Am Coll Cardiol 1993; 21:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/61\">",
"      Pagani M, Lombardi F, Guzzetti S, et al. Power spectral analysis of heart rate and arterial pressure variabilities as a marker of sympatho-vagal interaction in man and conscious dog. Circ Res 1986; 59:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/62\">",
"      Mortara A, La Rovere MT, Pinna GD, et al. Nonselective beta-adrenergic blocking agent, carvedilol, improves arterial baroflex gain and heart rate variability in patients with stable chronic heart failure. J Am Coll Cardiol 2000; 36:1612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/63\">",
"      Goldsmith RL, Bigger JT, Bloomfield DM, et al. Long-term carvedilol therapy increases parasympathetic nervous system activity in chronic congestive heart failure. Am J Cardiol 1997; 80:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/64\">",
"      Bekheit S, Tangella M, el-Sakr A, et al. Use of heart rate spectral analysis to study the effects of calcium channel blockers on sympathetic activity after myocardial infarction. Am Heart J 1990; 119:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/65\">",
"      Kaufman ES, Bosner MS, Bigger JT Jr, et al. Effects of digoxin and enalapril on heart period variability and response to head-up tilt in normal subjects. Am J Cardiol 1993; 72:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/66\">",
"      Brouwer J, van Veldhuisen DJ, Man in 't Veld AJ, et al. Heart rate variability in patients with mild to moderate heart failure: effects of neurohormonal modulation by digoxin and ibopamine. The Dutch Ibopamine Multicenter Trial (DIMT) Study Group. J Am Coll Cardiol 1995; 26:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/67\">",
"      Krum H, Bigger JT Jr, Goldsmith RL, Packer M. Effect of long-term digoxin therapy on autonomic function in patients with chronic heart failure. J Am Coll Cardiol 1995; 25:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/68\">",
"      Vardas PE, Kanoupakis EM, Kochiadakis GE, et al. Effects of long-term digoxin therapy on heart rate variability, baroreceptor sensitivity, and exercise capacity in patients with heart failure. Cardiovasc Drugs Ther 1998; 12:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/69\">",
"      Stein PK, Domitrovich PP, Hui N, et al. Sometimes higher heart rate variability is not better heart rate variability: results of graphical and nonlinear analyses. J Cardiovasc Electrophysiol 2005; 16:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/70\">",
"      Flapan AD, Nolan J, Neilson JM, Ewing DJ. Effect of captopril on cardiac parasympathetic activity in chronic cardiac failure secondary to coronary artery disease. Am J Cardiol 1992; 69:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/71\">",
"      Clemson B, Gaul L, Gubin SS, et al. Prejunctional angiotensin II receptors. Facilitation of norepinephrine release in the human forearm. J Clin Invest 1994; 93:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/72\">",
"      Zuanetti G, Latini R, Neilson JM, et al. Heart rate variability in patients with ventricular arrhythmias: effect of antiarrhythmic drugs. Antiarrhythmic Drug Evaluation Group (ADEG). J Am Coll Cardiol 1991; 17:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35449/abstract/73\">",
"      Dekker JM, Schouten EG, Klootwijk P, et al. Heart rate variability from short electrocardiographic recordings predicts mortality from all causes in middle-aged and elderly men. The Zutphen Study. Am J Epidemiol 1997; 145:899.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 995 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-B32189B1BC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_39_35449=[""].join("\n");
var outline_f34_39_35449=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4189833\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL USES OF HRV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RR variability and outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Low RR variability and outcome in the general population",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Low RR variability and outcome in older adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Low RR variability and outcome in patients referred for 24-hour Holter recording",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      RR variability and outcome in heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      RR variability in spontaneous ventricular tachycardias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      RR variability in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      RR variability in renal failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      RR variability in stroke patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RR variability to detect and quantity obstructive sleep apnea hypopnea syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      RR variability in amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      RR variability: effects of interventions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Effect of exercise on HRV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H452457250\">",
"      - Effect of caloric restriction on HRV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      RR variability to study drug effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Anticholinergic drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Digoxin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - ACE inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4189833\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/995\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/995|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/59/32701\" title=\"figure 1\">",
"      Heart rate variability HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/5/2141\" title=\"figure 2\">",
"      HRV arrhythmia cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/995|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/22/15725\" title=\"table 1\">",
"      Measures RR variability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16090?source=related_link\">",
"      ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36825?source=related_link\">",
"      Actions of angiotensin II on the heart",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/31/1530?source=related_link\">",
"      An overview of amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/10/23722?source=related_link\">",
"      Clinical manifestations and diagnosis of amyloid cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/28/14793?source=related_link\">",
"      Exercise and fitness in the prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/10/4264?source=related_link\">",
"      Heart rate variability: Technical aspects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/22/10601?source=related_link\">",
"      Heart rate variability: Use after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/41/31384?source=related_link\">",
"      Paroxysmal atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/38/31336?source=related_link\">",
"      Prophylaxis against ventricular arrhythmias following myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/36/10823?source=related_link\">",
"      Rationale for and mechanisms of benefit of cardiac resynchronization therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_39_35450="Chondrosarcoma";
var content_f34_39_35450=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chondrosarcoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/39/35450/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/39/35450/contributors\">",
"     AJ Gelderblom, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/39/35450/contributors\">",
"     Judith VMG Bov&eacute;e, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/39/35450/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/39/35450/contributors\">",
"     Robert Maki, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/39/35450/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/39/35450/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/39/35450/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chondrosarcomas are a heterogeneous group of malignant bone tumors that share in common the production of chondroid (cartilaginous) matrix [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/1\">",
"     1",
"    </a>",
"    ]. Chondrosarcomas are the third most common primary malignancy of bone after myeloma and osteosarcoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/2\">",
"     2",
"    </a>",
"    ]. They account for 20 to 27 percent of primary malignant osseous neoplasms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical behavior is variable. Ninety percent are conventional chondrosarcomas, 90 percent of which are low- to intermediate-grade tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/4\">",
"     4",
"    </a>",
"    ]. These tumors are slow growing with a low metastatic potential. They are considered relatively refractory to chemotherapy and radiation therapy.",
"   </p>",
"   <p>",
"    In contrast, high-grade chondrosarcomas, which include 5 to 10 percent of conventional chondrosarcomas as well as some rare variants, have a high metastatic potential and a poor prognosis following resection alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/4\">",
"     4",
"    </a>",
"    ]. Some of the rare subtypes are more responsive to chemotherapy and radiation.",
"   </p>",
"   <p>",
"    This topic review will provide an overview of the classification, clinical characteristics, and therapeutic options for chondrosarcoma. The rare chondrosarcomas involving the head and neck and skull base, as well as diagnosis and biopsy techniques for bone sarcomas in general, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/40/7815?source=see_link\">",
"     \"Chordoma and chondrosarcoma of the skull base\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34602?source=see_link\">",
"     \"Head and neck sarcomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/53/35673?source=see_link\">",
"     \"Bone tumors: Diagnosis and biopsy techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTOLOGIC GRADING AND PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologic grade is one of the most important indicators of clinical behavior and prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. Chondrosarcomas are graded on a scale from 1 to 3, based upon nuclear size, staining pattern (hyperchromasia), mitotic activity, and degree of cellularity (",
"    <a class=\"graphic graphic_picture graphicRef74562 \" href=\"mobipreview.htm?0/37/593\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/3,9\">",
"     3,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Grade 1 chondrosarcomas are moderately cellular, with an abundant hyaline cartilage matrix. The chondrocytes have small, round nuclei and are occasionally binucleate. Mitoses are absent. These tumors almost never metastasize (1 percent risk in one series of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/4\">",
"       4",
"      </a>",
"      ]) Ten-year survival is 83 to 95 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/4,5,10\">",
"       4,5,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Grade 2 chondrosarcomas are more cellular with less chondroid matrix than grade 1 tumors. Mitoses are present, but widely scattered. The chondrocyte nuclei are enlarged and can be either vesicular or hyperchromatic. The metastatic potential is intermediate between low-grade and high-grade chondrosarcomas (approximately 10 to 15 percent). Ten-year survival is approximately 64 to 86 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/4,5,10\">",
"       4,5,10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The vast majority of conventional (primary and secondary) chondrosarcomas are grade 1 or 2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/4,10,11\">",
"     4,10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Grade 3 chondrosarcomas are highly cellular, with nuclear pleomorphism and easily detected mitoses. Chondroid matrix is sparse or absent. High-grade chondrosarcomas have a high metastatic potential (approximately 32 to 70 percent) and a poor prognosis with surgical resection alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. The ten-year survival rate is about 29 to 55 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/4,10\">",
"       4,10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In most cases, the histologic grade of differentiation of a recurrent chondrosarcoma is the same as the primary lesion; however, up to 13 percent of recurrences exhibit a higher grade of malignancy when compared with the original neoplasm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/5,10,12\">",
"     5,10,12",
"    </a>",
"    ]. This suggests that chondrosarcomas can progress biologically.",
"   </p>",
"   <p>",
"    Histologic grading is subject to interobserver variability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/13,14\">",
"     13,14",
"    </a>",
"    ], which can be problematic since surgical therapy for grade 1 and grade 2 chondrosarcomas is often different. Because of this, there is an urgent need for molecular markers that can be used to predict clinical behavior, guide therapeutic decision making, and provide novel targets for molecularly targeted therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Surgical treatment'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H36\">",
"     'Novel therapies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLASSIFICATION, HISTOLOGY, AND CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Precursor lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two benign cartilaginous lesions that can precede chondrosarcoma are described:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Osteochondroma",
"    </span>",
"    &nbsp;&mdash;&nbsp;An osteochondroma (osteocartilaginous exostosis) is a cartilage-capped bony projection arising on the external surface of a bone (",
"    <a class=\"graphic graphic_picture graphicRef55666 \" href=\"mobipreview.htm?40/30/41445\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67448 \" href=\"mobipreview.htm?26/0/26625\">",
"     image 1",
"    </a>",
"    ); it contains a marrow cavity that is continuous with that of the underlying bone. The majority are located in the long bones, predominantly around the knee.",
"   </p>",
"   <p>",
"    The inherited condition multiple osteochondromas (hereditary multiple exostoses) is characterized by the development of two or more osteochondromas in the appendicular and axial skeleton (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59501 \" href=\"mobipreview.htm?12/35/12849\">",
"     image 2",
"    </a>",
"    ). This syndrome is inherited in an autosomal dominant fashion. The prevalence in the general population is 1:50,000, and males are affected slightly more often than females. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/60/24522?source=see_link&amp;anchor=H16#H16\">",
"     \"Overview of benign bone tumors in children and adolescents\", section on 'Osteochondroma and hereditary multiple osteochondromas'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Almost 90 percent of cases of multiple osteochondromas are caused by inheritance of a germline mutation in one of the tumor suppressor genes",
"    <em>",
"     EXT1",
"    </em>",
"    or",
"    <em>",
"     EXT2",
"    </em>",
"    . (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Molecular pathogenesis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although most are asymptomatic, osteochondromas can cause pain, functional problems, and deformity; they also carry a risk for fracture. Malignant transformation is estimated to occur in 5 percent of patients with a solitary or multiple osteochondromas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/16-21\">",
"     16-21",
"    </a>",
"    ]. In one series, the average time between initial diagnosis and malignant transformation was 9.8 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/20\">",
"     20",
"    </a>",
"    ]. All chondrosarcomas arising in the setting of an osteochondroma are secondary peripheral tumors.",
"   </p>",
"   <p>",
"    A change in the size of an osteochondroma or new onset of symptoms warrants investigation, as each may herald malignant transformation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Osteochondromas located at the pelvis, hips and shoulder girdle are reported to be particularly prone to malignant transformation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Among patients with multiple osteochondromas, malignant transformation appears to be unrelated to the presence or absence of an",
"    <em>",
"     EXT",
"    </em>",
"    mutation, sex, severity of disease, or the number of lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Enchondroma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enchondromas are common benign cartilaginous tumors that develop in the medulla (marrow cavity) of bone (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82362 \" href=\"mobipreview.htm?33/9/33951\">",
"     image 3",
"    </a>",
"    ). When multiple enchondromas are present, the condition is called enchondromatosis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64618 \" href=\"mobipreview.htm?2/12/2245\">",
"     image 4",
"    </a>",
"    ), of which the most common form is Ollier disease (estimated prevalence 1 in 100,000) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/24\">",
"     24",
"    </a>",
"    ]. When multiple enchondromas are associated with soft tissue hemangiomas, the designation is Maffucci syndrome (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70081 \" href=\"mobipreview.htm?24/56/25475\">",
"     image 5",
"    </a>",
"    ). Both are congenital but not inherited. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/60/24522?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of benign bone tumors in children and adolescents\", section on 'Enchondroma'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Although the vast majority are asymptomatic, clinical problems caused by enchondromas include skeletal deformity, limb-length discrepancy, and a risk for malignant transformation. Malignant transformation in a solitary enchondroma is presumed to be extremely rare (&lt;1 percent) but it has been described (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55316 \" href=\"mobipreview.htm?12/51/13107\">",
"     image 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/20\">",
"     20",
"    </a>",
"    ]. The risk of chondrosarcoma in patients with Ollier disease or Maffucci syndrome is as high as 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/24-29\">",
"     24-29",
"    </a>",
"    ]. The risk is highest with enchondromas located in the pelvis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/28\">",
"     28",
"    </a>",
"    ]. Malignant transformation usually presents after skeletal maturity and may be heralded by the development of pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The histologic and radiographic distinction between an enchondroma and a low-grade chondrosarcoma may be difficult, even in experienced hands (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Histologic appearance'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Conventional chondrosarcomas",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Central chondrosarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central chondrosarcomas of bone arise within the medullary cavity and constitute approximately 75 percent of all chondrosarcomas (",
"    <a class=\"graphic graphic_table graphicRef50684 \" href=\"mobipreview.htm?3/58/4013\">",
"     table 1",
"    </a>",
"    ). The majority are thought to arise primarily (ie, without a benign precursor lesion). However, the finding of remnants of a preexisting enchondroma in 40 percent of central chondrosarcomas and the fact that most enchondromas remain asymptomatic and clinically silent have led some to hypothesize that as many as 40 percent of central chondrosarcomas could be secondary to a preexisting enchondroma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of patients are over the age of 50. There is a slight male predominance.",
"   </p>",
"   <p>",
"    The most commonly involved skeletal sites are the proximal femur, bones of the pelvis (particularly the ilium), and proximal humerus (together accounting for about 75 percent of cases), followed by distal femur, ribs, tibia, and metacarpal and metatarsal bones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/3,4,9,31,32\">",
"     3,4,9,31,32",
"    </a>",
"    ]. Other less frequently involved sites include the spine, the skull base, and the craniofacial bones. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/40/7815?source=see_link\">",
"     \"Chordoma and chondrosarcoma of the skull base\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34602?source=see_link\">",
"     \"Head and neck sarcomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Local swelling and pain are the most common presenting symptoms. Pain is typically insidious, progressive, worse at night, and often present for months to years before presentation. A pathologic fracture is present at diagnosis in 3 to 17 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/3\">",
"     3",
"    </a>",
"    ]. Primary spinal chondrosarcomas are rare but can cause compression of the spinal cord.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Peripheral chondrosarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;By definition, all peripheral chondrosarcomas arise within the cartilage cap of a preexisting osteochondroma (",
"    <a class=\"graphic graphic_table graphicRef50684 \" href=\"mobipreview.htm?3/58/4013\">",
"     table 1",
"    </a>",
"    ). Patients with a peripheral chondrosarcoma are generally younger than those with a central chondrosarcoma (",
"    <a class=\"graphic graphic_table graphicRef50684 \" href=\"mobipreview.htm?3/58/4013\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/22\">",
"     22",
"    </a>",
"    ]. The clinical presentation is similar to that of central chondrosarcoma, usually pain and local swelling. The most commonly involved bones are the pelvis and bones of the shoulder girdle, although in some series, the long bones predominate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Periosteal chondrosarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fewer than one percent of conventional chondrosarcomas arise on the surface of a bone and are designated periosteal (previously termed juxtacortical) chondrosarcomas. They most frequently affect adults in their 20s and 30s, and have a slight male predilection. The metaphyses of long bones are most frequently involved, especially of the distal femur (",
"    <a class=\"graphic graphic_figure graphicRef76662 \" href=\"mobipreview.htm?22/53/23391\">",
"     figure 1",
"    </a>",
"    ). Patients typically present with a palpable, painless, slowly growing mass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Periosteal chondrosarcomas usually have a good prognosis after adequate local surgery despite histologic features of a high-grade lesion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/7,33-36\">",
"     7,33-36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Histologic appearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite their different origin and location, primary and secondary chondrosarcomas appear histologically similar (",
"    <a class=\"graphic graphic_picture graphicRef74562 \" href=\"mobipreview.htm?0/37/593\">",
"     picture 1",
"    </a>",
"    ). At low magnification, there is abundant cartilage matrix production, and the irregularly shaped lobules of cartilage, often separated by fibrous bands, may permeate the bony trabeculae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/9\">",
"     9",
"    </a>",
"    ]. Necrosis or mitoses may be seen in high-grade lesions. The histology of periosteal chondrosarcomas is similar except that the appearance is often more worrisome with increased cellularity and nuclear atypia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The histologic (and radiographic) distinction between a benign cartilage lesion and a malignant grade 1 chondrosarcoma can be extremely difficult [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/13,37,38\">",
"     13,37,38",
"    </a>",
"    ]. Chondrosarcomas are hypercellular when compared to benign cartilage lesions. The chondrocytes appear mildly to moderately atypical and contain enlarged hyperchromatic nucleoli. Permeation of preexisting host bone and mucomyxoid matrix changes are important characteristics that can be used to separate a chondrosarcoma from an enchondroma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/14\">",
"     14",
"    </a>",
"    ]. Periosteal chondrosarcoma is distinguished from periosteal chondroma based upon size (&ge;5 cm) and the presence of cortical invasion. For phalangeal enchondromas, more worrisome histologic features are tolerated, and the diagnosis of chondrosarcoma at this site is based upon the presence of cortical destruction, soft tissue invasion, and mitoses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fortunately, the distinction between enchondroma and grade 1 chondrosarcoma is not always essential for clinical decision making, since treatment (curettage and adjuvant phenol application or cryosurgery) is often similar for enchondromas as well as grade 1 central chondrosarcomas (see",
"    <a class=\"local\" href=\"#H24\">",
"     'Surgical treatment'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Rare chondrosarcoma subtypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to conventional central, peripheral, and periosteal chondrosarcomas, several rare subtypes are described, together constituting less than 10 percent of all chondrosarcomas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Dedifferentiated chondrosarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dedifferentiated chondrosarcomas contain two juxtaposed components: a well-differentiated cartilage tumor (which can be either an enchondroma or a low-grade chondrosarcoma), and a high-grade non-cartilaginous sarcoma which most frequently is an osteosarcoma, fibrosarcoma, or malignant fibrous histiocytoma (",
"    <a class=\"graphic graphic_picture graphicRef52315 \" href=\"mobipreview.htm?31/21/32083\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both components appear to share some genetic aberrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/41,42\">",
"     41,42",
"    </a>",
"    ] with additional genetic changes in the high-grade component [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/41-44\">",
"     41-44",
"    </a>",
"    ]. This suggests a common precursor cell with early divergence of the two components.",
"   </p>",
"   <p>",
"    The average age at presentation is older (between 50 and 60 years) than other chondrosarcoma subtypes (",
"    <a class=\"graphic graphic_table graphicRef50684 \" href=\"mobipreview.htm?3/58/4013\">",
"     table 1",
"    </a>",
"    ). The majority occur centrally in medullary bone; the most common sites of involvement are the pelvis, femur, and humerus. The typical presentation is with pain, although swelling, paresthesias, and pathologic fractures are also common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/9\">",
"     9",
"    </a>",
"    ]. The majority of patients have an associated soft tissue mass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dedifferentiated chondrosarcomas are biologically aggressive and they have a poor prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/12,45,46\">",
"     12,45,46",
"    </a>",
"    ]. In a multicenter review of 337 patients, 71 (21 percent) had metastases at the time of diagnosis; they had a 10 percent chance of survival at two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/12\">",
"     12",
"    </a>",
"    ]. Even for patients without metastases at diagnosis, survival was only 28 percent at 10 years. Poor prognostic factors include pathologic fracture, pelvic location, and older age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Mesenchymal chondrosarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mesenchymal chondrosarcomas are highly malignant tumors that are characterized by differentiated cartilage admixed with solid highly cellular areas that are composed of undifferentiated small round cells (",
"    <a class=\"graphic graphic_picture graphicRef52315 \" href=\"mobipreview.htm?31/21/32083\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The average age is 25, younger than that of other types of chondrosarcoma (",
"    <a class=\"graphic graphic_table graphicRef50684 \" href=\"mobipreview.htm?3/58/4013\">",
"     table 1",
"    </a>",
"    ). There is a high proportion of extraskeletal primary tumors, which is not seen with other chondrosarcoma subtypes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/47\">",
"     47",
"    </a>",
"    ]. Of the approximately one-third of cases that affect the extraskeletal soft tissues, the meninges are one of the most common sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/48\">",
"     48",
"    </a>",
"    ]. Also in contrast to conventional chondrosarcomas, mesenchymal tumors most commonly involve the axial skeleton, including the craniofacial bones (especially the jaw) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/49\">",
"     49",
"    </a>",
"    ], ribs, ilium, and vertebra, and there may be involvement of multiple bones. About 20 percent have metastatic disease at diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/40/7815?source=see_link&amp;anchor=H15#H15\">",
"     \"Chordoma and chondrosarcoma of the skull base\", section on 'Chondrosarcoma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34602?source=see_link&amp;anchor=H17#H17\">",
"     \"Head and neck sarcomas\", section on 'Chondrosarcoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The main symptoms are pain and swelling, and it is not uncommon for symptoms to have been present for many months.",
"   </p>",
"   <p>",
"    Mesenchymal chondrosarcomas have a tendency toward both local and distant recurrences, which may arise as long as 20 years following the initial diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/51\">",
"     51",
"    </a>",
"    ]. The prognosis is markedly worse than for conventional primary chondrosarcomas. Reported 10-year survival rates are 10 to 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/47,50-52\">",
"     47,50-52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Clear cell chondrosarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clear cell chondrosarcoma is a rare low-grade variant of chondrosarcoma which is characterized by the presence of lobulated groups of bland-appearing tumor cells with large, centrally-located nuclei and clear, empty cytoplasm in addition to hyaline cartilage (",
"    <a class=\"graphic graphic_picture graphicRef52315 \" href=\"mobipreview.htm?31/21/32083\">",
"     picture 3",
"    </a>",
"    ). Mitotic figures are rare. Many tumors contain zones of conventional chondrosarcoma with hyaline cartilage and minimally atypical nuclei.",
"   </p>",
"   <p>",
"    Although these tumors can arise at any age, most patients are between the ages of 25 and 50 (",
"    <a class=\"graphic graphic_table graphicRef50684 \" href=\"mobipreview.htm?3/58/4013\">",
"     table 1",
"    </a>",
"    ). Men are three times more likely as women to develop this particular subtype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/9\">",
"     9",
"    </a>",
"    ]. Approximately two-thirds of tumors arise in the epiphyseal ends of the humerus or femur (",
"    <a class=\"graphic graphic_figure graphicRef76662 \" href=\"mobipreview.htm?22/53/23391\">",
"     figure 1",
"    </a>",
"    ). Pain, which may have been present for longer than one year, is the most common complaint.",
"   </p>",
"   <p>",
"    Serum alkaline phosphatase levels are often elevated at diagnosis and may provide a useful tumor marker [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite their low-grade nature, marginal excision or curettage is associated with a 70 percent or higher recurrence rate and should be avoided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. In incompletely excised cases, metastases may develop, usually to the lungs and other skeletal sites, and the overall mortality rate is up to 15 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/9\">",
"     9",
"    </a>",
"    ]. In contrast, en bloc wide local excision is usually curative.",
"   </p>",
"   <p>",
"    Disease recurrence may occur up to 24 years after initial diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Long-term follow-up is mandatory.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Myxoid chondrosarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is debated whether myxoid chondrosarcoma of bone is a true separate entity or if it represents a high-grade conventional chondrosarcoma with prominent myxoid change. The light microscopic features of myxoid chondrosarcoma of bone are similar to those of the more commonly described extraskeletal myxoid chondrosarcoma (EMC), a soft tissue sarcoma which most commonly arises in the lower extremities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. However, these two entities are unrelated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/57\">",
"     57",
"    </a>",
"    ], and the term \"chondrosarcoma\" to describe EMC is a misnomer. Well-formed hyaline cartilage is found only in a minority of EMCs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/58,59\">",
"     58,59",
"    </a>",
"    ], while S100 expression (which is present in all or most chondrosarcomas) is often very focal or absent. Expression of collagen II and aggrecan (two other markers of cartilaginous differentiation) are absent in 86 percent of EMCs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Furthermore, the translocation t(9:22) that is specific for EMC is generally absent in so-called myxoid chondrosarcoma of bone, and its ultrastructure is different [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/58,60\">",
"     58,60",
"    </a>",
"    ]. The reported cases of myxoid chondrosarcoma of bone that contain a proven translocation of t(9:22) have a large soft tissue component which makes distinction from EMC with secondary bone destruction extremely difficult [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32042?source=see_link&amp;anchor=H24#H24\">",
"     \"Pathogenetic factors in soft tissue and bone sarcomas\", section on 'Extraskeletal myxoid chondrosarcoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, EMC and so-called myxoid chondrosarcoma of bone appear to represent two different entities. The 2002 WHO classification classifies the entity EMC in the \"tumors of uncertain differentiation\" category [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/11\">",
"     11",
"    </a>",
"    ]. Myxoid chondrosarcomas of bone are not designated as a unique entity, and these tumors should be regarded as a myxoid variant of intermediate- or high-grade conventional chondrosarcoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Molecular pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cartilaginous tumors are nearly always found in bones that arise from enchondral ossification. Research has uncovered some parallels between chondrocyte growth and differentiation in the normal growth plate and both benign and malignant cartilaginous tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Within the normal growth plate, resting zone chondrocytes proliferate and differentiate, becoming hypertrophic. These cells undergo apoptosis, allowing the invasion of vessels and osteoblasts that start to form bone and lead to longitudinal bone growth. This physiologic process is tightly regulated by components of the Indian hedgehog",
"    <span class=\"nowrap\">",
"     (IHH)/parathyroid",
"    </span>",
"    hormone related (PTHRP) protein signaling pathway.",
"   </p>",
"   <p>",
"    Patients with multiple osteochondromas (previously called hereditary multiple exostoses) have germline mutations in the exostosin (",
"    <em>",
"     EXT1",
"    </em>",
"    or",
"    <em>",
"     EXT2)",
"    </em>",
"    genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/63-65\">",
"     63-65",
"    </a>",
"    ], with loss of the remaining wild type allele in the cartilage cap of the osteochondroma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/66\">",
"     66",
"    </a>",
"    ]. The end result is decreased EXT expression. Loss of expression of the",
"    <em>",
"     EXT",
"    </em>",
"    genes through homozygous deletion of",
"    <em>",
"     EXT1",
"    </em>",
"    is also seen in solitary osteochondromas that are unassociated with the hereditary syndrome and in some peripheral chondrosarcomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. The",
"    <em>",
"     EXT",
"    </em>",
"    gene products are involved in the biosynthesis of heparan sulfate proteoglycans (HSPGs), which are essential for cell signaling through",
"    <span class=\"nowrap\">",
"     IHH/PTHLH",
"    </span>",
"    and other pathways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In osteochondromas where",
"    <em>",
"     EXT",
"    </em>",
"    is inactivated, the HSPGs seem to accumulate in the cytoplasm and Golgi apparatus instead of being transported to the cell surface [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/68\">",
"     68",
"    </a>",
"    ]. This hampers multiple growth signaling pathways (including the Indian hedgehog",
"    <span class=\"nowrap\">",
"     (IHH)/parathyroid",
"    </span>",
"    hormone related (PTHRP) protein pathways), which, as noted above, are important for normal chondrocyte proliferation and differentiation within the normal human growth plate.",
"   </p>",
"   <p>",
"    The specific trigger underlying malignant transformation of osteochondromas is unknown. A role for IHH signaling has been suggested, although the data are not entirely consistent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/70-74\">",
"     70-74",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PTHRP signaling, which is downstream of IHH and is involved in chondrocyte proliferation, is absent in osteochondromas, but upregulated with malignant transformation towards secondary peripheral chondrosarcoma, especially in high-grade lesions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/71,72,75-78\">",
"       71,72,75-78",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is decreased expression of downstream targets in the IHH signaling cascade during tumor progression in peripheral chondrosarcomas, while they are still active in central chondrosarcomas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Data from in vitro and in vivo models show that treatment of central chondrosarcoma cells with recombinant Hedgehog increases proliferation, whereas treatment with Hedgehog signaling inhibitors inhibits tumor proliferation and growth in a small subset of tumors and chondrosarcoma cell cultures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/74,79,80\">",
"       74,79,80",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A multistep genetic model for the development of secondary (peripheral) chondrosarcomas has been proposed (",
"    <a class=\"graphic graphic_figure graphicRef51711 \" href=\"mobipreview.htm?8/52/9039\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Until recently, less was known about the molecular genetics of enchondromas and the far more common primary (central) chondrosarcomas. However, recently, point mutations in isocitrate dehydrogenase-1 and isocitrate dehydrogenase 2 genes",
"    <em>",
"     IDH1",
"    </em>",
"    and",
"    <em>",
"     IDH2",
"    </em>",
"    have been identified in 40 to 56 percent of enchondromas and chondrosarcomas and seem to be an early event [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. Also, Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations in",
"    <em>",
"     IDH1",
"    </em>",
"    and",
"    <em>",
"     IDH2",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/81,83\">",
"     81,83",
"    </a>",
"    ]. The identification of",
"    <em>",
"     IDH1",
"    </em>",
"    and",
"    <em>",
"     IDH2",
"    </em>",
"    mutations in four chondrosarcoma cell lines provides an in vitro model to study the role of these mutations in tumorigenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, although",
"    <em>",
"     EXT",
"    </em>",
"    is not involved, involvement of the",
"    <span class=\"nowrap\">",
"     IHH/PTHLH",
"    </span>",
"    signaling pathway is suggested by the observations that parathyroid hormone-related protein (PTHRP) signaling is active in enchondromas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/75,78\">",
"     75,78",
"    </a>",
"    ], and hedgehog signaling is active in central chondrosarcomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/79\">",
"     79",
"    </a>",
"    ]. Moreover, a mutation in the gene encoding the receptor for PTHRP (PTH-1 receptor or PTH1R) has been identified in enchondromatosis that is claimed to lead to constitutive activation of IHH signaling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/73,84\">",
"     73,84",
"    </a>",
"    ]. Three new heterozygous missense mutations have been described in the",
"    <em>",
"     PTH1R",
"    </em>",
"    gene in patients with Ollier disease, which result in reduced receptor function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/85\">",
"     85",
"    </a>",
"    ]. Mutations in",
"    <em>",
"     PTH1R",
"    </em>",
"    have not been found in sporadic chondrosarcomas, nor in Maffucci syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/81,83,86\">",
"     81,83,86",
"    </a>",
"    ]; this gene may contribute to pathogenesis in only a very small subset (&lt;5 percent) of patients with Ollier disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      While enchondromas and low-grade chondrosarcomas are near-diploid and carry few karyotypic abnormalities, high grade chondrosarcomas are aneuploid and have complex karyotypes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/39,87\">",
"       39,87",
"      </a>",
"      ]. Some of the few consistent genetic aberrations include 12q13-15 and 9p21 rearrangements [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/39,87-90\">",
"       39,87-90",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chondrosarcoma progression has been linked to the",
"      <em>",
"       CDKN2A",
"      </em>",
"      (p16) tumor suppressor gene, located at 9p21 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/91,92\">",
"       91,92",
"      </a>",
"      ] and by alterations in p53 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/93\">",
"       93",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Activation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      overexpression of platelet-derived growth factor receptor-alpha (PDGFRA) and beta (PDGFRB) has been described in conventional primary chondrosarcomas, although activating mutations have not been found [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/94,95\">",
"       94,95",
"      </a>",
"      ]. The therapeutic implications of this finding are discussed below. (See",
"      <a class=\"local\" href=\"#H36\">",
"       'Novel therapies'",
"      </a>",
"      below.):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A multistep genetic model for development of primary chondrosarcomas has been proposed (",
"    <a class=\"graphic graphic_figure graphicRef71276 \" href=\"mobipreview.htm?1/38/1647\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC AND STAGING WORK-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of the preoperative evaluation are to establish the tissue diagnosis and evaluate disease extent, in order to select the appropriate therapeutic approach. One fundamental principle applying to diagnosis of both tumors of bone and cartilage is that both the histology and radiography of bone tumors are not specific. Integration of the clinical history, radiography, and pathology is necessary to render a specific diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Radiographic imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial imaging study in a patient with a painful musculoskeletal swelling is often a plain radiograph. The location and radiographic appearance of the different chondrosarcoma subtypes are often characteristic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/96\">",
"     96",
"    </a>",
"    ]. However, although plain radiographs can provide a clue as to the probable histology of a potentially malignant bone lesion, evaluation of tumor size and local extent is most accurately achieved by magnetic resonance imaging (MRI)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CT is optimal to detect matrix mineralization, particularly when it is subtle or the lesions are located in an anatomically complex area. Because of their high water content, most chondrosarcomas are of low attenuation on CT.",
"     </li>",
"     <li>",
"      MRI is better for delineating the extent of marrow and soft tissue involvement. The high water content of chondrosarcomas is manifest as very high signal intensity on T2-weighted images [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the long bones, central chondrosarcomas produce a fusiform expansion in the metaphysis or diaphysis (",
"    <a class=\"graphic graphic_figure graphicRef50795 \" href=\"mobipreview.htm?13/34/13864\">",
"     figure 4",
"    </a>",
"    ). The tumor has a mixed radiolucent and sclerotic appearance with the mineralized chondroid matrix appearing as a punctate or ring-and-arc pattern of calcifications that may coalesce to form a more radiopaque flocculent pattern of calcification (the so-called chondroid type of calcification, [ (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65087 \" href=\"mobipreview.htm?1/34/1572\">",
"     image 7",
"    </a>",
"    )]). Higher grade chondrosarcomas often contain relatively less extensive areas of mineralization (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65818 \" href=\"mobipreview.htm?12/18/12583\">",
"     image 8",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The cortex is often thickened but a periosteal reaction is scant or absent. There may be features of endosteal scalloping and soft tissue extension. Evidence of a large, soft tissue mass, particularly if unmineralized, that is associated with a lesion whose radiologic features otherwise suggest a chondrosarcoma should raise the level of suspicion for a high-grade tumor (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65818 \" href=\"mobipreview.htm?12/18/12583\">",
"     image 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70323 \" href=\"mobipreview.htm?8/19/8496\">",
"     image 9",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Conventional radiographs are not reliable to distinguish between an enchondroma and central grade 1 chondrosarcoma, [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/13,37,98,99\">",
"     13,37,98,99",
"    </a>",
"    ], although localization in the axial as opposed to the appendicular skeleton and size greater than 5 cm favor chondrosarcoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/37,100\">",
"     37,100",
"    </a>",
"    ]. The presence of a soft tissue mass excludes the diagnosis of an enchondroma. The thickness and staining characteristics of the cartilaginous cap on dynamic contrast-enhanced MRI provides a fairly reliable assessment of the likelihood of malignancy in an osteochondroma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/101,102\">",
"     101,102",
"    </a>",
"    ]. However, an absolute distinction between benign and malignant cannot be made on radiologic grounds alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/37,103,104\">",
"     37,103,104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Osteochondromas appear as a sessile or broadly-based smoothly calcified lesion at the surface of bone, with the cortex of the bone typically extending into the stalk of the osteochondroma and normal trabeculation centrally. The cartilaginous cap is best assessed on T2-weighted MRI and should not exceed 1.5 to 2 cm. The thickness and appearance of the cap on dynamic contrast-enhanced MRI provide a fairly reliable assessment of the likelihood of malignancy. A thickened cap and irregular distribution of vague calcifications suggest the development of a secondary chondrosarcoma.",
"   </p>",
"   <p>",
"    Periosteal chondrosarcomas appear as a round to oval soft tissue mass on the surface of bone, containing typical chondroid matrix mineralization. They cause variable amounts of cortical bone erosion and appear to be covered by an elevated periosteum (Codman triangles). The medullary canal is typically not involved. The radiographic differentiation between a periosteal chondrosarcoma, periosteal osteosarcoma, and parosteal osteosarcoma can be difficult.",
"   </p>",
"   <p>",
"    Clear cell chondrosarcomas have a predilection for the epiphyseal ends of the femur and humerus (",
"    <a class=\"graphic graphic_figure graphicRef76662 \" href=\"mobipreview.htm?22/53/23391\">",
"     figure 1",
"    </a>",
"    ). Radiographs reveal a well-defined, predominantly lytic lesion, sometimes with a sclerotic rim. Matrix mineralization is not as frequently apparent as with conventional chondrosarcoma.",
"   </p>",
"   <p>",
"    As noted above, aggressive chondrosarcomas, such as the mesenchymal and dedifferentiated subtypes, often contain areas of matrix mineralization that suggest a low-grade chondroid neoplasm; however these areas are relatively less extensive compared to conventional chondrosarcoma and usually ill-defined. On CT and MRI imaging, dedifferentiated chondrosarcomas may be seen to contain two distinct areas with differing radiographic characteristics: the low-grade conventional chondrosarcomatous component has low attenuation on CT and high signal intensity on T2-weighted MRI images, while the high-grade noncartilaginous component may have soft tissue attenuation on CT (isointense to muscle) and variable signal intensity on MRI T2-weighted images. There may be intraosseous lytic areas and an aggressive pattern of bone destruction with a moth-eaten or permeative pattern. These aggressive tumors are often associated with perforation of the cortex and a large soft tissue mass.",
"   </p>",
"   <p>",
"    Imaging features of extraskeletal mesenchymal chondrosarcomas are nonspecific, with chondroid-type calcification and foci of lost signal intensity within enhancing lobules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Role of PET",
"    </span>",
"    &nbsp;&mdash;&nbsp;The imaging methods described above provide limited information as to the biologic activity of a suspected chondrosarcoma. PET scanning with fluorodeoxyglucose (FDG) has been proposed as a noninvasive method to assess tumor grade, to distinguish benign from malignant chondroid lesions, to identify otherwise occult metastatic disease, and differentiate recurrent tumor from postoperative change [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/106-109\">",
"     106-109",
"    </a>",
"    ]. However, the overall place of PET in the diagnostic and staging evaluation remains uncertain:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although grade 2 and 3 chondrosarcomas have a higher glucose metabolism (and therefore, a higher standardized uptake value [SUV]), PET cannot differentiate between benign cartilage tumors and a grade 1 chondrosarcoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/109\">",
"       109",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The value of PET scanning to screen for metastatic or recurrent disease is also uncertain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For suspicious lesions, a diagnostic biopsy is frequently undertaken to establish the diagnosis and plan the surgical approach. The initial percutaneous biopsy may not accurately reflect the true histologic grade of the lesion because of lesion heterogeneity and the possibility of sampling error [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/110\">",
"     110",
"    </a>",
"    ]. If it is undertaken, biopsy should always be directed at the more aggressive-appearing areas as seen on the radiographic studies (ie, the soft tissue components, or the more diffusely enhancing regions with limited or no matrix mineralization).",
"   </p>",
"   <p>",
"    Specific issues surrounding the diagnostic biopsy for suspected primary bone tumors are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/53/35673?source=see_link\">",
"     \"Bone tumors: Diagnosis and biopsy techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Staging system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The staging system used for bone sarcomas was developed by Enneking et al at the University of Florida and based upon a retrospective review of cases of primary malignant tumors of bone treated by primary surgical resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/111,112\">",
"     111,112",
"    </a>",
"    ]. This system characterizes nonmetastatic malignant bone tumors by grade (low grade [stage I] versus high grade [stage II]), and further subdivides these stages according to the local anatomic extent (intracompartmental [A] versus extracompartmental [B]). The compartmental status is determined by whether the tumor extends through the cortex of the involved bone. Patients with distant metastases are categorized as stage III.",
"   </p>",
"   <p>",
"    The American Joint Committee on Cancer (AJCC) had a similar staging system in its 1997 fifth edition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/113\">",
"     113",
"    </a>",
"    ], but this was modified in 2002, with additional minor refinements in the latest 2010 edition (",
"    <a class=\"graphic graphic_table graphicRef62124 \" href=\"mobipreview.htm?25/43/26301\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/114\">",
"     114",
"    </a>",
"    ]. The TNM classification is not widely used for primary bone tumors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Completing the staging workup",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with other sarcomas, the lungs are the main site of metastatic disease; much less commonly, the regional nodes and liver are involved. Given the low rate of metastases in patients with grade 1 chondrosarcoma (less than 10 percent), imaging of the lungs is generally not necessary. However, patients with intermediate and high-grade chondrosarcomas have a higher rate of metastatic disease (10 to 50 percent for grade 2 lesions and 50 to 70 percent for grade 3 lesions) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]. In these patients, the staging evaluation should at least include a thoracic CT to rule out the presence of pulmonary metastases.",
"   </p>",
"   <p>",
"    As noted above, the place of PET scanning (which in other oncologic settings is generally more sensitive but less specific than CT for detection of metastatic disease) is uncertain. Although the use of PET can reveal sites of metastatic disease among patients with grade 2 or 3 chondrosarcomas, it is clear that sensitivity is lower than that of conventional CT for small lung metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/109\">",
"     109",
"    </a>",
"    ]. The utility of integrated",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    has not been addressed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SURGICAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;For all grades and subtypes of nonmetastatic chondrosarcoma, surgical treatment offers the only chance for cure. The optimal type of surgical management depends upon histologic grade, location, and tumor extent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Intermediate and high-grade tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wide en bloc local excision is the preferred surgical treatment for all nonmetastatic intermediate- and high-grade chondrosarcomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/8\">",
"     8",
"    </a>",
"    ]. Depending on the location of the primary, wide excision can lead to considerable morbidity and may require a demanding reconstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Low-grade central tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of minimizing functional disability provides the rationale for pursuing less extensive surgery for grade 1 central chondrosarcomas that are confined to the bone. In appropriately selected cases, extensive intralesional curettage, followed by local adjuvant chemical treatment (phenolization) or cryotherapy, and cementation or bone grafting of the cavity produces satisfactory long-term local control while minimizing the need for extensive reconstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/115-120\">",
"     115-120",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The best outcomes are with small extremity conventional central chondrosarcomas. For patients with large tumor size, intraarticular or soft tissue involvement, and the periosteal, clear cell, mesenchymal and dedifferentiated subtypes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/36\">",
"     36",
"    </a>",
"    ], intralesional excision represents an inadequate form of local treatment, with high rates of local recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/3,121\">",
"     3,121",
"    </a>",
"    ]. Wide local resection is preferred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/121\">",
"     121",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For large tumors, curettage can be technically difficult, and sampling error may result in a focus of higher-grade disease being missed. The tumor size cutoff beyond which a wide resection is preferred has not been studied and is highly dependent on location.",
"   </p>",
"   <p>",
"    Most authors also consider wide local excision to be the preferred treatment for a low-grade chondrosarcoma involving the axial skeleton and pelvis. Several (but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/8,53,122\">",
"     8,53,122",
"    </a>",
"    ]) reports note higher local recurrence rates with curettage or marginal excision of tumors at these sites, with a higher tendency to metastasize [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/121-125\">",
"     121-125",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The decision to perform a curettage rather than wide local excision on the basis of a diagnostic biopsy is complicated by tumor heterogeneity and variation in histopathologic interpretation. A failure to recognize higher-grade areas of differentiation in a predominantly low-grade chondrosarcoma is possible when a needle or limited open biopsy has been performed. Thus, a presumed low-grade chondrosarcoma treated by curettage and local adjuvant treatment that is found to contain foci of intermediate- or high-grade differentiation on the final histologic sections might require additional surgery. In order to minimize this risk, the diagnostic biopsy should always be directed at the more aggressive-appearing areas on the radiographic studies (ie, the soft tissue components or the more diffusely enhancing regions with limited or no matrix mineralization). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Histologic grading and prognosis'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H21\">",
"     'Biopsy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Peripheral chondrosarcomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with a preexisting osteochondroma, complete surgical removal of the cartilage cap with the pseudocapsule provides excellent long-term clinical and local results. In one series of 107 patients with a tumor arising in solitary or multiple osteochondromas, five- and 10-year local recurrence rates after surgery were 16 and 18 percent, and the 10-year mortality rate was only 5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/22\">",
"     22",
"    </a>",
"    ]. Of the 63 patients who had their primary treatment at the author's institution, 26 had wide excision (none of whom recurred), 36 had a marginal excision (ten of whom recurred locally), and the one patient who had an intralesional excision also developed a local recurrence. Of the 45 patients who received treatment for a local recurrence, 15 died of their disease.",
"   </p>",
"   <p>",
"    When these tumors arise in the pelvis, the large cartilage cap can be difficult to excise, but outcomes are better if the excision is complete [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/121,126\">",
"     121,126",
"    </a>",
"    ]. As an example, in a series of 61 patients with grade 1 or 2 secondary peripheral chondrosarcoma of the pelvis, local recurrence rates after wide local or incomplete excision were 3 versus 23 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/126\">",
"     126",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Management of recurrent disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local recurrence of a grade 1 chondrosarcoma in the long bones compromises survival, and aggressive management is warranted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/127\">",
"     127",
"    </a>",
"    ]. If the local recurrence is solitary, without progression in grade and located in the long bones, repeat intralesional resection with local adjuvant therapy is reasonable. Local recurrence of an intermediate- or high-grade chondrosarcoma located in the long bones or recurrence of any grade histology in the flat bones is an indication for a wide excision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/122\">",
"     122",
"    </a>",
"    ], although it is often challenging to reach adequate wide resection margins in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     RADIOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As most chondrosarcomas are slow growing, with a relatively low fraction of dividing cells and radiation-related cytotoxicity is dependent upon cell division, chondrogenic tumors are considered relatively (but not absolutely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/128,129\">",
"     128,129",
"    </a>",
"    ]) radioresistant. Nevertheless, radiation therapy (RT) may be of benefit in two situations: after an incomplete resection of a high-grade conventional, dedifferentiated, or mesenchymal chondrosarcoma to maximize the likelihood of local control (potentially curative intent) and in situations where resection is not feasible or would cause unacceptable morbidity (palliative intent).",
"   </p>",
"   <p>",
"    When RT is given with curative intent, doses in excess of 60 Gy are required to achieve local control. However, application of this dose with conventional high energy photons is often impossible in the vicinity of critical structures, especially in chondrosarcomas arising in the skull base and axial skeleton. Unfortunately, it is in this exact situation that postoperative RT is often indicated, as these tumors are less accessible for radical resection as compared to lesions in the appendicular skeleton. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/40/7815?source=see_link\">",
"     \"Chordoma and chondrosarcoma of the skull base\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The benefits of RT can be illustrated by a series of 21 patients with primary chondrosarcoma of the spine who underwent 28 surgical procedures that included seven complete and 21 subtotal resections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/130\">",
"     130",
"    </a>",
"    ]. The median survival for the entire group was six years, and the addition of RT to resection prolonged the median disease-free interval from 16 to 44 months. Others have shown a high rate of local control (90 percent) with the addition of neoadjuvant or adjuvant RT to surgical resection in a group of 60 patients with high-risk extracranial chondrosarcoma, of whom 50 percent had either an R1 (microscopically positive) or R2 (grossly positive margins) resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/131\">",
"     131",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Palliative RT is also a reasonable option for local treatment of a primary or locally recurrent chondrosarcoma if resection is not feasible or would cause unacceptable morbidity. This is particularly true for mesenchymal chondrosarcomas, which, in our experience, are more radiosensitive than are other subtypes.",
"   </p>",
"   <p>",
"    The benefit of RT in this setting can be illustrated by a retrospective review of 15 patients with mesenchymal chondrosarcoma (all but one nonmetastatic, most extraosseous) treated in several protocols of the German Society of Pediatric Oncology and Hematology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/47\">",
"     47",
"    </a>",
"    ]. All patients had surgical resection, which was complete in eight; 13 received chemotherapy and six were irradiated. At a median follow-up of 9.6 years, four of seven incompletely resected patients were still alive, three of whom had been irradiated.",
"   </p>",
"   <p>",
"    Conventional RT can sometimes provide local control and symptom relief for other histologies, as long as sufficient doses are administered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/132,133\">",
"     132,133",
"    </a>",
"    ]. In an early report from M. D. Anderson of 20 patients with chondrosarcoma who were treated for cure, 5 of 11 patients who received RT as monotherapy achieved local control with doses from 40 to 70 Gy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/132\">",
"     132",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Charged particle irradiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the limitations of conventional photon irradiation, alternative radiation modalities have been tested. Unlike photons, which lack mass and charge, particle beams interact more densely with tissue, causing greater levels of ionization per unit length, and therefore, an increased radiobiologic effect (RBE). The most data are available for protons, but there is limited experience with carbon ions as well.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Proton beam irradiation &mdash; The theoretical advantage of charged particle irradiation using protons is in its dose distribution. The physical characteristics of the proton beam result in the majority of the energy being deposited at the end of a linear track, in what is called a Bragg peak. The radiation dose falls rapidly to zero beyond the Bragg peak. Proton beam therapy permits the delivery of high doses of RT to the target volume while limiting the \"scatter\" dose received by surrounding tissues.",
"      <br/>",
"      <br/>",
"      Proton beam RT has been studied most for incompletely resected chondrogenic tumors of the skull base and axial skeleton. Local control rates of 78 to 100 percent with mixed photon-proton or proton only protocols (doses up to 79 centigray-equivalents [CGE]) are reported by several authors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/134-138\">",
"       134-138",
"      </a>",
"      ], with limited severe late effects (&lt;10 percent RTOG grade 3 toxicity). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/40/7815?source=see_link\">",
"       \"Chordoma and chondrosarcoma of the skull base\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Carbon ions &mdash; Carbon ions represent another attractive radiation modality, which combines the physical advantages of protons with a higher radiobiological activity. The available data are in patients treated for skull based chondrosarcomas, which are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/40/7815?source=see_link\">",
"       \"Chordoma and chondrosarcoma of the skull base\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although promising, these techniques are not widely available, in contrast to photon irradiation. Particle beam irradiation requires adaptation of particle accelerators designed for other purposes or specialized dedicated equipment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/40/7815?source=see_link\">",
"     \"Chordoma and chondrosarcoma of the skull base\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SYSTEMIC TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy is generally considered ineffective in chondrosarcomas, especially for the most frequently observed conventional type and the rare (low grade) clear cell variant (",
"    <a class=\"graphic graphic_table graphicRef50684 \" href=\"mobipreview.htm?3/58/4013\">",
"     table 1",
"    </a>",
"    ). Chemoresistance in these tumors may be attributable to several factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most chondrosarcomas are slow-growing, with a relatively low fraction of dividing cells; most conventional chemotherapeutic agents act on actively dividing cells.",
"     </li>",
"     <li>",
"      Expression of the multidrug-resistance-1 gene, P-glycoprotein, by chondrosarcoma cells may also play a role [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/139,140\">",
"       139,140",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Access of anticancer agents to the tumor may be hampered because of the large amount of extracellular matrix and the poor vascularity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The benefit of chemotherapy for higher-grade (grade 2 or 3) chondrosarcomas is difficult to assess. Due to the rarity of chondrosarcomas in general and especially of intermediate and high-grade tumors, there are few prospective studies, and no randomized trials. The reported series are few in number, retrospective, and consist mainly of a small number of patients. There is an urgent need for inclusion of these patients in prospective trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Adjuvant chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;While there is no role for adjuvant chemotherapy in patients who undergo surgical treatment for a grade 1 chondrosarcoma, its benefit for dedifferentiated and mesenchymal chondrosarcomas is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Dedifferentiated chondrosarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least two studies (both retrospective) suggest that patients with dedifferentiated chondrosarcoma who are managed with surgery and chemotherapy may have a better outcome than those managed with surgery alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/141,142\">",
"     141,142",
"    </a>",
"    ]. However, benefit from chemotherapy in patients with nonmetastatic disease is not a universal observation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/12,45,46,143\">",
"     12,45,46,143",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest that eligible patients consider enrolling in clinical trials testing the value of adjuvant chemotherapy. As an example, patients with dedifferentiated chondrosarcomas are allowed in the EUROBOSS adjuvant chemotherapy trial of the Scandinavian Sarcoma Group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/144\">",
"     144",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Mesenchymal chondrosarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited experience with adjuvant (or neoadjuvant) chemotherapy in patients with mesenchymal chondrosarcoma suggests a potential benefit for chemotherapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An early study suggested chemotherapy responsiveness in patients with a prominent small round cell content [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/52\">",
"       52",
"      </a>",
"      ]. In a retrospective series of nine patients with mesenchymal chondrosarcoma treated with preoperative chemotherapy, six received a multiagent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      -containing Rosen T-10 or T-11 osteosarcoma protocol, and there were three complete and three partial responses.",
"     </li>",
"     <li>",
"      The potential benefit of neoadjuvant chemotherapy in high-grade spindle cell sarcomas of bone (other than osteosarcoma or malignant fibrous histiocytoma) was addressed in a prospective study conducted by the European Osteosarcoma Intergroup [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/143\">",
"       143",
"      </a>",
"      ]. Of the 21 patients with potentially resectable localized tumors who underwent attempted resection after three cycles of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based chemotherapy, one of two patients with a mesenchymal chondrosarcoma had a good pathological response in the primary tumor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/143\">",
"       143",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Experience with 15 cases of mesenchymal chondrosarcoma (all but one nonmetastatic, most extraosseous) was reported from the soft tissue and osteosarcoma study groups of the German Society of Pediatric Oncology and Hematology [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/47\">",
"       47",
"      </a>",
"      ]. All patients had surgical resection, which was complete in eight; 13 received chemotherapy and six were irradiated. The treatment regimens consisted of a variety of chemotherapy drugs given in various combinations in several trials.",
"      <br/>",
"      <br/>",
"      Response to induction chemotherapy could be assessed in seven patients, four of whom had a 50 percent reduction in tumor volume or &ge;50 percent \"histologic devitalization\". At a median follow-up of 9.6 years, characteristic late recurrences were not observed, and the actuarial event-free and overall survival rates at 10 years were 53 and 67 percent. The authors concluded that these outcomes were better than expected, and attributed the improved outcomes to combined modality treatment.",
"     </li>",
"     <li>",
"      A retrospective series of 26 patients with mesenchymal chondrosarcoma treated at the Rizzoli Institute included 24 surgically treated patients, 12 of whom received chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/50\">",
"       50",
"      </a>",
"      ]. After a median follow-up of 48 months, 10 remained alive. The 10-year rates of disease-free survival were markedly higher among those who received chemotherapy (31 versus 19 percent) as was overall survival (76 versus 17 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Questions will remain as to the worth of adjuvant chemotherapy until randomized trials are carried out. However, even in the absence of prospective trials, there is evidence that mesenchymal chondrosarcomas are sensitive to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    -based combination chemotherapy as used in other bone tumors. The poor prognosis seen with surgery alone provides a strong argument to consider the use of adjuvant chemotherapy in patients who are medically fit and able to tolerate the therapy. Initial induction chemotherapy is a reasonable option if the disease is locally advanced, and a response to therapy might increase the likelihood of function-preserving surgery.",
"   </p>",
"   <p>",
"    The best regimen is unknown, but it seems reasonable to use a",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"      doxorubicin",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"      cisplatin",
"     </a>",
"     -based",
"    </span>",
"    chemotherapy regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/143\">",
"     143",
"    </a>",
"    ], as is used for osteosarcoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39050?source=see_link\">",
"     \"Chemotherapy and radiation therapy in the management of osteosarcoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Advanced disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the majority of patients with recurrent or metastatic sarcoma do not respond to the usual chemotherapy regimens for advanced sarcoma, there have been isolated reports of successful treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    alone or with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , or single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/47,52,145-147\">",
"     47,52,145-147",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High-grade chondrosarcomas seem to preferentially benefit, but this is unpredictable. In the small prospective European trial in high-grade spindle cell sarcomas of bone described above, two of six patients treated for an advanced dedifferentiated chondrosarcoma had a complete response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , while the best response among five patients with metastatic mesenchymal chondrosarcoma was stable disease in two [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/143\">",
"     143",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Novel therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relative lack of efficacy of conventional chemotherapy and the discovery of novel signaling pathways in several histologic subtypes of chondrosarcoma has prompted interest in molecularly-targeted therapies, particularly for chemotherapy refractory nonoperable or metastatic chondrosarcomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/62\">",
"     62",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most active kinases in chondrosarcoma were shown to be",
"      <span class=\"nowrap\">",
"       Akt1/GSK3beta,",
"      </span>",
"      the src pathway and PDGFR [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/148\">",
"       148",
"      </a>",
"      ]. Activation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      overexpression of platelet-derived growth factor receptor-alpha (PDGFRA) and PDGFR-beta (PDGFRB) has been described in conventional chondrosarcomas, although activating mutations have not been found [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/94,95\">",
"       94,95",
"      </a>",
"      ]. Investigators have shown that SU6668, an inhibitor of several tyrosine kinase receptors, including PDGFRB, represses the growth of chondrosarcoma xenografts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/149\">",
"       149",
"      </a>",
"      ]. Although the role of these receptors in molecular pathogenesis or malignant transformation remains uncertain, these data suggest a therapeutic potential for inhibitors of these receptor tyrosine kinases. Unfortunately clinical trials have been disappointing to date:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A phase II trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      , a",
"      <span class=\"nowrap\">",
"       PDGFR/C-KIT",
"      </span>",
"      tyrosine kinase inhibitor, failed to demonstrate meaningful clinical activity in 26 patients with metastatic nonresectable chondrosarcoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/150\">",
"       150",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The tyrosine kinase inhibitor",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/39/22136?source=see_link\">",
"       dasatinib",
"      </a>",
"      was explored in a SARC trial which included a cohort of 32 patients with chondrosarcoma within a larger group of indolent sarcoma subtypes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/151\">",
"       151",
"      </a>",
"      ]. The chondrosarcoma cohort did not meet its primary endpoint (&gt;50 percent six month PFS) and the drug was considered inactive in this group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Estrogen is important in the regulation of longitudinal skeletal growth. Estrogen receptors and aromatase activity have been identified in chondrosarcomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/152-154\">",
"     152-154",
"    </a>",
"    ]. Interference with estrogen signaling may have therapeutic value in this disease. However, in one study, dose-response assays showed no effect of any of the aromatase inhibitors on proliferation of conventional chondrosarcoma in vitro, and the median progression-free survival of patients treated with aromatase inhibitors did not significantly deviate from untreated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/154\">",
"     154",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    There are other promising areas of investigation. Antitumor effects of histone deacetylase (HDAC) and angiogenesis inhibitors have been described in chondrosarcoma cell lines and in vivo models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/149,155\">",
"     149,155",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several phase I studies report incidental responses of chondrosarcomas to newer targeted agents, such as vascular endothelial growth factor antisense molecules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/156\">",
"     156",
"    </a>",
"    ], recombinant human",
"    <span class=\"nowrap\">",
"     Apo2L/TRAIL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/157\">",
"     157",
"    </a>",
"    ], and a fully human IgG1 monoclonal antibody that triggers the extrinsic apoptosis pathway through death receptor 5 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/158\">",
"     158",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the absence of effective systemic therapy, eligible patients should be encouraged to enroll in phase I or multi tumor-type trials testing novel strategies (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/\">",
"     www.clinicaltrials.gov",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with other bone sarcomas, there are no prospective data that address the appropriate schedule or selection of tests for surveillance after initial treatment for localized disease. Consensus-based guidelines from the National Comprehensive Cancer Network (NCCN) recommend physical examination, complete blood count, and chest as well as local imaging every three months for the first two years, every four months during year three, every six months for years four and five, then annually [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/159\">",
"     159",
"    </a>",
"    ]. Routine posttreatment surveillance should be extended to ten years, as late recurrences can occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Our practice is to perform MRI of the lesion one, two, and five years after initial surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/48/27394?source=see_link\">",
"       \"Patient information: Chondrosarcoma (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/63/33778?source=see_link\">",
"       \"Patient information: Bone cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chondrosarcomas are a very heterogeneous group of malignant bone tumors that share in common the production of chondroid (cartilaginous) matrix. Clinical behavior is variable and predicted by the histologic grade. Ninety percent are conventional chondrosarcomas, the majority of which are low-grade tumors which are slow growing with a low metastatic potential. High-grade chondrosarcomas, which include 5 to 10 percent of conventional chondrosarcomas as well as the dedifferentiated and mesenchymal subtypes, have a high metastatic potential and a poor prognosis following resection alone. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Experienced assessment of radiographic imaging studies (conventional X-ray, MRI, and CT) and histopathologic grade as assessed on a diagnostic biopsy are used to guide treatment decisions. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Diagnostic and staging work-up'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Surgical resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;For all grades and subtypes of nonmetastatic chondrosarcoma, surgical treatment offers the only chance for cure. The optimal type of surgical management depends upon histologic grade, location, and tumor extent. The goal of surgery is complete excision while minimizing functional disability. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Surgical treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For small, central low-grade chondrosarcomas involving an extremity that are confined to the bone, we suggest intralesional curettage with local adjuvant therapy (phenol application or cryosurgery followed by cementation or bone graft of the cavity) rather than wide local excision (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For all other patients with intermediate or high-grade histology (including the mesenchymal and dedifferentiated subtypes), large tumor size, intraarticular or soft tissue involvement, periosteal or clear cell subtypes, a low-grade central chondrosarcoma in the pelvis or axial skeleton, or a peripheral chondrosarcoma, we recommend wide local resection (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Locally recurrent chondrosarcomas should be managed aggressively, as they may be of higher histological grade than the original tumor, increasing the risk of metastases and fatal outcome. For nonmetastatic recurrence of a low-grade central chondrosarcoma, we suggest repeat intralesional resection with local adjuvant therapy if the local recurrence is solitary, without progression in grade and located in the long bones (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Otherwise, wide local excision is preferred. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Management of recurrent disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Role of radiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;While most low-grade chondrosarcomas are considered relatively radioresistant, radiation therapy (RT) may be of benefit in two situations (see",
"    <a class=\"local\" href=\"#H29\">",
"     'Radiotherapy'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We generally suggest adjuvant radiotherapy for incompletely excised high-grade conventional, dedifferentiated, or mesenchymal chondrosarcomas (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Doses of more than 60 Gy are needed for maximal local control after incomplete resection, and depending on the tumor site, this may not be feasible with conventional photon beam irradiation. In such cases, referral for treatment using newer techniques, such as proton beam irradiation, is appropriate, where available.",
"     </li>",
"     <li>",
"      Palliative RT is a reasonable option for local treatment of patients with a primary or locally recurrent chondrosarcoma if resection is not feasible or would cause unacceptable morbidity, as well as for those with symptomatic metastatic disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conventional low-grade and clear cell chondrosarcomas are chemotherapy-resistant. Chemotherapy is possibly effective in the mesenchymal subtype, particularly those that contain a high percentage of round cells, and is of uncertain value in dedifferentiated chondrosarcoma; both subtypes are rare and bear a poor prognosis. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Systemic treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h3\">",
"     Adjuvant chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no role for adjuvant chemotherapy after complete resection of a conventional low-grade chondrosarcoma, and we recommend not pursuing this approach (",
"    <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"     Grade 1C",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The role of chemotherapy after complete resection of a dedifferentiated chondrosarcoma is unknown. Retrospective studies suggest that patients who are managed with surgery and chemotherapy have a better outcome than those managed with surgery alone. We recommend that eligible patients be enrolled on clinical trials testing adjuvant chemotherapy, such as the Euroboss I trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/39/35450/abstract/144\">",
"     144",
"    </a>",
"    ]. If the protocol is not available or if patients are unable or unwilling to participate, we manage these patients on a case by case basis. If the high-grade component is an osteosarcoma, we treat the patient as per osteosarcoma protocols. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Adjuvant chemotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients with a completely resected mesenchymal chondrosarcoma, retrospective studies suggest that those with a substantial round cell component are sensitive to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    -based combination chemotherapy. The poor prognosis seen with surgery alone provides a strong argument to discuss the risks and potential benefits of adjuvant doxorubicin-based chemotherapy with these patients as long as they are medically fit and able to tolerate the therapy. Initial induction chemotherapy is a reasonable option if the disease is locally advanced, and a response to therapy might increase the likelihood of complete resection or function-preserving surgery. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Adjuvant chemotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Advanced disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of conventional chemotherapy is limited in advanced disease, with the exception of mesenchymal osteosarcomas. We suggest that patients be enrolled in clinical trials testing new strategies. If trial enrollment is not available or not feasible, we use a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    combination as is used for other bone sarcomas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39050?source=see_link\">",
"     \"Chemotherapy and radiation therapy in the management of osteosarcoma\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     WHO: Cartilage tumours. In: World health organization classification of tumours. Pathology and genetics - Tumours of soft tissue and bone, Fletcher CDM, Unni KK, Mertens F (Eds), 2002. p.234.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/2\">",
"      Dorfman HD, Czerniak B. Bone cancers. Cancer 1995; 75:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/3\">",
"      Murphey MD, Walker EA, Wilson AJ, et al. From the archives of the AFIP: imaging of primary chondrosarcoma: radiologic-pathologic correlation. Radiographics 2003; 23:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/4\">",
"      Angelini A, Guerra G, Mavrogenis AF, et al. Clinical outcome of central conventional chondrosarcoma. J Surg Oncol 2012; 106:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/5\">",
"      Evans HL, Ayala AG, Romsdahl MM. Prognostic factors in chondrosarcoma of bone: a clinicopathologic analysis with emphasis on histologic grading. Cancer 1977; 40:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/6\">",
"      Pring ME, Weber KL, Unni KK, Sim FH. Chondrosarcoma of the pelvis. A review of sixty-four cases. J Bone Joint Surg Am 2001; 83-A:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/7\">",
"      Giuffrida AY, Burgueno JE, Koniaris LG, et al. Chondrosarcoma in the United States (1973 to 2003): an analysis of 2890 cases from the SEER database. J Bone Joint Surg Am 2009; 91:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/8\">",
"      Fiorenza F, Abudu A, Grimer RJ, et al. Risk factors for survival and local control in chondrosarcoma of bone. J Bone Joint Surg Br 2002; 84:93.",
"     </a>",
"    </li>",
"    <li>",
"     Pathology and Genetics of tumours of soft tissue and bone, Fletcher CDM, Unni KK, Mertens F (Eds), IARC, Lyon, France 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/10\">",
"      Bj&ouml;rnsson J, McLeod RA, Unni KK, et al. Primary chondrosarcoma of long bones and limb girdles. Cancer 1998; 83:2105.",
"     </a>",
"    </li>",
"    <li>",
"     Cartilage tumours. In: World health organization classification of tumours. Pathology and genetics. Tumours of soft tissue and bone, Fletcher CD, Unni KK, Mertens F (Eds), 2002. p.233.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/12\">",
"      Grimer RJ, Gosheger G, Taminiau A, et al. Dedifferentiated chondrosarcoma: prognostic factors and outcome from a European group. Eur J Cancer 2007; 43:2060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/13\">",
"      Skeletal Lesions Interobserver Correlation among Expert Diagnosticians (SLICED) Study Group. Reliability of histopathologic and radiologic grading of cartilaginous neoplasms in long bones. J Bone Joint Surg Am 2007; 89:2113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/14\">",
"      Eefting D, Schrage YM, Geirnaerdt MJ, et al. Assessment of interobserver variability and histologic parameters to improve reliability in classification and grading of central cartilaginous tumors. Am J Surg Pathol 2009; 33:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/15\">",
"      Bov&eacute;e JV, Cleton-Jansen AM, Taminiau AH, Hogendoorn PC. Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. Lancet Oncol 2005; 6:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/16\">",
"      Bov&eacute;e JV. Multiple osteochondromas. Orphanet J Rare Dis 2008; 3:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/17\">",
"      Schmale GA, Conrad EU 3rd, Raskind WH. The natural history of hereditary multiple exostoses. J Bone Joint Surg Am 1994; 76:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/18\">",
"      Wicklund CL, Pauli RM, Johnston D, Hecht JT. Natural history study of hereditary multiple exostoses. Am J Med Genet 1995; 55:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/19\">",
"      Peterson HA. Multiple hereditary osteochondromata. Clin Orthop Relat Res 1989; :222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/20\">",
"      Altay M, Bayrakci K, Yildiz Y, et al. Secondary chondrosarcoma in cartilage bone tumors: report of 32 patients. J Orthop Sci 2007; 12:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/21\">",
"      Pedrini E, Jennes I, Tremosini M, et al. Genotype-phenotype correlation study in 529 patients with multiple hereditary exostoses: identification of \"protective\" and \"risk\" factors. J Bone Joint Surg Am 2011; 93:2294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/22\">",
"      Ahmed AR, Tan TS, Unni KK, et al. Secondary chondrosarcoma in osteochondroma: report of 107 patients. Clin Orthop Relat Res 2003; :193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/23\">",
"      Pierz KA, Womer RB, Dormans JP. Pediatric bone tumors: osteosarcoma ewing's sarcoma, and chondrosarcoma associated with multiple hereditary osteochondromatosis. J Pediatr Orthop 2001; 21:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/24\">",
"      Silve C, J&uuml;ppner H. Ollier disease. Orphanet J Rare Dis 2006; 1:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/25\">",
"      Liu J, Hudkins PG, Swee RG, Unni KK. Bone sarcomas associated with Ollier's disease. Cancer 1987; 59:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/26\">",
"      Schwartz HS, Zimmerman NB, Simon MA, et al. The malignant potential of enchondromatosis. J Bone Joint Surg Am 1987; 69:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/27\">",
"      Albregts AE, Rapini RP. Malignancy in Maffucci's syndrome. Dermatol Clin 1995; 13:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/28\">",
"      Verdegaal SH, Bov&eacute;e JV, Pansuriya TC, et al. Incidence, predictive factors, and prognosis of chondrosarcoma in patients with Ollier disease and Maffucci syndrome: an international multicenter study of 161 patients. Oncologist 2011; 16:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/29\">",
"      Pannier S, Legeai-Mallet L. Hereditary multiple exostoses and enchondromatosis. Best Pract Res Clin Rheumatol 2008; 22:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/30\">",
"      Brien EW, Mirra JM, Kerr R. Benign and malignant cartilage tumors of bone and joint: their anatomic and theoretical basis with an emphasis on radiology, pathology and clinical biology. I. The intramedullary cartilage tumors. Skeletal Radiol 1997; 26:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/31\">",
"      Young CL, Sim FH, Unni KK, McLeod RA. Chondrosarcoma of bone in children. Cancer 1990; 66:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/32\">",
"      Damron TA, Ward WG, Stewart A. Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: National Cancer Data Base Report. Clin Orthop Relat Res 2007; 459:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/33\">",
"      Vanel D, Picci P, De Paolis M, Mercuri M. Radiological study of 12 high-grade surface osteosarcomas. Skeletal Radiol 2001; 30:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/34\">",
"      Schajowicz F, Sissons HA, Sobin LH. The World Health Organization's histologic classification of bone tumors. A commentary on the second edition. Cancer 1995; 75:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/35\">",
"      Schajowicz F. Juxtacortical chondrosarcoma. J Bone Joint Surg Br 1977; 59-B:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/36\">",
"      Papagelopoulos PJ, Galanis EC, Mavrogenis AF, et al. Survivorship analysis in patients with periosteal chondrosarcoma. Clin Orthop Relat Res 2006; 448:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/37\">",
"      Geirnaerdt MJ, Hermans J, Bloem JL, et al. Usefulness of radiography in differentiating enchondroma from central grade 1 chondrosarcoma. AJR Am J Roentgenol 1997; 169:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/38\">",
"      Mirra JM, Gold R, Downs J, Eckardt JJ. A new histologic approach to the differentiation of enchondroma and chondrosarcoma of the bones. A clinicopathologic analysis of 51 cases. Clin Orthop Relat Res 1985; :214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/39\">",
"      Bov&eacute;e JV, Cleton-Jansen AM, Kuipers-Dijkshoorn NJ, et al. Loss of heterozygosity and DNA ploidy point to a diverging genetic mechanism in the origin of peripheral and central chondrosarcoma. Genes Chromosomes Cancer 1999; 26:237.",
"     </a>",
"    </li>",
"    <li>",
"     Milchgrub S, Hogendoorn PCW. Dedifferentiated chondrosarcoma. In: Dedifferentiated chondrosarcoma, Fletcher CDM, Unni KK, Mertens F (Eds), 2002. p.252.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/41\">",
"      Bov&eacute;e JV, Cleton-Jansen AM, Rosenberg C, et al. Molecular genetic characterization of both components of a dedifferentiated chondrosarcoma, with implications for its histogenesis. J Pathol 1999; 189:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/42\">",
"      R&ouml;pke M, Boltze C, Neumann HW, et al. Genetic and epigenetic alterations in tumor progression in a dedifferentiated chondrosarcoma. Pathol Res Pract 2003; 199:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/43\">",
"      Grote HJ, Schneider-Stock R, Neumann W, Roessner A. Mutation of p53 with loss of heterozygosity in the osteosarcomatous component of a dedifferentiated chondrosarcoma. Virchows Arch 2000; 436:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/44\">",
"      Coughlan B, Feliz A, Ishida T, et al. p53 expression and DNA ploidy of cartilage lesions. Hum Pathol 1995; 26:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/45\">",
"      Staals EL, Bacchini P, Bertoni F. Dedifferentiated central chondrosarcoma. Cancer 2006; 106:2682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/46\">",
"      Dickey ID, Rose PS, Fuchs B, et al. Dedifferentiated chondrosarcoma: the role of chemotherapy with updated outcomes. J Bone Joint Surg Am 2004; 86-A:2412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/47\">",
"      Dantonello TM, Int-Veen C, Leuschner I, et al. Mesenchymal chondrosarcoma of soft tissues and bone in children, adolescents, and young adults: experiences of the CWS and COSS study groups. Cancer 2008; 112:2424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/48\">",
"      Rushing EJ, Armonda RA, Ansari Q, Mena H. Mesenchymal chondrosarcoma: a clinicopathologic and flow cytometric study of 13 cases presenting in the central nervous system. Cancer 1996; 77:1884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/49\">",
"      Vencio EF, Reeve CM, Unni KK, Nascimento AG. Mesenchymal chondrosarcoma of the jaw bones: clinicopathologic study of 19 cases. Cancer 1998; 82:2350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/50\">",
"      Cesari M, Bertoni F, Bacchini P, et al. Mesenchymal chondrosarcoma. An analysis of patients treated at a single institution. Tumori 2007; 93:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/51\">",
"      Nakashima Y, Unni KK, Shives TC, et al. Mesenchymal chondrosarcoma of bone and soft tissue. A review of 111 cases. Cancer 1986; 57:2444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/52\">",
"      Huvos AG, Rosen G, Dabska M, Marcove RC. Mesenchymal chondrosarcoma. A clinicopathologic analysis of 35 patients with emphasis on treatment. Cancer 1983; 51:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/53\">",
"      Donati D, Yin JQ, Colangeli M, et al. Clear cell chondrosarcoma of bone: long time follow-up of 18 cases. Arch Orthop Trauma Surg 2008; 128:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/54\">",
"      It&auml;l&auml; A, Leerapun T, Inwards C, et al. An institutional review of clear cell chondrosarcoma. Clin Orthop Relat Res 2005; 440:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/55\">",
"      Kawaguchi S, Wada T, Nagoya S, et al. Extraskeletal myxoid chondrosarcoma: a Multi-Institutional Study of 42 Cases in Japan. Cancer 2003; 97:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/56\">",
"      Drilon AD, Popat S, Bhuchar G, et al. Extraskeletal myxoid chondrosarcoma: a retrospective review from 2 referral centers emphasizing long-term outcomes with surgery and chemotherapy. Cancer 2008; 113:3364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/57\">",
"      Goh YW, Spagnolo DV, Platten M, et al. Extraskeletal myxoid chondrosarcoma: a light microscopic, immunohistochemical, ultrastructural and immuno-ultrastructural study indicating neuroendocrine differentiation. Histopathology 2001; 39:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/58\">",
"      Antonescu CR, Argani P, Erlandson RA, et al. Skeletal and extraskeletal myxoid chondrosarcoma: a comparative clinicopathologic, ultrastructural, and molecular study. Cancer 1998; 83:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/59\">",
"      Aigner T, Oliveira AM, Nascimento AG. Extraskeletal myxoid chondrosarcomas do not show a chondrocytic phenotype. Mod Pathol 2004; 17:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/60\">",
"      Brody RI, Ueda T, Hamelin A, et al. Molecular analysis of the fusion of EWS to an orphan nuclear receptor gene in extraskeletal myxoid chondrosarcoma. Am J Pathol 1997; 150:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/61\">",
"      Kilpatrick SE, Inwards CY, Fletcher CD, et al. Myxoid chondrosarcoma (chordoid sarcoma) of bone: a report of two cases and review of the literature. Cancer 1997; 79:1903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/62\">",
"      Bov&eacute;e JV, Hogendoorn PC, Wunder JS, Alman BA. Cartilage tumours and bone development: molecular pathology and possible therapeutic targets. Nat Rev Cancer 2010; 10:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/63\">",
"      Ahn J, L&uuml;decke HJ, Lindow S, et al. Cloning of the putative tumour suppressor gene for hereditary multiple exostoses (EXT1). Nat Genet 1995; 11:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/64\">",
"      Stickens D, Clines G, Burbee D, et al. The EXT2 multiple exostoses gene defines a family of putative tumour suppressor genes. Nat Genet 1996; 14:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/65\">",
"      Wuyts W, Van Hul W, Wauters J, et al. Positional cloning of a gene involved in hereditary multiple exostoses. Hum Mol Genet 1996; 5:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/66\">",
"      Bov&eacute;e JV, Cleton-Jansen AM, Wuyts W, et al. EXT-mutation analysis and loss of heterozygosity in sporadic and hereditary osteochondromas and secondary chondrosarcomas. Am J Hum Genet 1999; 65:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/67\">",
"      Hameetman L, Szuhai K, Yavas A, et al. The role of EXT1 in nonhereditary osteochondroma: identification of homozygous deletions. J Natl Cancer Inst 2007; 99:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/68\">",
"      Hameetman L, David G, Yavas A, et al. Decreased EXT expression and intracellular accumulation of heparan sulphate proteoglycan in osteochondromas and peripheral chondrosarcomas. J Pathol 2007; 211:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/69\">",
"      McCormick C, Leduc Y, Martindale D, et al. The putative tumour suppressor EXT1 alters the expression of cell-surface heparan sulfate. Nat Genet 1998; 19:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/70\">",
"      van der Eerden BC, Karperien M, Gevers EF, et al. Expression of Indian hedgehog, parathyroid hormone-related protein, and their receptors in the postnatal growth plate of the rat: evidence for a locally acting growth restraining feedback loop after birth. J Bone Miner Res 2000; 15:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/71\">",
"      Bov&eacute;e JV, van den Broek LJ, Cleton-Jansen AM, Hogendoorn PC. Up-regulation of PTHrP and Bcl-2 expression characterizes the progression of osteochondroma towards peripheral chondrosarcoma and is a late event in central chondrosarcoma. Lab Invest 2000; 80:1925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/72\">",
"      Hameetman L, Kok P, Eilers PH, et al. The use of Bcl-2 and PTHLH immunohistochemistry in the diagnosis of peripheral chondrosarcoma in a clinicopathological setting. Virchows Arch 2005; 446:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/73\">",
"      Hopyan S, Gokgoz N, Poon R, et al. A mutant PTH/PTHrP type I receptor in enchondromatosis. Nat Genet 2002; 30:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/74\">",
"      Tiet TD, Hopyan S, Nadesan P, et al. Constitutive hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation. Am J Pathol 2006; 168:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/75\">",
"      Rozeman LB, Hameetman L, Cleton-Jansen AM, et al. Absence of IHH and retention of PTHrP signalling in enchondromas and central chondrosarcomas. J Pathol 2005; 205:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/76\">",
"      Amling M, P&ouml;sl M, Hentz MW, et al. PTHrP and Bcl-2: essential regulatory molecules in chondrocyte differentiation and chondrogenic tumors. Verh Dtsch Ges Pathol 1998; 82:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/77\">",
"      Kunisada T, Moseley JM, Slavin JL, et al. Co-expression of parathyroid hormone-related protein (PTHrP) and PTH/PTHrP receptor in cartilaginous tumours: a marker for malignancy? Pathology 2002; 34:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/78\">",
"      Pateder DB, Gish MW, O'Keefe RJ, et al. Parathyroid hormone-related Peptide expression in cartilaginous tumors. Clin Orthop Relat Res 2002; :198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/79\">",
"      Schrage YM, Hameetman L, Szuhai K, et al. Aberrant heparan sulfate proteoglycan localization, despite normal exostosin, in central chondrosarcoma. Am J Pathol 2009; 174:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/80\">",
"      Tang GQ, Yan TQ, Guo W, et al. (-)-Epigallocatechin-3-gallate induces apoptosis and suppresses proliferation by inhibiting the human Indian Hedgehog pathway in human chondrosarcoma cells. J Cancer Res Clin Oncol 2010; 136:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/81\">",
"      Pansuriya TC, van Eijk R, d'Adamo P, et al. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet 2011; 43:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/82\">",
"      Amary MF, Bacsi K, Maggiani F, et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol 2011; 224:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/83\">",
"      Amary MF, Damato S, Halai D, et al. Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nat Genet 2011; 43:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/84\">",
"      Pansuriya TC, Kroon HM, Bov&eacute;e JV. Enchondromatosis: insights on the different subtypes. Int J Clin Exp Pathol 2010; 3:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/85\">",
"      Couvineau A, Wouters V, Bertrand G, et al. PTHR1 mutations associated with Ollier disease result in receptor loss of function. Hum Mol Genet 2008; 17:2766.",
"     </a>",
"    </li>",
"    <li>",
"     Mertens F, Unni KK. Enchondromatosis: Ollier disease and MAffucci syndrome. In: World health organization classification of tumours. Pathology and genetics. Tumours of soft tissue and bone, Fletcher CDM, Unni KK, Mertens F (Eds), 2002. p.356.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/87\">",
"      Tallini G, Dorfman H, Brys P, et al. Correlation between clinicopathological features and karyotype in 100 cartilaginous and chordoid tumours. A report from the Chromosomes and Morphology (CHAMP) Collaborative Study Group. J Pathol 2002; 196:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/88\">",
"      Sandberg AA. Genetics of chondrosarcoma and related tumors. Curr Opin Oncol 2004; 16:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/89\">",
"      Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: chondrosarcoma and other cartilaginous neoplasms. Cancer Genet Cytogenet 2003; 143:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/90\">",
"      Larramendy ML, Tarkkanen M, Valle J, et al. Gains, losses, and amplifications of DNA sequences evaluated by comparative genomic hybridization in chondrosarcomas. Am J Pathol 1997; 150:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/91\">",
"      van Beerendonk HM, Rozeman LB, Taminiau AH, et al. Molecular analysis of the INK4A/INK4A-ARF gene locus in conventional (central) chondrosarcomas and enchondromas: indication of an important gene for tumour progression. J Pathol 2004; 202:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/92\">",
"      Asp J, Sangiorgi L, Inerot SE, et al. Changes of the p16 gene but not the p53 gene in human chondrosarcoma tissues. Int J Cancer 2000; 85:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/93\">",
"      Rozeman LB, Hogendoorn PC, Bov&eacute;e JV. Diagnosis and prognosis of chondrosarcoma of bone. Expert Rev Mol Diagn 2002; 2:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/94\">",
"      Lagonigro MS, Tamborini E, Negri T, et al. PDGFRalpha, PDGFRbeta and KIT expression/activation in conventional chondrosarcoma. J Pathol 2006; 208:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/95\">",
"      Sulzbacher I, Birner P, Trieb K, et al. Platelet-derived growth factor-alpha receptor expression supports the growth of conventional chondrosarcoma and is associated with adverse outcome. Am J Surg Pathol 2001; 25:1520.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone, IARC Press, Lyon 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/97\">",
"      Littrell LA, Wenger DE, Wold LE, et al. Radiographic, CT, and MR imaging features of dedifferentiated chondrosarcomas: a retrospective review of 174 de novo cases. Radiographics 2004; 24:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/98\">",
"      Sanerkin NG. The diagnosis and grading of chondrosarcoma of bone: a combined cytologic and histologic approach. Cancer 1980; 45:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/99\">",
"      Schiller AL. Diagnosis of borderline cartilage lesions of bone. Semin Diagn Pathol 1985; 2:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/100\">",
"      Flemming DJ, Murphey MD. Enchondroma and chondrosarcoma. Semin Musculoskelet Radiol 2000; 4:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/101\">",
"      Geirnaerdt MJ, Bloem JL, Eulderink F, et al. Cartilaginous tumors: correlation of gadolinium-enhanced MR imaging and histopathologic findings. Radiology 1993; 186:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/102\">",
"      Geirnaerdt MJ, Hogendoorn PC, Bloem JL, et al. Cartilaginous tumors: fast contrast-enhanced MR imaging. Radiology 2000; 214:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/103\">",
"      Hudson TM, Manaster BJ, Springfield DS, et al. Radiology of medullary chondrosarcoma: preoperative treatment planning. Skeletal Radiol 1983; 10:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/104\">",
"      Dietlein M, F&eacute;aux de Lacroix W, Neufang KF, et al. [Assessment of the grading of cartilaginous tumors of the long tubular bones from the radiologic and pathologic viewpoint]. Rontgenblatter 1990; 43:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/105\">",
"      Shapeero LG, Vanel D, Couanet D, et al. Extraskeletal mesenchymal chondrosarcoma. Radiology 1993; 186:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/106\">",
"      Brenner W, Conrad EU, Eary JF. FDG PET imaging for grading and prediction of outcome in chondrosarcoma patients. Eur J Nucl Med Mol Imaging 2004; 31:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/107\">",
"      Feldman F, Vanheertum R, Saxena C. 18Fluoro-deoxyglucose positron emission tomography evaluation of benign versus malignant osteochondromas: preliminary observations. J Comput Assist Tomogr 2006; 30:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/108\">",
"      Feldman F, Van Heertum R, Saxena C, Parisien M. 18FDG-PET applications for cartilage neoplasms. Skeletal Radiol 2005; 34:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/109\">",
"      Lee FY, Yu J, Chang SS, et al. Diagnostic value and limitations of fluorine-18 fluorodeoxyglucose positron emission tomography for cartilaginous tumors of bone. J Bone Joint Surg Am 2004; 86-A:2677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/110\">",
"      Normand AN, Cannon CP, Lewis VO, et al. Curettage of biopsy-diagnosed grade 1 periacetabular chondrosarcoma. Clin Orthop Relat Res 2007; 459:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/111\">",
"      Enneking WF. A system of staging musculoskeletal neoplasms. Clin Orthop Relat Res 1986; :9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/112\">",
"      Wolf RE, Enneking WF. The staging and surgery of musculoskeletal neoplasms. Orthop Clin North Am 1996; 27:473.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 5th, Fleming ID, Cooper JS, Henson DE, et al (Eds), Lippincott-Raven, Philadelphia 1997. p.143.",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Spring, New York 2010. p.281.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/115\">",
"      Leerapun T, Hugate RR, Inwards CY, et al. Surgical management of conventional grade I chondrosarcoma of long bones. Clin Orthop Relat Res 2007; 463:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/116\">",
"      van der Geest IC, de Valk MH, de Rooy JW, et al. Oncological and functional results of cryosurgical therapy of enchondromas and chondrosarcomas grade 1. J Surg Oncol 2008; 98:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/117\">",
"      Hickey M, Farrokhyar F, Deheshi B, et al. A systematic review and meta-analysis of intralesional versus wide resection for intramedullary grade I chondrosarcoma of the extremities. Ann Surg Oncol 2011; 18:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/118\">",
"      Donati D, Colangeli S, Colangeli M, et al. Surgical treatment of grade I central chondrosarcoma. Clin Orthop Relat Res 2010; 468:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/119\">",
"      Bauer HC, Brosj&ouml; O, Kreicbergs A, Lindholm J. Low risk of recurrence of enchondroma and low-grade chondrosarcoma in extremities. 80 patients followed for 2-25 years. Acta Orthop Scand 1995; 66:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/120\">",
"      Aarons C, Potter BK, Adams SC, et al. Extended intralesional treatment versus resection of low-grade chondrosarcomas. Clin Orthop Relat Res 2009; 467:2105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/121\">",
"      Streitb&uuml;rger A, Ahrens H, Balke M, et al. Grade I chondrosarcoma of bone: the M&uuml;nster experience. J Cancer Res Clin Oncol 2009; 135:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/122\">",
"      Weber KL, Pring ME, Sim FH. Treatment and outcome of recurrent pelvic chondrosarcoma. Clin Orthop Relat Res 2002; :19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/123\">",
"      Shearer D, Patt JC, Cizic A, et al. Curettage and cryotherapy for treatment of low grade chondrosarcoma (abstract). Proc Connect Tissue Oncol Soc 2006; 12:760a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/124\">",
"      Wirbel RJ, Schulte M, Maier B, et al. Chondrosarcoma of the pelvis: oncologic and functional outcome. Sarcoma 2000; 4:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/125\">",
"      Normand AN, Lin RP, Cannon CP, et al. Local recurrence of pelvic chondrosarcoma: an analysis of 19 patients (abstract). Proc Connect Tissue Oncol Soc 2006; 12:746a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/126\">",
"      Donati D, El Ghoneimy A, Bertoni F, et al. Surgical treatment and outcome of conventional pelvic chondrosarcoma. J Bone Joint Surg Br 2005; 87:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/127\">",
"      Schwab JH, Wenger D, Unni K, Sim FH. Does local recurrence impact survival in low-grade chondrosarcoma of the long bones? Clin Orthop Relat Res 2007; 462:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/128\">",
"      Le A, Ball D, Pitman A, et al. Chondrosarcoma of bone complicating Ollier's disease: report of a favourable response to radiotherapy. Australas Radiol 2003; 47:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/129\">",
"      Normand AN, Ballo MT, Yasko AW, et al. Palliative radiation therapy for chondrosarcoma (abstract). Proc Connect Tissue Oncol Soc 2006; 12:745a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/130\">",
"      York JE, Berk RH, Fuller GN, et al. Chondrosarcoma of the spine: 1954 to 1997. J Neurosurg 1999; 90:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/131\">",
"      Goda JS, Ferguson PC, O'Sullivan B, et al. High-risk extracranial chondrosarcoma: Long-term results of surgery and radiation therapy. Cancer 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/132\">",
"      McNaney D, Lindberg RD, Ayala AG, et al. Fifteen year radiotherapy experience with chondrosarcoma of bone. Int J Radiat Oncol Biol Phys 1982; 8:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/133\">",
"      Krochak R, Harwood AR, Cummings BJ, Quirt IC. Results of radical radiation for chondrosarcoma of bone. Radiother Oncol 1983; 1:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/134\">",
"      No&euml;l G, Habrand JL, Jauffret E, et al. Radiation therapy for chordoma and chondrosarcoma of the skull base and the cervical spine. Prognostic factors and patterns of failure. Strahlenther Onkol 2003; 179:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/135\">",
"      Hug EB, Loredo LN, Slater JD, et al. Proton radiation therapy for chordomas and chondrosarcomas of the skull base. J Neurosurg 1999; 91:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/136\">",
"      Weber DC, Rutz HP, Pedroni ES, et al. Results of spot-scanning proton radiation therapy for chordoma and chondrosarcoma of the skull base: the Paul Scherrer Institut experience. Int J Radiat Oncol Biol Phys 2005; 63:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/137\">",
"      Rosenberg AE, Nielsen GP, Keel SB, et al. Chondrosarcoma of the base of the skull: a clinicopathologic study of 200 cases with emphasis on its distinction from chordoma. Am J Surg Pathol 1999; 23:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/138\">",
"      DeLaney TF, Liebsch NJ, Pedlow FX, et al. Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas. Int J Radiat Oncol Biol Phys 2009; 74:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/139\">",
"      Wyman JJ, Hornstein AM, Meitner PA, et al. Multidrug resistance-1 and p-glycoprotein in human chondrosarcoma cell lines: expression correlates with decreased intracellular doxorubicin and in vitro chemoresistance. J Orthop Res 1999; 17:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/140\">",
"      Terek RM, Schwartz GK, Devaney K, et al. Chemotherapy and P-glycoprotein expression in chondrosarcoma. J Orthop Res 1998; 16:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/141\">",
"      Mitchell AD, Ayoub K, Mangham DC, et al. Experience in the treatment of dedifferentiated chondrosarcoma. J Bone Joint Surg Br 2000; 82:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/142\">",
"      Staals EL, Bacchini P, Mercuri M, Bertoni F. Dedifferentiated chondrosarcomas arising in preexisting osteochondromas. J Bone Joint Surg Am 2007; 89:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/143\">",
"      Nooij MA, Whelan J, Bramwell VH, et al. Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: a European Osteosarcoma Intergroup Study. Eur J Cancer 2005; 41:225.",
"     </a>",
"    </li>",
"    <li>",
"     Euroboss I protocol available online at www.radium.no/sarcoma/FTP/pdf/Euroboss1.pdf (Accessed on June 08, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/145\">",
"      La Rocca RV, Morgan KW, Paris K, Baeker TR. Recurrent chondrosarcoma of the cranial base: a durable response to ifosfamide-doxorubicin chemotherapy. J Neurooncol 1999; 41:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/146\">",
"      Delepine N, Cornille H, Delepine G, et al. [Objective response of dedifferentiated chondrosarcoma to neoadjuvant chemotherapy (weekly high-dose methotrexate)]. Bull Cancer 1988; 75:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/147\">",
"      Debruyne PR, Dumez H, Demey W, et al. Recurrent low- to intermediate-grade chondrosarcoma of the thumb with lung metastases: an objective response to trofosfamide. Onkologie 2007; 30:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/148\">",
"      Schrage YM, Briaire-de Bruijn IH, de Miranda NF, et al. Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment. Cancer Res 2009; 69:6216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/149\">",
"      Klenke FM, Abdollahi A, Bertl E, et al. Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo. BMC Cancer 2007; 7:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/150\">",
"      Grignani G, Palmerini E, Stacchiotti S, et al. A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-&alpha; or -&beta;: An Italian Sarcoma Group study. Cancer 2011; 117:826.",
"     </a>",
"    </li>",
"    <li>",
"     Schuetze SM, Wathen JK, Choy E, et al. SARC009, a phase II study of dasatanib: results in alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor (abstract 114). Data presented at the 16th annual  meeting of the Connective Tissue Oncology Society, Paris France,  November 11-13, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/152\">",
"      Cleton-Jansen AM, van Beerendonk HM, Baelde HJ, et al. Estrogen signaling is active in cartilaginous tumors: implications for antiestrogen therapy as treatment option of metastasized or irresectable chondrosarcoma. Clin Cancer Res 2005; 11:8028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/153\">",
"      Grifone TJ, Haupt HM, Podolski V, Brooks JJ. Immunohistochemical expression of estrogen receptors in chondrosarcomas and enchondromas. Int J Surg Pathol 2008; 16:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/154\">",
"      Meijer D, Gelderblom H, Karperien M, et al. Expression of aromatase and estrogen receptor alpha in chondrosarcoma, but no beneficial effect of inhibiting estrogen signaling both in vitro and in vivo. Clin Sarcoma Res 2011; 1:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/155\">",
"      Sakimura R, Tanaka K, Yamamoto S, et al. The effects of histone deacetylase inhibitors on the induction of differentiation in chondrosarcoma cells. Clin Cancer Res 2007; 13:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/156\">",
"      Levine AM, Tulpule A, Quinn DI, et al. Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy. J Clin Oncol 2006; 24:1712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/157\">",
"      Herbst RS, Eckhardt SG, Kurzrock R, et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 2010; 28:2839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/39/35450/abstract/158\">",
"      Camidge DR, Herbst RS, Gordon MS, et al. A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin Cancer Res 2010; 16:1256.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7724 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-1759BFA714-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_39_35450=[""].join("\n");
var outline_f34_39_35450=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H38\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTOLOGIC GRADING AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLASSIFICATION, HISTOLOGY, AND CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Precursor lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Osteochondroma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Enchondroma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Conventional chondrosarcomas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Central chondrosarcoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Peripheral chondrosarcoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Periosteal chondrosarcoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Histologic appearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Rare chondrosarcoma subtypes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Dedifferentiated chondrosarcoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Mesenchymal chondrosarcoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Clear cell chondrosarcoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Myxoid chondrosarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Molecular pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIAGNOSTIC AND STAGING WORK-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Radiographic imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Role of PET",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Staging system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Completing the staging workup",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SURGICAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Intermediate and high-grade tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Low-grade central tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Peripheral chondrosarcomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Management of recurrent disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      RADIOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Charged particle irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SYSTEMIC TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Adjuvant chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Dedifferentiated chondrosarcoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Mesenchymal chondrosarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Advanced disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Novel therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Surgical resection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Role of radiotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      - Adjuvant chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Advanced disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7724\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7724|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?26/0/26625\" title=\"diagnostic image 1\">",
"      Osteochondroma humerus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?12/35/12849\" title=\"diagnostic image 2\">",
"      Multiple exostoses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?33/9/33951\" title=\"diagnostic image 3\">",
"      Solitary enchondroma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?2/12/2245\" title=\"diagnostic image 4\">",
"      Enchondromatosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?24/56/25475\" title=\"diagnostic image 5\">",
"      Maffucci syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?12/51/13107\" title=\"diagnostic image 6\">",
"      Enchondroma malignant transformation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?1/34/1572\" title=\"diagnostic image 7\">",
"      Chondro low radiographs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?12/18/12583\" title=\"diagnostic image 8\">",
"      Chondro high radiographs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?8/19/8496\" title=\"diagnostic image 9\">",
"      CT chondro",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7724|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/53/23391\" title=\"figure 1\">",
"      Components of a long bone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/52/9039\" title=\"figure 2\">",
"      Prop gen model peri chondro",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/38/1647\" title=\"figure 3\">",
"      Prop gen model cen chondro",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/34/13864\" title=\"figure 4\">",
"      Bone tumor locations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7724|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/37/593\" title=\"picture 1\">",
"      Chondro histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/30/41445\" title=\"picture 2\">",
"      Osteochondroma cross-section",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/21/32083\" title=\"picture 3\">",
"      Chondro histology rare",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7724|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/58/4013\" title=\"table 1\">",
"      Clin char Rx opts chondro",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/43/26301\" title=\"table 2\">",
"      TNM staging bone tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/53/35673?source=related_link\">",
"      Bone tumors: Diagnosis and biopsy techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39050?source=related_link\">",
"      Chemotherapy and radiation therapy in the management of osteosarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/40/7815?source=related_link\">",
"      Chordoma and chondrosarcoma of the skull base",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34602?source=related_link\">",
"      Head and neck sarcomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/60/24522?source=related_link\">",
"      Overview of benign bone tumors in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32042?source=related_link\">",
"      Pathogenetic factors in soft tissue and bone sarcomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/63/33778?source=related_link\">",
"      Patient information: Bone cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/48/27394?source=related_link\">",
"      Patient information: Chondrosarcoma (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_39_35451="Rx myasthenic crisis";
var content_f34_39_35451=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F82137&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F82137&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of myasthenic crisis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Admit to intensive care unit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Measure FVC frequently, as often as every two hours if respiratory status is deteriorating",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Electively intubate in the presence of any of the following conditions:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        FVC less than 15 mL/kg body weight",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Declines in serial measurements of FVC approaching 15 mL/kg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Declines in serial measurements of NIF approaching 25 cmH2O",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Clinical signs of respiratory distress",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Difficulty handling oral secretions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Withdraw anticholinesterase medications to reduce airway secretions in patients who are intubated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Begin rapid therapy with plasmapheresis or IVIG to treat myasthenic crisis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Begin immunomodulating therapy with high dose glucocorticoids (eg, prednisone 60 to 80 mg per day). Consider azathioprine, mycophenolate mofetil, or cyclosporine if glucocorticoids are contraindicated or previously ineffective",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Initiate weaning from mechanical ventilation when respiratory muscle strength is improving with plasmapheresis or IVIG treatment, as quantified by a FVC &gt;15 mL/kg and NIF &gt;30 cm H2O",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     FVC: forced vital capacity; IVIG: intravenous immune globulin; NIF: negative inspiratory force.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_39_35451=[""].join("\n");
var outline_f34_39_35451=null;
var title_f34_39_35452="Performance Arozullah index";
var content_f34_39_35452=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F52339%7EPC%2F62775&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F52339%7EPC%2F62775&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Performance of the Arozullah respiratory failure index",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Class",
"       </td>",
"       <td class=\"subtitle1\">",
"        Point total",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent respiratory failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        &le;10",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        11 to 19",
"       </td>",
"       <td>",
"        1.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        20 to 27",
"       </td>",
"       <td>",
"        4.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        28 to 40",
"       </td>",
"       <td>",
"        10.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        &gt;40",
"       </td>",
"       <td>",
"        26.6",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Arozullah, AM, Daley, J, Henderson, WG, Khuri, SF, Ann Surg 2000; 232:242.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Arozullah respiratory failure index",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Preoperative predictor",
"       </td>",
"       <td class=\"subtitle1\">",
"        Point value",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        Type of surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Abdominal aortic aneurysm",
"       </td>",
"       <td class=\"sublist_other\">",
"        27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Thoracic",
"       </td>",
"       <td class=\"sublist_other\">",
"        21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Neurosurgery, upper abdominal,",
"peripheral vascular",
"       </td>",
"       <td class=\"sublist_other\">",
"        14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Neck",
"       </td>",
"       <td class=\"sublist_other\">",
"        11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Emergency surgery",
"       </td>",
"       <td>",
"        11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Albumin &lt;3.0 g/dL",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        BUN &gt;30 mg/dL",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Partially or fully dependent functional status",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of chronic obstructive pulmonary disease",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        Age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &gt;70 years",
"       </td>",
"       <td class=\"sublist_other\">",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        60 to 69 years",
"       </td>",
"       <td class=\"sublist_other\">",
"        4",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Arozullah, AM, Daley, J, Henderson, WG, Khuri, SF, Ann Surg 2000; 232:242.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_39_35452=[""].join("\n");
var outline_f34_39_35452=null;
var title_f34_39_35453="Presenting features NHL types";
var content_f34_39_35453=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F64113&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F64113&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Presenting features of common B and T-cell non-Hodgkin lymphomas",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Neoplasm",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Frequency*&bull;",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Male",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Stage",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        B Sx",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        EN",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        BM",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        GI",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        IPI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        I",
"       </td>",
"       <td class=\"subtitle2\">",
"        II",
"       </td>",
"       <td class=\"subtitle2\">",
"        III",
"       </td>",
"       <td class=\"subtitle2\">",
"        IV",
"       </td>",
"       <td class=\"subtitle2\">",
"        0/1",
"       </td>",
"       <td class=\"subtitle2\">",
"        2/3",
"       </td>",
"       <td class=\"subtitle2\">",
"        4/5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DLBCL",
"       </td>",
"       <td>",
"        31",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        46",
"       </td>",
"       <td>",
"        19",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mediastinal DLBCL",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        37",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        31",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        52",
"       </td>",
"       <td>",
"        37",
"       </td>",
"       <td>",
"        11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Follicular",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        42",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        51",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        42",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SLL/CLL",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        53",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MALT lymphoma",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        31",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        98",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        44",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mantle cell",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        23",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peripheral T-Cell",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        52",
"       </td>",
"       <td>",
"        31",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ALCL",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        69",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        53",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        21",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     BSx: B-symptoms; EN: involvement of any extranodal site, including bone marrow; BM: bone marrow involvement; Gl: gastrointestinal tract involvement; IPI: intemational prognosticindex; DLBCL: diffuse large B-cell lymphoma; SLL/CLL: small lymphocytic lymphoma/chronic lymphocytic leukemia; MALT: mucosa associated lymphoid tissue; ALCL: anaplastic large cell lymphoma.",
"     <br>",
"      * Percent of total cases.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       With the exception of median age at time of diagnosis, all numbers represent percent of patients with the listed feature.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Armitage, JO, et al. J Clin Oncol 1998; 16:2780.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_39_35453=[""].join("\n");
var outline_f34_39_35453=null;
var title_f34_39_35454="Microinjection into fert egg";
var content_f34_39_35454=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F77166&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F77166&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Microinjection into fertilized egg",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photomicrograph showing microinjection of DNA into fertilized egg.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Transgenic mouse and gene targeting core. Http://cancer.ucsd.edu/tgm/ genetargeting.html/#injection. Copyright &copy; 2002 University of California, San Diego.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_39_35454=[""].join("\n");
var outline_f34_39_35454=null;
var title_f34_39_35455="Excision of pilonidal tract and sinus";
var content_f34_39_35455=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F87170&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F87170&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Excision of pilonidal tract and sinus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The entire extent of pilonidal disease is encised en bloc to the level of the sacrococcygeal fascia.",
"    <br>",
"     Figure A depicts a pilonidal sinus and tract.",
"     <br>",
"      Figure B depicts the extext of the excision.",
"      <br>",
"       Figure C depicts the depth of&nbsp;the incision to the level of the sacrococcygeal fascia.",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_39_35455=[""].join("\n");
var outline_f34_39_35455=null;
